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Abstract
Haemophilia is an X-linked recessive genetic disorder characterised by bleeding within
soft tissue and joints. Multi-joint disease is a common feature of severe haemophilia
where the ankle is prone to haemarthrosis and haemarthropathy, but little is known about
the effect on individual joints, impact on health-related quality of life (HRQoL) and foot
and ankle outcome measures.
A multi-methods approach was used to improve the understanding of ankle
haemarthrosis and resultant haemarthropathy. The prevalence of ankle haemarthrosis
and incidence at individual joints with concurrent joint health in patients compliant with
prophylaxis without an active inhibitor were investigated. Approximately 60% and 40%
of people with haemophilia A and B respectively experienced a minimum of one
haemarthrosis over the 12 month study period. Whilst haemarthrosis incidence at
individual joints was similar, the ankle was the most affected by haemarthropathy. A
multi-centre patient questionnaire of the impact of ankle haemarthrosis and
haemarthropathy identified that HRQoL and foot and ankle outcome measures were poor
regardless of haemophilia type, severity or treatment regime. A consultant survey
identified adequate access to Musculoskeletal (MSK) services across the UK. However,
only 12% and 49% of patients used footwear and foot orthoses respectively. Finally, a
biomechanical study was established in a healthy cohort of males, the kinetic and
kinematic effect of the Leeds Ankle Stabilising Enhanced Rocker intervention, a footwear
and foot orthoses intervention used clinically in the management of haemophilia.
Significant reductions in the primary outcome of ankle moment of force were reported
when compared to a trainer, with a minimal effect on proximal joints.
The work presented in this thesis improves the understanding of the current prevalence,
incidence and impact of ankle haemarthrosis and haemarthropathy. Gaps in the access
to MSK services have been identified and the mechanism of action of a targeted
intervention has been established, providing a basis for future research in a pathological
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Chapter 1 - Introduction
This review provides a description of haemophilia, a detailed review of the biological and
mechanical drivers of haemarthrosis; the effect of intra-articular bleeding on structures
and function, with particular focus on the foot and ankle; and the final section reviews in
detail current treatment modalities of ankle haemarthrosis and haemarthropathy outside
of replacement factor concentrate haemostasis.
1.1 Background
Haemophilia, an X-linked recessive genetic disorder is characterised by bleeding within
soft tissue and joints [1]. Severe and moderate levels of haemophilia A and B are
associated with multi-joint haemarthropathy whereby haemarthrosis and the process of
the removal of blood products lead to synovitis, cartilage damage and eventual bony joint
changes with loss of joint structure and function. The replacement of Factor VIII and IX
with clotting factor concentrates (CFC) treatment has revolutionised haemophilia care
with reductions in annual bleed rates (ABR) and annual joint bleed rates (AJBR) [2].
However, despite adequate availability of CFC in western medicine, treatment is still
regarded as sub-optimal with low treatment doses ABR and AJBR are still regarded as
high [3-5].
The consequence of bleeding is reflected in the levels of haemarthropathy at the most
affected joints, the elbows knees and ankles. Until the introduction of prophylaxis, the
knee was the most affected by haemarthropathy, however, the ankle has become the
most affected joint [6, 7]. In adults, ankle joint changes are reported in the second and
third decade of life with a gradual change in joint structure and function leading to gradual
plantarflexion deformity and loss of ankle sagittal plane range of motion of up to 80% [8].
The ankle joint has been identified as the most common site of haemarthrosis but little
has been reported on prevalence and incidence at an individual joint level, or the impact
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on health-related quality of life (HRQoL) and foot and ankle outcomes [9]. Footwear and
orthoses have the potential to reduce pain, AJBR and lessen the burden of disease, but
there is yet to be any definitive trial that informs clinical management guidelines.
The ankle joint is problematic in the management of pain and haemarthropathy with the
suggestion that the ankle may disproportionality affect HRQoL and the burden of disease
compared to the other commonly affected joints. [10, 11]. It remains unclear as to the
true impact of ankle haemarthropathy and the effect of haemophilia type, severity and
treatments regimes.
Access to musculoskeletal (MSK) services for the management of haemarthropathy
forms part of the United Kingdom Haemophilia Centres Doctors Organisation standards
of care including services such as orthopaedics, diagnostic imaging services and
physiotherapy [12, 13]. Podiatry services reported at two United Kingdom haemophilia
centres (Leeds and Kent) provide services as part of the clinical comprehensive care
model with good patient satisfaction [14]. Improvements in pain, HRQoL and reductions
in AJBR are reported when orthoses and footwear are provided, but there is yet to be
any national recommendation on use. It is unclear if this service is provided nationally,
or if there are disparities in the provision of MSK services [15, 16].
In diseases that affect the foot and ankle such as rheumatoid arthritis and diabetes, there
is good evidence that functional foot orthoses (FFO) and footwear prevent foot deformity,
provide stability and improve patient-reported outcome measures [17-20]. However in
haemophilia and ankle haemarthropathy the evidence is less conclusive, limited to small
studies and often used as an adjunct to other therapies [8, 21-25].
The Leeds comprehensive care centre has used FFO and a modified military boot for a
decade to manage ankle haemarthrosis, haemarthropathy and reduce patient-reported
pain and disability [15]. Whilst audit data has identified improvements in pain and foot
and ankle outcomes, little is known about the mechanical effect of the Leeds Ankle
3
Stabilising Enhanced Rocker (LASER) intervention at the ankle and the proximal joints
of the lower limb.
1.2 Thesis hypothesis, and objectives
The two linked hypotheses explored in this thesis are:
· The prevalence and incidence of haemarthrosis disproportionately affects
ankle joint health and the impact of ankle haemarthropathy is a major
contributor to the decline in health-related quality of life and foot and
ankle outcomes
· Improving the understanding of the mechanics of footwear modification
and foot orthoses will lead to better targeted non-pharmacological
interventions in the management of ankle haemarthropathy
Objectives
· Establish the current prevalence and incidence of haemarthrosis in adults
with severe and moderate haemophilia and concurrent joint health
· To understand the impact of haemarthropathy on HRQoL and foot and ankle
outcomes
· Investigate current access to clinical services at comprehensive care and
haemophilia treatment centres
· Understand patient perceptions of access to clinical services
· To understand the mechanical effect of the LASER intervention on individual
and combined footwear components as a potential non-pharmacological
treatment in ankle haemarthropathy
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1.3 Thesis structure and overview
Chapter Two - Narrative literature review
This narrative literature review presents the current background and treatment of
haemophilia with themes of prevalence of haemophilia, structural and functional
consequences of ankle haemarthropathy providing context to this thesis.
Chapter Three - The prevalence of ankle haemarthrosis in moderate and severe
haemophilia A and B
This prevalence chapter uses data provided by the national haemophilia database to
determine the current prevalence of ankle haemarthrosis and other commonly affected
joints of the knees and elbows in adults with moderate and severe haemophilia.
Chapter Four - The impact of blood induced ankle arthritis in patients with
moderate and severe haemophilia A and B: The HAPII study
The impact of blood induced ankle arthritis has been investigated in this chapter with a
specific focus on the impact on HRQoL and foot and ankle outcomes. Details of effect at
other joints, pain, treatment and management were collected and compared across
haemophilia type, severity and treatment regime.
Chapter Five - A mechanism of action study to explore the individual and
combined components of the Leeds Ankle Stabilising Enhanced Rocker (LASER)
Boot
A mechanism of action study was undertaken to determine the kinetic and kinematic
effect of the Leeds Ankle Stabilising Enhanced Rocker intervention in terms of the
individual and combined components. This chapter used a group of healthy controls to
determine the kinetic and kinematic effects of the LASER intervention and improve
understanding of the proposed clinical effect. Findings from this chapter aim to inform a
future study of the LASER intervention in those affected with ankle haemarthropathy.
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Chapter Six - Discussion, future direction and conclusions
This chapter discusses the main finding of the thesis, the future direction of research and
a conclusion on the overall body of work. Future directions for research are discussed
and an overall conclusion is drawn.
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Chapter 2 - Literature review
This review provides a description of haemophilia, a detailed review of the biological and
mechanical drivers of haemarthrosis; the effect of intra-articular bleeding on structures
and function, with particular focus on the foot and ankle; and the final section reviews in
detail current treatment modalities of ankle haemarthrosis and haemarthropathy outside
of replacement factor concentrate haemostasis.
2.1 Haemophilia
This section describes haemophilia, current treatment approaches and complications
and the pathogenesis of haemarthropathy with a specific focus on ankle joint
haemarthropathy.
Haemophilia is a rare X-linked recessive genetic disorder characterised by bleeding into
soft tissue and joints whereby there is an absence, reduction or dysfunction of circulating
clotting factor needed to maintain haemostasis [1]. The most common types of
haemophilia are A and B, an absence of clotting factor VIII and IX, respectively.
Haemophilia is further characterised as mild (>0.05 - <0.24 IU/mL), moderate (0.01-0.05
IU/mL) or severe (<0.01 IU/mL) dependant of the level of clotting factor absence [26].
The global prevalence of haemophilia A and B is approximately 1:5000 and 1:30000,
respectively, regardless of ethnicity or descent [27, 28]. Diagnosis of haemophilia occurs
because of known family history or at the presentation of bleeding.  Most children are
symptom-free until they start learning to crawl and walk when the risk of spontaneous
and traumatic bleeding is increased [1]. Severe haemophiliacs are most at risk of
spontaneous bleeding events while those with moderate disease often bleed because of
trauma. However recent focus has been placed on moderate haemophilia where patients
who have a tendency to bleed or have a “bleeding phenotype” require regular clotting
factor concentrate (CFC) treatment [4, 29]. The treatment of severe and moderate
(bleeding phenotype) haemophilia is by the replacement of clotting factors termed
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‘replacement therapy’ to elevate a patient’s trough level (FVIII/ FIX) to a level adequate
for stopping or minimising spontaneous bleeding events and subsequent joint damage
[30, 31]. Nilsson et al. (1970) observed that children with moderate haemophilia did not
display the same tendency for episodes of acute spontaneous bleeding as those with
severe disease. Therefore elevation of trough levels above 1% (>0.01 IU/mL) by regular
infusion of anti-haemophilia concentrate termed prophylaxis treatment may minimise
spontaneous bleeds [32]. Longitudinal studies of prophylaxis verses episodic on-demand
treatment have reported successful reduction of haemarthrosis and structural joint
damage [33-36].
Episodic on-demand treatment whereby CFC is administered after a bleed, or at the
patients chosen time such as before physical activities, is often adopted in socially
economically deprived countries [1]. In the United Kingdom (UK), the numbers of patients
who treat on-demand have declined dramatically since the introduction of prophylaxis.
Nearly all children (94%) and 74% of older adults aged 30 years and above with severe
haemophilia A are now adopting a prophylaxis treatment regime [2]. On-demand
treatment is associated with a higher risk of complications, long-term disability caused
by intra-cranial haemorrhage and high incidence of joint damage, disability and reduced
life expectancy [11, 37]. A proportion of adult patients still choose to treat on-demand,
due to a lack of treatment compliance, infusion difficulties or mistrust of treatments [4,
38]. In adults where treatment was either unavailable in early years or a preference for
on-demand treatment, secondary prophylaxis is often adopted in later years [30]. Collins
et al. (2011) examined the efficacy and safety of secondary prophylaxis in adults with
severe haemophilia A (n=19). In this crossover study, patients were observed over a six
month period treating on-demand with CFC. Over the following six months patients
received prophylaxis with standard half-life (SHL) CFC of 20-40 IU kg-1 three times per
week [2]. Results identified that when adhering to a prophylaxis treatment regimen, the
cohort reduced episodes of bleeding and haemarthrosis from a median of 15.0 (IQR 11
to 16) to 0 (IQR 0 to 3) (P=<0.001) [2]. Results provide evidence of the effectiveness of
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prophylaxis even where joint disease is established. Findings made little difference to
joint health and the reduction of pain with mean (standard deviation) visual analog scales
(VAS) of 3.7 (SD 2.9) to 3.3 (SD 3.0) over the 13 month study period was not significant.
Quality of life (QoL) was not affected by treatment, though little detail was provided on
total HEAMO-QoL-A or domains scores which may have provided more insight to effect
[2].
2.1.1 Anti-factor antibodies
Whilst prophylaxis has revolutionised haemophilia treatment it is not without
complication. Inhibitor development whereby anti-Factor antibodies are produced in
response to the infusion of CFC triggers an immune response that inhibits the effect of
CFC treatment [39]. The incidence for inhibitor development is higher in haemophilia A
than haemophilia B. Development of anti-Factor VIII (FVIII) antibodies occurs in 30%,
and anti-Factor IX (FIX) antibodies occur in 3% of previously untreated patients, with risk
of inhibitor development observed in the first 20-30 days or 20-100 treatment exposures
[1, 39, 40]. The development of inhibitors can be catastrophic if not identified, with
treatment essentially ineffective. Where bleeding continues, restoration of haemostasis
requires the use of bypassing agents such as activated prothrombin complex
concentrates, recombinant factor VIIIa and more recently recombinant, humanized,
bispecific monoclonal antibodies [41, 42]. Hanley et al. (2017) indicate that the frequency
of spontaneous joint and soft tissue bleeds in patients with inhibitors are comparable to
non-inhibitor cases, but inhibitor cases have a higher tendency to develop “target joints”,
i.e. a joint that is particularly prone to bleeding [43]. A target joint is defined as a joint that
has had three or more haemarthrosis episodes within a six month period resulting in joint




Haemarthrosis, whereby single significant or repeated episodes of bleeding occurs with
a joint space is an inherent clinical feature of haemophilia [46]. The presence of blood
within the joint space and the process of removal is associated with synovial hypertrophy,
haemosiderin deposition and eventual arthropathic changes to joint structure [23]. A
single traumatic episode of bleeding into a joint can lead to a biological cascade that
causes joint damage and disability (Figure 1). This is a particular concern in children
where musculoskeletal immaturity exposes joints to a greater risk of damage and rapid
decline in joint health if haemarthrosis is not prevented [3].
One large European study of haemophilia reported high annual bleed rates (ABR) across
multiple countries [3]. The study identified patients with severe haemophilia A reporting
median ABRs between 1.0 and  4.0 across Belgium, France, Germany, Italy, Spain,
Sweden and the UK [3]. ABR in patients with moderate haemophilia was higher (2.0 to
8.0), suggesting patients with moderate haemophilia report an increased incidence of
bleeding. However, moderate haemophilia has been previously associated with low
annual joint bleed rates (AJBR), less haemarthropathy and burden of disease [5]. The
findings suggested that European patients are undertreated, with treatment doses low
across haemophilia types thus increasing the risk of bleed related complications and
decline in joint health. In this study, 43% of bleeds occurred within soft tissue and joints,
but the study failed to identify the prevalence of haemarthrosis in specific joints, therefore
the specific implications of under treatment were not reported [3]. In addition,
examination of United Kingdom Haemophilia Doctors Organisation (UKHCDO) National
Haemophilia Database (NHD) bleed data has identified that patients with moderate
haemophilia A with a bleeding phenotype, have ABR and AJBR similar to those with
severe disease despite the suggestion they are less affected by bleeding and joint
disease [4, 5]. Despite continuing, advancement in treatments across disease types and
severity, such as extended half-life (EHL) products and reductions in CFC costs, reported
ABR/ AJBR are still regarded as sub-optimal across Europe and the UK with low
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tolerance for treatment dose (IU/kg) and regimes [3, 4]. Therefore the progression of joint
diseases is likely to remain largely unchanged based on current pharmacological
treatment.
Before the introduction of CFC prophylaxis, the knees were the most common site of
haemarthrosis in children and adults with severe haemophilia [6, 7]. Since the
introduction of prophylaxis, an investigation of bleeding patterns in children (n=55) and
adults (n=45) by Stephensen et al. (2009) in severe haemophilia A identified that the
ankle joint had become the most prevalent site of haemarthrosis and joint health
deterioration [9]. Changing prevalence and patterns of haemarthrosis may emerge with
the introduction of newer treatment products and increased interest in the effects of
haemarthrosis on moderate haemophilia types. The current prevalence of ankle
haemarthrosis is unknown, nor is its context understood in other at-risk joints of the upper
and lower limbs.
Advances in the treatment of haemophilia with recombinant factor concentrate, EHL
products, better inhibitor management and new anti-virial therapies means that the life
expectancy of people with haemophilia has significantly increased [47]. Those
individuals with moderate and severe haemophilia have a life expectancy that is 15 years
and three years lower in severe and moderate haemophilia respectively, compared to
the general population [48]. Although the gap between the general population and severe
haemophilia is still significant, lower deaths rates caused by intracranial haemorrhage
has seen the focus of treatment switch to the management of haemarthropathy and
maintenance of joint health status [4, 49]. In those with severe and moderate
haemophilia, it is paramount that haemarthropathy is reduced so that disability is
minimised throughout their lives [50]. Despite some advancements, CFC treatment is
still sub-optimal, and new therapies such as novel Factor bypassing agents and gene
therapy are yet to evaluate their effect on the development of joint disease [3, 4, 51].
Therefore, haemarthropathy will remain a hallmark feature of the disease in people with
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haemophilia who receive sub-optimal treatment or continue to present with clinical and
radiological evidence of haemarthrosis and haemarthropathy [3, 4].
Figure 1: Schematic representation of a healthy joint (left) and
haemophilic arthropathy (right) [52].
2.1.3 Haemarthropathy
Haemarthropathy is the most common clinical manifestation associated with severe
haemophilia (Figure 1). Disability is a hallmark feature of the disease accounting for the
majority of health-related complications [1]. Since the introduction of replacement CFC,
the ankle has become the most common site of haemarthrosis, followed by the elbow
and knee [9]. It is not fully understood why the incidence of haemarthrosis at the ankle
has increased. A plausible cause is that during activities of daily living (ADL),  the ankle
is exposed to high compressive and shear forces, when combined with highly
vascularised synovium and a shift in haemostatic balance, the risk of haemarthrosis is
increased [9, 53]. Haemarthrosis causes blood products to accumulate within a joint,
leading to inflammatory changes and eventual haemarthropathy [1]. When traumatic or
acute joint haemorrhage occurs, patients often present with swelling, loss of function,
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and pain [43]. Replacement CFC has seen a decrease in joint haemarthropathy. A pivotal
study by Manco-johnson et al. (2007) compared the use of prophylaxis versus on-
demand treatment in 65 haemophiliac children [33]. This randomised controlled trial
(RCT) found that those children (n=32) treated with 25 IU/kg of factor VIII every other
day (prophylaxis) reported a reduction in haemarthropathy. The prophylaxis group was
then compared to a group that was only treated clinically on demand during a
recognisable joint haemorrhage (40 IU/kg for 24 hours, 20 IU/kg at 24, 72 hours) over a
mean period of 49 months. Patients randomised to the prophylaxis arm reported a
dramatic reduction in haemarthrosis with an AJBR rate of 0.6 (SD 1.4) compared to 4.9
(SD 3.6) in the on-demand treatment group indicating the effectiveness of prophylaxis
treatment. Despite the positive results of this study, changes reported by Magnetic
Resonance Imaging (MRI) correlated poorly with clinical presentation. Similarly, the
method of clinical assessment lacked the sensitivity to detect all clinically evident
haemarthrosis [33]. Whilst the prophylaxis regime was effective at reducing bleeding, it
does not protect against all haemarthrosis. This suggests that even those on primary
prophylaxis, the gold standard of treatment, still experience episodes of bleeding that
may not represent the patient-reported clinical signs and symptoms of haemarthrosis
[54]. Undetectable subclinical and micro bleeding has been suggested as a potential
mechanism for joint health decline but this is yet to be shown definitively [46, 55].
2.1.4 Pathogenesis of haemarthropathy
2.1.4.1 Pathophysiology
Haemarthropathy refers to secondary joint damage caused by a single significant or
repeated minor incidences of haemarthrosis in people with haemophilia [56, 57]. In the
presence of a single bleed, people with haemophilia report pain, swelling, warmth, loss
of joint range of motion (ROM) and muscle spasm [58]. Haemophilic joint disease shares
some characteristic joint changes with both rheumatoid arthritis (RA) and osteoarthritis
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(OA), in the presentation of synovitis, bone reabsorption and articular cartilage
degeneration [59, 60].
2.1.4.2 Synovitis
Synovial tissue lines the joints of the body providing lubrication, nutrition and facilitating
the removal of waste products [57]. The synovial tissue is highly vascularised and where
large or repeated haemarthrosis occurs, the synovium’s ability to remove blood products
is exceeded [61]. Haemosiderin is a by-product of haemoglobin, the oxygen-carrying
protein in red blood cells, and has been identified as the main instigator of joint synovitis
in people with haemophilia and the release of pro-inflammatory mediators [58]. In vitro
studies have identified interleukin (IL) 1, IL 6 and tumour necrosis factor-alpha as the
main cytokines that drive inflammatory response [59]. Repeated episodes of
haemarthrosis and recurrent synovitis, results in abnormal vascularity that is particularly
fragile and is more prone to bleeding, with associated synovial hypertrophy leading to a
vicious circle of haemarthrosis and synovitis [52, 61].
2.1.4.3 Cartilage damage
Cartilage is an avascular structure made up of chondrocytes that maintains an
extracellular matrix of cartilage, consisting of collagens, proteoglycans, and proteins.
Cartilage when lubricated with synovial fluid facilitates smooth joint movement and
resists compressive and shear forces during joint loading [57]. As a result of
haemarthrosis and in conjunction with fibrosis of the synovial lining, the joint cartilage
becomes damaged [58]. Changes to hyaline cartilage are both chemical and mechanical
in aetiology. Iron-catalysed reactive oxygen intermediates induce apoptosis of the
chondrocytes leading to changes in the composition of the articular cartilage matrix [61].
Contamination of the joint with 10% and 20% blood products over a 48 hour period, has
been shown to change cartilage matrix properties causing irreversible damage [57, 62].
Eight-week exposure resulted in more deformable cartilage, with less resistance to shear
forces when compared to a control group which may provide insight into the changes in
vitro [58]. Recent advances in MRI have challenged the concept that cartilage damage
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occurs by pro-inflammatory mediators released from haemosiderin-burdened synovium
alone. MRI of cartilage from weight-bearing symptomatic joints (knees and ankles n=16)
with concurrent histological analysis using post-operative joint arthroplasty tissue
identified direct iron deposition within cartilage chondrocytes [63]. Iron accumulation
within the cartilage plays a direct and continuous role in cartilage toxicity, independent
of synovial changes. The potential for this MR “iron” imaging technique is timely, with
bleed rates reducing and a paradigm shift in treatment. The potential to use this
sequence and identify iron deposition within cartilage as a biomarker for subclinical joint
changes are promising but sequencing is yet to be refined or validated in people with
haemophilia.
2.1.4.4 Bone damage
The mechanism by which bone damage occurs is yet to be established in
haemarthropathy [59]. The process of degenerative bone damage is thought to be similar
to that of OA with the chronic inflammatory process seen in RA [58, 59]. Bone changes
occur in the presence of cartilage damage, but not in isolation. The initiation of
osteoclastogenesis, which is enhanced by cytokines, is thought to initiate inflammation
and bone reabsorption caused by an imbalance of bone turnover by osteoclast and
osteoblasts. Osteochondral changes in haemarthropathy include erosion, cyst formation,
osteonecrosis and eventual joint failure [64]. The risk of bone damage is complicated by
an increased incidence of osteoporosis, which occurs in the presence of infectious
comorbidities such as hepatitis C, and human immune-deficiency virus (HIV) [65]. Loss
of bone mineral density (BMD) has been reported in this population and may contribute
to the advancement of haemarthropathy [66]. In haemophilic children, the presence of
low BMD has been associated with the reduction of activity and parental fear of bleeding,
resulting in periods of inactivity related to joint bleeds [67]. In the pathogenesis of
haemophilia, reduced BMD may further complicate the multifactorial nature of
haemarthropathy and damage. In established haemarthropathy, plain film radiographs
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identify osteonecrosis, epiphyseal overgrowth, bone cyst formation, and bone fusion [68,
69].
In advancing ankle haemarthropathy, subchondral cyst formation is often featured on
diagnostic imaging. The presence of bone cysts with the tibia and talus represent not
only advancing disease but changes to the joint contact pressures. Finite element (FE)
modelling has shown cyst formation in the tibia increases joint contact pressure by a
mean of 77% (SD 48%) and in the talus increases by 66% (SD 107%) [70]. The cartilage
contact pressures also increased by 120% (SD 145%) indicating increases in contact
pressure are not exclusive to the bone. The presence of increased contact pressure
values may affect joint health with the potential to increase the rate of joint disease. This
is the first study to model the changes of ankle haemarthropathy and contact forces and
whilst published as an abstract, it shows promise in understanding the effects of bone
cysts on joint health [70]. The combination of synovitis, cartilage damage and bone
pathology leads to fibrosis of the joint and ultimately destruction [53]. In weight-bearing
joints such as the ankle, the process of deterioration leads to potential functional changes
in gait and structural changes and subsequent decline in patient-reported pain and
disability [18].
2.1.5 The haemophilic ankle
The ankle joint complex (Figure 2) consists of multiple articulations that facilitate
functional movement of the body over the foot. The ankle and foot are made up of 28
bones including the tibia and fibula form a total of 33 joints. Specifically, the ankle joint
complex is made up of several articulations of the talocrural joint (tibiotalar), subtalar joint
talocalcaneal and talonavicular joints [71, 72]. OA of the talocrural joint referred to as the
“ankle joint”, secondary to haemarthrosis, is common in moderate and severe
haemophilia. It has been hypothesised that increased physical activity in combination
with the mechanical demands required of the ankle joint during ADL, expose the ankle
joint to greater compressive and shear forces [73]. Pathology of the foot and ankle is
predominantly reported at the ankle joint, with the subtalar joint affected in >50% of cases
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[74]. The articulations of the talonavicular and calcaneocuboid joints are rarely affected
by haemarthrosis, however secondary OA related to the biomechanical failure of the
proximal subtalar and ankle joints are reported [75, 76].
Figure 2: Anatomy of the ankle joint complex
(Primal pictures 2021, image produced for thesis)
Although an inherited condition, people with haemophilia experience incidents of
bleeding in the early years of life. Repeated episodes of haemarthrosis lead to the
formation of abnormal highly vascularised synovium with excessive blood flow to the
epiphyseal plates [77]. Increased blood flow to growth plates leads to accelerated
ossification and growth of the epiphyses resulting in angular deviations such as tibial
rotation at the ankle joint and potential for leg length discrepancies [78]. Structural joint
changes appear to occur during the second decade of life with the formation of
osteophytes, driven by chronic synovitis [68, 79]. At the ankle joint, osteophyte formation
is seen at the anterior margin of the tibia but can occur posteriorly in end-stage joint
disease [80]. The occurrence of osteophytes (Figure 3) further complicates the risk of
haemarthrosis by synovial impingement during dorsiflexion and plantarflexion [64].
Osseous hindfoot eversion with significant foot deformity is associated with disease of
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the subtalar joint, a common site of disease activity seen in inflammatory arthritis [77,
81, 82].
Figure 3: Radiographs of the ankle joint with haemarthropathy in a 26-
year-old male
Figure 3a: Changes to joint geometry of ankle joint and loss of joint space. The blue line
represents the shape change of the talar dome and red arrows identify sites of
osteophyte formation. Figure 3b: Loss of joint space at the ankle joint and irregularity of
the joint surfaces (fibula, tibia and talus).
Progression of haemarthropathy of the ankle joint leads to plantarflexion deformity due
to further osseous and soft tissue changes at the ankle joint. Where bleeding occurs in
the gastrocnemius and soleus muscles of the lower limb, soft tissue contracture and scar
tissue formation occur leading to plantarflexion. This further changes the anatomical
structure of the ankle joint as well as leading to functional changes [80]. Talar dome
necrosis has been reported in children with haemophilia but only in a small number of
case reviews (n=4), with changes in geometry and subchondral bone cyst formation [83,
84]. A study of people with haemophilia undergoing radioactive synovectomy (n=9, 19
joints) reports 50% of study participants having subtalar joint involvement, but all







participants had an inhibitor, requiring a bypassing clotting factor concentrate, which
does not represent typical treatment and therefore may have affected results [85]. A
recent publication by Lobet et al. (2017) highlighted the significant contribution that
subtalar joint disease may play in the progression of foot deformity as the ankle joint
becomes limited in function [86, 87]. This is contrary to earlier research that reported that
whilst the subtalar joint is affected in isolation to the ankle joint, 50% of affected patients
in a study of ankle haemarthropathy had some form of subtalar joint disease [85]. The
pathological changes reported in ankle haemarthropathy lead to changes in ankle joint
structure and impact on function [19].
The biomechanical changes related to haemarthrosis and haemarthropathy are
discussed in section 2.2.1.2. Firstly the biomechanics of the ankle, data collection
methods and modelling are presented to provide context to changes reported in
haemophilia.
2.2 Ankle joint biomechanics
Biomechanics of the ankle joint in normal and pathological haemarthropathy are
presented in section 2.2. The current methods of modelling the kinetics and kinematics
of the lower limbs and foot and ankle are also described.
The ankle joint forms a kinetic linkage between the lower limb and foot allowing
interaction with the ground, providing a platform for gait. The ankle joint forms the
connection between the tibia, fibula and the talus with the load-bearing surface of the
joint occurring at the tibia and talus interface [72]. Movement at the ankle joint occurs
mainly in the sagittal plane in plantarflexion and dorsiflexion (Figure 4) with up to 20∞ of
dorsiflexion and 45∞ of plantarflexion ROM, although during ADL such as walking, the
ankle joint only requires 30∞ ROM [88]. The subtalar joint is formed by the articulation of
the talus and calcaneus and forms a tri-planar, uniaxial joint with the tibia. The geometry
of the subtalar joint permits inversion and eversion of the foot allowing adaption to
uneven terrain during ADL [89]. The foot is in a slightly supinated position at heel strike
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(heel rocker) and pronates through the midstance phase of gait (ankle rocker) before the
foot begins to supinate in preparation for propulsion (forefoot rocker) [90].
Figure 4: Foot and ankle motion in the sagittal, frontal and transverse
planes
(Primal pictures 2021, image produced for thesis)
Ankle joint geometry means that when fully dorsiflexed, the ankle is at its most stable
(closed packed position). Forces are transferred across the talar dome and account for
77-90% of load with the remaining force (10-23%) transferred across the medial and
lateral talar facets [71]. The over simplification of the ankle as a simple hinge joint has
been challenged by Leardini et al.(2018) who identify the ankle as a complex
biomechanical structure playing a fundamental role in gait and ADL [88]. Specifically, the
complex interaction between the talocrural and subtalar joint provides the three ankle
rockers for normal motion during the walking cycle [88]. The first rocker is described as
the heel rocker, the second the ankle rocker and the third, the forefoot rocker (Figure 5).
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The heel rocker (Figure 5a) describes the point at which the heel makes contact with the
floor (heel strike). Gradual plantarflexion occurs until the forefoot makes contact with the
floor. As the ankle rocker (Figure 5b) starts, the shank progresses over the ankle joint
causing gradual dorsiflexion of the ankle until the point at which the heel starts to lift.
During this third rocker (Figure 5c), the foot is maximally dorsiflexed and the heel lifts off
the floor. The foot generates power through plantarflexion and continues until maximum
plantarflexion is achieved and “toe-off” occurs leading to the swing phase of gait [88].
Figure 5: Ankle rockers
a first rocker, b: second rocker c; third rocker (Image produced for this thesis)
In non-pathological gait, at heel strike during the first ankle rocker, GRF is posterior to
the ankle joint centre creating a small external dorsiflexion moment as the dorsiflexors
(anterior muscle group) contract to control the rotation of the foot onto the ground,
preventing foot slap (Figure 6). From heel strike, GRF passes anterior to the ankle
(second rocker) creating an internal plantarflexion moment that increases with the
posterior muscle group concentrically contracting towards toe-off (third rocker) [89, 91].
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Figure 6: Ankle moments
Sagittal plane external dorsiflexion moment and internal plantarflexion moment (Primal
pictures 2021, image produced for thesis)
2.2.1 Kinematics and kinetics of the lower limb
Observation of the human body during walking or evaluation of the kinetics and
kinematics of the lower limb seeks to understand the effect of pain and disability on
biomechanical function [89]. Instrumented mats may be used to obtain temporal and
spatial parameters of gait, which record outputs such as walking speed and stance time,
providing measures of walking function [92]. The measurement of joint angles and
positions (kinematics) and the observation of forces acting on joints (kinetics) require a
more sophisticated method of measurement [91].
2.2.1.1.1 Lower limb models
Quantification of the kinetics and kinematics in normal and pathological locomotion is
undertaken using 3D gait analysis, often using an infrared camera system that tracks
passive reflective markers [91]. Skin mounted markers are placed on the segment or
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body segments of interest as the individual moves/walk through the capture volume with
the 3D trajectory of each marker captured (Figure 7) [93]. 3D motion capture systems
and force plates allow for the calculation of 3D temporal/spatial, kinematics and kinetics.
Data acquisition requires the placement of reflective markers on specific anatomical
landmarks and segments to provide 3D spatial positions, such as the axis of the knee
where alignment requires accurate placement to capture the knee varus/valgus and
flexion-extension ROM [91].
Figure 7: Segment tracking
a: gait laboratory, b: Vicon 3D gait system visualisation (C-Motion, Germantown, USA)
There are two common biomechanical gait models, the “conventional gait model” and
the “Calibrated Anatomical System Technique” (CAST) [91]. The conventional gait
model, such as Plug-in-Gait (PiG, Vicon Motion Systems, Oxford, UK) uses
computational methods that assume the markers are rigid and attached to bony
landmarks and segments [94, 95]. Joint angles are then calculated using Cardan angles
between adjacent segments defined by the 3D position of the markers.
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PiG is commonly used and widely adopted in clinical gait analysis laboratories [95]. The
PiG model requires fewer marker trajectories (16 markers) when compared to more
sophisticated models, and benefits from a reduction in data collection times and therefore
is more conducive to clinical research and practice [96]. The PiG has been more widely
validated than any other model and its repeatability has been established in multiple
studies [97-100]. However, the accuracy of the PiG model has been challenged.
Predictive methods used to calculate joint centres are known to incorporate error due to
marker misallocation, skin movement artefact and inaccuracies of subject
measurements such as ankle width used to calculate joint centres [101-103].
In an improved approach, an inverse dynamics model is used to calculate kinetics around
the kinematics. The joints are linked by segment kinematics, external force data and
input of anthropometric and inertial characteristics derived from cadaveric studies [104,
105]. The CAST was developed by Cappozzo et al. (1996) to standardise movement
description in research and clinical practice and is classed as the gold standard protocol
for 3D kinematic analysis [91, 106]. The CAST model is different to the PiG as it uses
tracking pads to track segments, rather than a single marker, therefore reducing skin,
anatomical frame and location artefact [107]. The use of the CAST model has shown
less tendency to incorporate errors when generating ankle kinetics. The addition of the
medial malleolus marker within the anatomical reference frame (medial and lateral
malleolus) provides a better estimation of the ankle joint centre. [108].
The variability of different gait models assessed by Ferrari et al. (2008) [109] was
undertaken using a single marker set made up of 60 markers in three asymptomatic
subjects. Both the CAST and PiG models were compared with other lower limb
biomechancal models (Total 3D Gait (T3Dg), Servizio di Analisi della Funzione
Locomotoria (SAFLo) and Laboratorio per l’Analisi del Movimento nel Bambino (LAMB)).
General uniformity was found between the PiG and CAST models with good consistency
for sagittal plane joint angles and kinetic variables especially at the ankle (r>0.988,
p<0.001). The frontal plane mean error was small in the CAST model mean error of up
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to 2.5° (2.2SD)  (LAMB, SAFLo, T3Dg) when compared to PiG  (8.1°, SD 8.2). Therefore
findings suggest the CAST model is more robust in all three planes when modelling the
lower limbs.
2.2.1.1.2 Modelling of ankle kinetics and kinematics
The complexities of the foot and ankle are subject to theoretical concepts and paradigms
of foot function and its relationship to ankle biomechanics in normal and pathological gait
[110]. The association of segments at a single joint such as the knee are relatively
straightforward in marker placement and segmental kinematics, but the large number of
bones and articulations in the foot makes biomechanical modelling complex [111].
Any single segment foot model treats the foot as a single segment linked to the shank to
generate ankle kinetic and kinematic data [106]. This method is relatively simple and
when the complexities of the foot can be ignored, a majority of biomechanical studies
use this approach. This can be due to the aim of the study where the complex interaction
of the foot is not required and for simplicity in data collection methods [91, 99]. Single-
segment foot models report kinematic changes at the ankle in the presence of ankle
pathology [19, 112-114]. Limitations of ankle and foot modelling are reflected in the
criticisms of PiG and its reliance on anatomical and tracking markers to calculate ankle
joint forces, associated with incorporation of error, single-axis 2d modelling and the
requirement of additional markers to obtain inversion/ eversion foot data [100]. A single
segment approach is acceptable when assessing the pathology of the ankle. The axis of
the ankle joint is primarily in the sagittal plane, therefore a single segment foot model
would provide the necessary detail to report kinematic changes associated with
pathology such as ankle haemarthropathy. Movement at the ankle joint occurs mainly in
the sagittal (65-75° ROM) and transverse planes (35° inversion/eversion) [72]. A single
segment foot model with six degrees of freedom would therefore capture the necessary
data to quantify changes in ankle kinetics and kinematics.
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3D multi-segment foot modelling has become increasingly used in research and clinical
practice where the foot is divided into smaller functional segments, allowing the
quantification of movement between coupled units such as the hindfoot and forefoot.
This is of particular importance in the foot where pathology may be isolated to single
joints within the foot, such as the first metatarsal-phalangeal (MTP) joint where OA
changes are common [115]. Skin mounted markers are the most common method of
obtaining kinematic data and be adequately reliable when compared to the “gold
standard” intra-cortical pins [99, 111, 116]. Two of the most widely cited in multiple
clinical research studies multi-segment foot models are the Oxford Foot Model (OFM)
and Leardini foot model [20, 99, 111]. The OFM divides the foot into four segments (tibia,
hindfoot, forefoot and hallux) and the Leardini foot model uses five segments (shank,
calcaneus, midfoot, 1st metatarsal and proximal hallux) [117, 118]. In particular, the OFM
is used for gait analysis in adults and children and demonstrates strong reliability, but to
date validation of both models has been limited by a small sample size limiting inference
to large populations [99]. Another limitation of a multi-segment foot model is the
calculation of ankle kinetics, which are limited to single segment calculation [99]. The
multi-segment models that incorporate kinetics are too complex for use in clinical practice
and limited to a small number of experimental studies [119, 120]. This is due to the
complexities of calculating the inertial properties of the foot with multiple articulations,
muscles, tendons and variations in alignment. Similarly, there is no one universally
adopted multi-segment foot model where the inertial properties could be established,
limiting standardised adoption of a multi-segment kinetic foot model [99]. Attempts have
been made to calculate multi-segment joint kinetics using segmental inverse dynamic
models to divide the foot up based on the combination of segment coordinates and
compared to a single segment PiG model [121, 122]. In both studies, the single segment
foot model over reported ankle sagittal plane ROM of between 2.5 and 3.6 degrees, but
peak plantarflexion moments were not affected in either study [121, 122]. Both studies
were limited by small samples (n=10) therefore lacking the power to make any definitive
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conclusions. The methods used to calculate ankle joint kinetics and kinematics may
therefore be overly complicated in clinical research and a single segment approach
remains the most appropriate method to calculate ankle joint kinetics [121, 122].
2.2.1.1.3 In-shoe foot kinematics
The quantification of foot movement within footwear provides a further level of complexity
when modelling foot and ankle kinematics [123]. The use of shoe-mounted markers
make assumptions that foot and ankle kinematics are representative of foot movement
within the shoe, but there is an emerging body of evidence that suggests this is not the
case [123]. During activities such as walking and running, the foot moves within the shoe
presenting the possibility of larger inaccuracies of measurement in “true” foot position
relative to the 3D space incorporating error by under/over-reporting of kinematics.
Differences between the tibio-calcaneal kinematics of skin and shoe-mounted markers
have been investigated by Sinclair et al. (2013). Kinematics were measured using a 3D
analysis system with widows cut within an athletic running trainer [124].  Findings indicate
that shoe-mounted marker sets under-report foot kinematics during gait and therefore
have the potential to misinterpret foot and ankle kinematics.
Similarly, Alcantara et al. (2018) compared skin mounted calcaneus and footwear
mounted markers [125]. Significant differences (p=< 0.001) were reported in ROM with
shoe-mounted markers under-reporting ROM at the calcaneus by 5.9° sagittal, 1.5°
frontal and 1.5° in the transverse planes. Three 25mm holes were cut into the heel, which
has since been recommended as optimal hole size when collecting in-shoe data
supporting data collection methods. However, the proximity of holes raises questions
about shoe integrity which may increase movement within the shoe and therefore over
report kinematic data [126]. Observation of midfoot OA and subsequent pain have been
compared in barefoot and in gait shoe conditions [127]. A plimsoll with a 6mm thick
rubber sole unit and fabric upper contained windows to allow placement of a foot-
mounted OFM marker set. Hindfoot sagittal and frontal plane motion obtaining coefficient
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of multiple correlations (CMC) of 0.967 and 0.981, respectively. Halstead et al. (2016)
work contradict the findings of the previously mentioned studies in that both hindfoot
conditions were similar [127]. The shod footwear condition examined in a research
setting shows promise for the evaluation of in-shoe orthotic devices, but does not
represent the more structured footwear type used in clinical practice. Whilst limitations
are acknowledged by the author windows cut into the shod upper may have affected
structural shod integrity, therefore, incorporating measurement error. Also, the use of a
single kinematic trial for analysis is not the convention in gait analysis [111]. Higher
numbers of trials are reported to increase the reliability of gait parameters. Comparison
of a single trial to five representative trials reports lower values of repeatability and larger
variability in between subject values in single-trial studies [111, 128].
There are several limitations to the use of in-shoe foot modelling. Firstly, the size of the
window in which the marker is placed, secondly the type of markers used and thirdly
changes in the structural integrity of footwear when incorporating windows. Several
studies have used windows of varying sizes to analyse optimal size [125, 127, 129]. The
size of the hole within the shoe may introduce contact artefact with the marker fouled by
the margin of the shoe if too small, introducing error to the gait model. Bishop et al. (2015)
investigated shoe hole size effect on movement and segment motion of marker hole
fouling and contact artefact [126]. Three different footwear conditions were altered with
circular holes of different sizes (15, 20 and 25mm), with marker trajectories mounted on
wands placed through windows at the medial, lateral and posterior calcaneus and the 1st
and 5th MTP joints. Only marker placement in the 25mm condition did not exceed the
radius at all sites. Likewise, the 25mm condition was most similar to the barefoot
condition, with similar isotropy index scores, a measure of the marker movement within
the hole (no significant scores between conditions). Bishops et al. (2015) study used a
25mm wand that protruded from the hole with the marker mounted at the distal end. The
wand facilitated better clearance from the 25mm hole and they recommend that the wand
diameter should not exceed 4mm in width (compared to a standard 9mm marker) [126].
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Cutting larger holes in footwear appears to compromise structural integrity.  Loss of heel
contour stability of 10% has been reported by Butler et al. (2006) when cutting a single
hole in a shoe heel contour [126, 130]. It seems obvious that hole size and the amount
of material removed should be minimal for the chosen foot model. Removal of large
portions of the footwear upper that compromise shoe integrity may not be suitable for
more robust footwear such as a military boot [127, 131].
2.2.1.2 Biomechanics of ankle haemarthrosis and associated
haemarthropathy
Early observations of the biomechanical effects of haemophilia on the immature ankle
reported changes to the articulation position with gradual plantarflexion with hindfoot
valgus/varus and loss of ROM [8]. Changes in foot position as a compensatory
mechanism, caused by knee flexion deformity have been attributed to adaptive limb
length differences [77]. Biomechanical changes to the lower limb are further confounded
by muscle atrophy, neurological deficit, axial deformity and structural changes [86].
In children and adolescents, the biomechanical changes associated with haemarthrosis
and haemarthropathy are reported in only a small number of studies. Young children
aged 7-13 on prophylaxis treatment (n=14) with a target ankle joint, report similar
temporal and spatial and sagittal plane ROM to age-matched controls. However greater
mean knee ROM was reported in the haemophilia group of (22.2 SD 8.77°) compared
to normal (16.0 SD 6.08°; P< 0.05) with significant increases in knee flexion moments
(0.35 Nm/kg; P < 0.05), ankle plantarflexion moment (0.10 Nm/kg; P < 0.05) and hip
flexor moment (−0.31 Nm/kg; P< 0.05) in the haemophilia group. It is unclear if the
patients’ target joint was measured in isolation or both limbs were used to collect kinetic
and kinematic data.  This may have affected results with potential findings lost in the
inclusion of the unaffected limb. The biomechanical methods used are known to
incorporate error by how joint centres are defined, therefore moment data may not be
reliable in this small sample [101-103]. The treatment regime was not reported which
may have affected patients. A “target joint” would suggest that the cohort of participants
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were not adherent to treatment, or were undertreated therefore limiting the
generalisability of findings. However, changes in moments suggest whilst the clinical
signs of ankle joint pathology are low (≤2 of 25) there are measurable mechanical joint
changes [73, 132].
In older haemophilia children aged 11-18 years, significant differences in stance time
59.0% (1.3 SD) and 57.8% (1.4 SD, P<.03) and swing time 41.1% (1.3 SD) and 42.3%
(± 1.37SD, P<.03), are reported between control and haemophilia groups respectively
however the difference are small in magnitude despite significance [133]. No differences
were reported in sagittal plane kinematics at the ankles, knees and hips. Self-reported
bleed rates were collected, but with no clinical measure of joint health, it is unclear how
finds apply to biomechanical parameters in the absence of pathology. Data produced by
Suckling et al. (2015) and Stephensen et al. (2009) indicate whilst gait changes occur in
children and adolescents with haemophilic ankle haemarthrosis, they predominantly
affect ankle joint moments [73, 134].
In adults with established ankle haemarthropathy, biomechanical changes are more
apparent. Changes in both ankle joint structure and function do not present until later
years [132]. In one gait reproducibility study undertaken by Lobet et al. (2010), changes
were identified in adults (n=18) with severe and moderate haemophilia during the push-
off phase of gait ankle. Power generation decreased, with compensatory increases at
the hip and power absorption at the knee during swing. One incidental finding of the
study identified that over the 18 week period biomechanical parameters declined [135].
Calculation of mechanical lower limb workings (kinetic movement of segments in relation
to the bodies centre of mass) reported recovery index score a measure of the efficacy of
gait mechanisms to passively recovery energy whilst walking,  decline from 65.4% (SD
8.0) at baseline to 63.3% (SD 7.9) at follow-up (P=0.01) representing a 3.2% impairment
between visits [135]. The author suggests this decline represents the natural progression
of joint damage. Whilst the findings of this study provide insight into decline over time
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several factors may have influenced findings, such as pain levels, bleed incidence and
patients QoL.
Radiological, clinical and 3D gait parameters have been compared in adults with
haemophilia and ankle haemarthropathy. Foot function index-revised (FFI-R) subscales
of pain and stiffness were compared to ankle power, an objective 3D gait parameter that
can be used to represent ankle function [19]. No significant differences were reported
between clinical and radiological scores and ankle function and therefore clinical and
radiological scores alone did not predict joint function. In clinical practice, patients with
radiological evidence of ankle haemarthropathy continue to function reasonably well for
many years and therefore reliance on clinical and radiological measures alone may not
provide a true measure of function [77]. Lobet et al. (2010) concluded that radiological
and clinical scores do not properly integrate joint function, supporting the use of 3D gait
analysis as a measure of function in adults and children with haemophilia [135].
In the presence of multiple joint haemarthropathy, Lobet et al. (2012) using 3D lower limb
kinematics reported no changes at the knee, but a significant reduction in ankle ROM
(P<0.001) and hip ROM (P<0.001). Centre of mass variation in vertical displacement
was also significantly higher (P<0.001) resulting in lower muscle efficiency and increased
net energy consumption. Mechanical changes associated with multiple joint involvement
appear to lead to greater energy consumption, but in this study, cohort participants
adopted a walking strategy to compensate. In a similar follow-up study the impact of
ankle haemarthropathy was studied and its effect on energetic and mechanics of gait
[18]. When compared to healthy controls changes in kinetics and kinematics of the ankle
resulted in increased stance 64.1% vs 61.4% (P=0.012) in the ankle and control group
respectively. Kinematics at the ankle indicated significant mean changes at the ankle
during the push-off (third rocker) (−2.55° (0.82) P<0.001) with the ankle OA group
achieving a mean value of 16° of dorsiflexion compared to the control group of 28.7°.
Ankle peak plantarflexion moment (Nm/kg−1) was also higher (1.19, P=0.031) than the
control group (1.06). One explanation provided was the presence of bony deformity
31
limiting ROM. Additional work may be required from the proximal joints by means of
compensation, with lower knee peak flexion moments (P=0.001) positive hip flexor power
during early swing (P=0.001) and lower peak knee extensor moment (P=0.004) during
loading and lower peak eccentric knee extensor power during swing.
More recently, the association of MRI features of ankle haemarthropathy and clinical gait
features have been explored using multi-segment foot modelling. Eerdekens et al. (2020)
conducted an observational study of 48 ankles with ankle haemarthropathy [136]. A large
negative association was found between ankle joint peak power and MRI scores (ρ =
−0.631; p = <.001), based on increasing osteochondral sub-scores (P= −0.701; P=
<.001), the worsening severity of synovial hypertrophy (P= −0.507; P = <.001) and
progressive haemosiderin deposition (P= −0.400; P=0.005). Association was found
between osteochondral IPSG-MRI scores and ankle joint peak power absorption. The
results indicated that in the presence of ankle haemarthropathy, there is a reduction in
ankle joint mechanical loading during walking. Whist the sample size used in this study
was small (n=48 ankles/ 24 participants) the data provides insight into the mechanical
effect of severely damaged ankle joints. Specifically, in the presence of severe ankle
haemarthropathy, there is a decrease in absorption of power, potentially caused by pain,
muscle atrophy and/or weakness.
In people with haemophilia, kinematic analyses of sagittal plane motion have reported a
strong correlation with patient-reported ankle pain and changes in movement [18].
Haemarthropathic structural changes at the ankle joint are associated with a reduction
in peak power generation, reduced stride length and greater energy expenditure due to
compensatory gait changes at the hip and knee [18]. Function is further impacted by the
loss of muscle mass, muscular damage due to repeated bleeding and reduced activity
[137]. Loss of muscle mass and proprioception consequently proceed functional
impairment at the ankle. Finally, the proprioceptive changes lead to an inability to
maintain dynamic joint stabilisation and the functional inability to protect the ankle joint
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complex from ground reaction forces and shear further exposing the ankle to greater
biomechanical stress [53, 86, 137-139].
2.3 Management and treatment of ankle haemarthrosis and
haemarthropathy
The literature presented in section 2.3 provides an overview of the methods currently
adopted in the management of ankle haemarthrosis and the resultant haemarthropathy.
This section, therefore, contains an overview of physical, injectable and surgical
management of the ankle. Details of current research of foot orthoses and footwear
management of ankle pathology in haemophilia are also presented.
2.3.1 Physical rehabilitation
Maintenance of good musculoskeletal (MSK) health is paramount in the avoidance of
soft tissue bleeding and haemarthrosis. Multiple studies have now suggested physical
activity should be undertaken to maintain function, structure and good bone health [140].
Exercise as a prescription has been widely researched in haemophilia [141]. The ageing
population and the increased life expectancy of those patients on regular treatment now
increase the need for the management of multi-morbidities. The use of physical therapy
is well established in the management of ankle haemarthropathy and forms part of the
World Federation of Haemophilia (WFH) and UKHCDO recommendations for the
management of acute and chronic joint bleeds [25, 43]. Rehabilitation aims to reduce
pain, restore normal functional values of body strength, muscle tone, ROM and prevent
disability [142, 143]. Following acute episodes of soft tissue bleeding or haemarthrosis,
a period of immobilisation is recommended until the pain subsides. Rehabilitation is then
focused on the restoration of joint strength and mobility. In the acute stages of
haemarthrosis ‘protection, rest, ice, compression and elevation’ (PRICE) therapy forms
part of the UKHCDO guidelines [43]. Management in the initial stages of haemarthrosis
requires joint rest and protection to relieve acute pain and reduce the risk of repeated
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bleeding and prolonged exposure to blood products. Therefore a period of non-weight-
bearing at the ankle may reduce the risk of joint damage by reducing mechanical stress
to the ankle joint [144]. Diagnostic MSK ultrasound evaluation of joints following
haemarthrosis has identified that despite the subsidence of pain, the joint may still
contain blood products that exacerbate synovitis and change cartilage properties [145].
Deficiencies in proprioception have been identified following haemarthrosis resulting in
reduced joint stability which further supports the requirement for immobilisation.
Prolonged immobilisation may also have an impact on overall strength, ROM and
dynamic joint control, therefore immobilisation should be kept to a minimum or where
clinical symptoms of pain in combination with the restoration of ROM are evident [146].
No consensus has been produced on what is regarded as the optimum duration of
immobilisation. This is due to the variable nature and severity of presentation, although
the WFH recommend non-weight-bearing until the pain subsides, with empirical
evidence from Rodriguez-Merchan et al. (2008) suggesting non-weight-bearing for four
days [147]. In reality, the clinical presentation dictates the length of time non-weight-
bearing is required. In the presence of synovitis and ankle haemarthropathy,
maintenance of trough levels to halt bleeding is paramount. Where joint damage has
occurred, physical therapy recommendations from the UKHCDO are based on
identifying mechanical causes associated with arthropathy and referral for conservative
interventions such as radioactive synovectomy. Physical therapy maintains joint ROM,
prevents mechanical changes that increase the risk of haemarthrosis and
haemarthropathy and decreases patient-reported pain and disability and improves QoL.
2.3.2 Intra-articular therapy
Intra-articular (IA) therapy has been investigated more than any other approach in the
non-surgical management of foot and ankle OA [148]. A recent systematic review of IA
therapy in foot and ankle OA and RA reported 22 studies, but only five RCTs of IA
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injection therapy in foot and ankle OA. In haemophilia, IA therapies such as
corticosteroid, viscosupplementation and platelet-rich plasma (PRP) have the potential
to aid rehabilitation and reduce the burden of joint disease.
2.3.2.1 Corticosteroid
The use of IA corticosteroid is beneficial in the modification of disease activity and
suppression of joint inflammation in OA as an adjunct therapy [149]. In haemarthropathy,
evidence for use is limited to small studies and narrative reviews; orthopaedic
management of disease and clinical opinion on the effect demonstrate anecdotal benefits
between two and four weeks after injection [23, 150]. In a small study (n=10) of patients
who did not respond to CFC, IA injection of 80mg of methylprednisolone was used to
treat haemarthrosis induced knee synovitis. The patients were followed up over 12
months and demonstrated reductions in synovitis. Scoring methods used to describe
improvements and patient treatment regimens were not reported. Therefore over the 12
month period it is unclear if the IA corticosteroid reduced synovitis, or a change in CFC
treatment with higher troughs and different products were used, which would have a
direct effect on joint health by reduction of haemarthrosis [123]. The case series reported
by Martin et al. (2017) investigated the efficacy of US-guided IA corticosteroid joint
injection therapy in patients with haemarthropathy. In total 45 IA injections (14 ankles,
18 knees, and 13 elbows) were administered with reported reductions in pain VAS from
seven to one (P<0.001) over 12 weeks. Participants with more radiological changes
(higher Pettersson score) had a shorter therapeutic benefit, with 10-12 weeks of pain
relief [151]. The use of corticosteroids may therefore provide the most benefit where
synovitis is present and bone and cartilage damage is limited. This study concludes that
the use of ultrasound (US) guided IA corticosteroid injections for haemarthropathy is a
safe and clinically effective therapeutic intervention for pain [151]. No recommendations
for IA corticosteroid injection are included in the UKHCDO guidelines, although the
comment is made that in individual cases IA corticosteroid may provide short term
symptomatic relief [43]. In a condition that requires regular rehabilitation and
35
management of chronic pain, these short term benefits may provide a window of
opportunity to rehabilitate joints such as the ankle where pain and soft tissue fibrosis limit
full rehabilitation.
2.3.2.2 Hyaluronan
Hyaluronan is a viscosupplementation where hyaluronic acid is administered by IA
injection. Hyaluronan is used to restore the viscoelastic properties of the synovial fluid
as well as change the disease process of the joint by stimulating synovium production of
endogenous hyaluronic acid [108]. The effect of hyaluronan in OA and haemarthropathy
is theoretical and it is thought to inhibit tissue nociceptors, stimulate the production of
endogenous hyaluronan, anti-inflammatory and inhibit matrix metalloproteinase activity
[152]. In a long-term follow-up study of 46 patients with haemarthropathy, affected joints
were injected 3-5 times during a one to four week period. Improvement at six-month
follow-up in VAS, joint function and QoL scores were reported in eight of 10 elbows, 15
of 24 knees, but the most improvement was observed at the ankle (22 of 25 joints). At
the ankle, VAS scores were significantly reduced (p<0.05) compared to pre-intervention
at six months (5.22 to 2.50), as were WFH Score (6.72 to 5.61), SF-36 (53.54 to 75.43)
and ankle dorsiflexion (2.14° to 7.56°), but was not maintained at 12 months [153].
Caarulli et al’s. (2013) follow-up study evaluated the long-term effect of IA hyaluronan
over six years [152]. Participants with haemarthropathy of the knee (n=27) received a
minimum of two injections over six years. Again, VAS, SF-36, ROM and WFH score
improvements were observed at six months and up to 12 months, but as with the original
study returned to the pre-injection state after 12 months [152]. Results suggest the use
of hyaluronan may have benefit in the short-term management of ankle haemarthropathy
but high-quality evidence is required to underpin universal adoption of hyaluronan use,
However, the existing evidence provides insight into the potential benefits in early




PRP is a high platelet-rich plasma concentrate containing high levels of growth factors
that play a key role in the regeneration and stimulation of tissue healing, which includes
cell proliferation, matrix remodelling and angiogenesis [154]. Two studies to date have
investigated the effect of IA PRP in haemarthropathy [154, 155]. IA injection of PRP was
followed up over a two to six month period. Caviglia et al. (2017) reported improvements
in total HJHS from 15.750 (SD 0.729) to 9.786 (SD 0.671) over six months [154]. For the
ankle, Vladimir & Bobek (2014) reported improvement of ankle HJHS from a pre-IA
injection of 6.75 (3-12) and a reduction to 4.85 (1-10) after two month follow-up period
[155]. Outcomes, confirmed with MRI, demonstrated a reduction in thickening of the
synovial membrane and a dramatic decrease in joint effusion. MRI findings reported
haemosiderin levels within the synovium did not change, and therefore the risk of future
haemarthrosis complications may only be delayed. Pain measured by VAS (0-10) also
improved from a mean of 5.57 pre-injection to 1.21 at three months and 0.64 at six
months (p<0.001). In the shorter two month study by Vladimir & Bobek (2014), significant
reductions of 0.75 (P= ≤0.0001) between pre (2.85) and post (2.05) PRP were reported.
In both studies, PRP reduces pain, with the largest effect reported at six months, but with
small differences in pain reported over two months raises questions whether short term
reductions in pain are clinically meaningful. Data on the minimal clinical important
changes of pain in haemophilic synovitis of the ankle are yet to be established. In chronic
MSK pain intensity, a VAS change of one has been associated with “slightly better”
change and two as “much better” pain, therefore the significance of the VAS pain
reduction of 0.75 should be interpreted with caution [156]. The use of PRP may provide
potential therapeutic benefits in the short term management of synovitis, but based on
current evidence is unlikely to become part of routine clinical practice.
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2.3.3 Joint aspiration
The practice of aspirating blood products from a joint following intra-articular
haemorrhage is thought to reduce the volume of haemoglobin within the joint, and
therefore lessen the demands on the synovium and cartilage leading to an accelerated
rehabilitation time [57]. Knee joint aspiration at 24 hours and up to five days post
haemarthrosis are reported to make little difference to patient-reported pain, ROM and
knee circumference when compared to a control group [157]. The author reported
extreme pain and hypersensitivity of the knee during the procedure, where the joint
capsule was very swollen and tight. The author was reluctant to recommend the
procedure, concluding that aspiration in clinical practice would only be a consideration
once the joint became lax or moderately swollen. More recently the UKHCDO
recommend that aspiration should not routinely take place unless there is a suspicion of
septic arthritis. Where pain does not subside aspiration may be considered but only with
the correct haemostatic therapy cover [43].
2.3.4 Synovectomy
Synovectomy is a procedure performed in haemarthropathy to reduce the thickness of
the synovial line of the joint by ablation, or surgical removal [158]. Reduction in this
thickness leads to a reduction in the neovascularisation of the joint synovium and in effect
“resetting” the joint. The ankle joint is a common site for synovectomy due to the high
functioning nature of the joint [159].
2.3.4.1 Radioactive synovectomy
Radiosynoviorthesis or radioactive synovectomy refers to the restoration of synovia by
the local application of a radiopharmaceutical agent which emits Beta-radiation [160].
Radioactive synovectomy is indicated to prevent the progression of haemarthropathy by
restoring the synovial joint lining and reducing synovial hypertrophy [159]. Radioactive
synovectomy offers long term benefits to haemarthrosis in target joints or those with
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moderate synovitis, but several authors have raised concerns around the potential
hazards [161-163]. Radioactive isotope leakage from the joint, subsequently causing soft
tissue damage such as chromosomal changes and accumulation in other tissues such
as lymph nodes is of concern [161, 163, 164]. Safety reports have identified incidence of
isotope leak range from zero to 70% but without complications of malignancy [165]. A
recent Canadian retrospective analysis of 2412 haemophilia and rheumatology patients
who had undergone a radioactive synovectomy between 1976 and 2001 investigated the
incidence of cancer. In both haemophilia and RA, the risk of cancer development was
the same as the general population [163]. Recommendations for the most appropriate
time to perform a radioactive synovectomy is yet to be standardised. Where
haemophiliac synovitis is unresponsive to haematological treatment, a radioactive
synovectomy is recommended as soon as possible and before radiological evidence of
cartilage damage [43].
2.3.4.2 Surgical synovectomy
Reduction of synovitis by surgical approach is only indicated where there has been a
failure of consecutive measures or radioactive synovectomy to halt haemarthrosis and
reduce synovitis [166]. The surgical approach favours arthroscopy, by its nature is a less
invasive approach. Open surgery is only undertaken when significant synovial tissue
requires radical resection. Where advanced haemarthropathy leads to cartilage damage,
subchondral cyst formation and arthritic changes, typically narrowing of the joint space,
decreased joint ROM and pain make the effectiveness of radioactive synovectomy
limited in its therapeutic benefit. At this stage, joint surgery is indicated [150, 166].
2.3.5 Ankle surgery in haemophilia
Where conservative, pharmacological and radiopharmaceutical measures cease to
provide clinical benefit, surgical interventions are considered [8]. The main clinical
presentations of ankle haemarthropathy are a gradual drift of the foot into plantarflexion,
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soft tissue contracture, and gradual joint malalignment [53]. These structural and
functional changes leading to osteophyte formation at joint margins, worsening ankle
haemarthropathy and eventual chronic end-stage ankle haemarthropathy [150].
2.3.5.1 Joint sparing surgery
Surgical removal of the osteophytes formed on the posterior and anterior joint line is a
potential surgical treatment where functional ankle dorsiflexion has been lost or
increases the risk of haemarthrosis [8]. Worsening haemarthrosis occur which are
identified by loss of dorsiflexion and increased patient-reported pain but in reality, by this
stage, there is already significant cartilage bone damage and subchondral cyst formation
limiting the benefit of the procedure [75]. In ankle OA, arthroscopic debridement of
anterior ankle osteophytes, before the loss of joint space occurred, resulted in 90%
excellent or good results. However, in patients with ankle joint space narrowing only 50%
reported good results. In haemophilia, the clinical benefit is less clear. A review of ankle
management by Rodriguez-Merchan [167] indicates the use of osteophyte debridement
is a treatment option for patients with ankle haemarthropathy, however no detail of the
procedure, PROMs or measures of function are reported.
2.3.5.2 Ankle replacement
The use of TAR as a treatment for ankle haemarthropathy demonstrates good pain relief,
improved PROMs, and increase ankle function [168-170]. Traditionally haemophilia
patients undergoing TAR between the second and third decades of life are at a higher
risk of revision in later years. This has been attributed to increased rates of aseptic
loosening, deep sepsis and long-term consequences of failure and revision surgery [8].
There is now emerging mid to long-term evidence that TAR may be a viable treatment
option to reduce pain and retain a level of ankle function. In haemophilia adults with a
mean age of 44 years (SD12) short to medium term outcomes (4.4 years, SD1.7, range
2.2-9.4), of TAR (n=32 ankles) report maintained improvements in pain, function and
ankle alignment [171]. Similarly, medium to long term TAR follow-up (n=14), undertaken
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by Eckers et al. (2018) over a mean of 9.6 years reported improvement in pain. Measured
using VAS (0-10) patients reported pain levels of 2.9 with high levels of patient
satisfaction and increased ankle ROM which improved on average by a mean of 10.2
(SD16.5) degrees (P=0.037) [172]. Systematic review and meta-analysis of long term
TAR survival rates in (n=2239)  have identified with non-haemophilic ankle OA TAR
survival rates at 10 years of the median (95% confidence interval) 89% (95% CI 85 to
93). However annual failure rates of 3.2% (95% CI 2.0 to 4.4) [173]. The patients in Zaidi
et al. (2013) study was a mean age of 60 which is higher than haemophilia TAR
populations (43-44 years), and questions the longevity of TAR in ankle haemarthropathy.
If failure rates in haemophilia are similar to the general population then patients may
require conversion to ankle fusion at a much younger age, complicated by the loss of
bone at the implant site and increased surgical risk, therefore it remains a selective
treatment option [150].
2.3.5.3 Ankle fusion
Ankle fusion is the most common long-term treatment of chronic end-stage ankle
haemarthropathy where conservative treatments have failed [8]. Incidence of talocrural
joint fusion with subtalar joint fusion occurs in up to 26% of ankle fusion. Fusion of the
subtalar joint in isolation is reported between 16 to 30% of cases [74, 76]. Longitudinal
data of haemophilia patients who have undergone ankle fusion surgery (n=57) and
followed up over a mean of 6.6 years (range 4 months to 20 years) report VAS of 0.75
(1.3SD) indicated that those with long-term fusion have low levels of pain [76]. Likewise,
the American Orthopaedic Foot and Ankle Society (AOFAS) scores were 90.4 points
(8.6SD) which represents a positive outcome (100 best score). In a similar study
undertaken by Tsailas & Wiedel (2010), 20 ankle joints and subtalar (in isolation and
together) joint fusions were followed up over a mean of 9.4 (range 1-18) years [74].
Again, an improvement in symptom scores (modified Mazur score) were reported with a
symptom score of 94.9 (of 100) indicating excellent symptom outcomes. AOFAS scores
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indicate a favourable functional outcome and support the use of fusion in the long-term
treatment (>10 years) of end-stage ankle haemarthropathy.
Complications of ankle joint fusion in haemophilia occur due to post-operative bleeding,
infection and the complication of HIV infection. In addition, non-union rates vary
considerably with ankle fusion procedure failure rates in haemophilia reported as high
as one in four and as low as one in 75 procedures [167, 174]. Functional consequences
following fusion on the ankle joint in this patient group are not fully understood. The
mechanical consequences of fusion and the additional non-surgical and non-
pharmacological effect of postoperative management with devices, such as modified
footwear, are yet to be investigated to determine the long-term effect that they have on
patient-reported outcomes, proximal arthropathy of the knee and hip, and incidence of
bleeding.
2.3.6 Orthotic devices and footwear
2.3.6.1 Foot orthoses
In-shoe orthoses, insoles, casted insoles, functional foot orthoses (FFO) stirrup and
braces describe devices that exert, change or redistribute forces and pressures at the
shoe-foot interface and stabilise the ankle joint in the presence of pathology [20, 108].
To provide clarity, the terms FFO and casted orthoses will be used to describe
prefabricated and casted devices respectively in this section. Evidence supports the use
of in-shoe casted orthoses and FFOs in the prevention of foot deformity and provides
stabilisation in OA, IA and the management of the diabetic foot, but evidence for the
management of ankle haemarthropathy is limited [17-20]. Review articles recommend
the use of casted orthoses and FFOs in the management of ankle haemarthropathy,
many of which refer to the use of orthoses as an adjunct to physical therapy but without
any reported outcomes such as pain and functional changes [8, 21-25].
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The effect of FFO on pain in patients with ankle haemarthropathy has been investigated
[175]. Patients with haemophilia A (n=16) with varying levels of haemarthropathy
received a set of casted orthoses made of polypropylene and four degrees rearfoot
medial posting. Pre-intervention FFI scores were collected and repeated at a six weeks
follow-up. Paired t-tests were used to analyse the two time points using the FFI
subscales of pain, disability, activity and total FFI. Significant changes reported in pain
(p<0.05) and overall disability/pain FFI (P=<0.05) index suggests casted orthoses are
beneficial to people with haemophilia A, but in the absence of any clarification regarding
the participant's severity (mild, moderate, severe), inhibitor status or treatment regime
lessens the generalisability of the study findings. Those patients with less than 30
degrees of total ankle ROM were not included therefore excluding a large proportion of
ankle haemarthropathy participants where up to 80% of ankle function is lost by the third
decade of life [79]. Despite limitations in methodology, Slattery and Tinley (2001)
reported a reduction in the incidence of bleeding in the study cohort. Findings
represented not only the potential of casted orthoses as a non-pharmacological
treatment but also represented significant cost saving in CFC treatment and significant
benefit in participants QoL [158].
In the characterisation of rearfoot instabilities, Jorge et al. (2006) used plantar pressure
measurement to quantify changes attributed to the use of FFOs in combination with
airstrip devices and modified footwear to stabilise the ankle in the presence of
haemarthropathy [176]. In-shoe plantar pressure analysis was used to observe changes
in the centre of pressure (CoP) that have been reported in 43 haemophilia A and B
patients with ankle haemarthropathy. Changes in the medial and lateral variance of CoP
trajectory was reported indicating a more stable gait pattern with less variation in subtalar
joint movement [177]. Kinematic 3D data was not collected in this study so it is unclear
how reductions to the subtalar joint motion were attributed to CoP data only. In addition
to the functional changes, FFO reduced ankle AJBR six months following use of the
intervention. Unfortunately, as with Slattery & Tinley (2001) no analysis was performed
43
by Jorge et al. (2006) so it is unclear if functional and clinical changes were clinically
significant, however less variation in CoP is a potential positive finding where
haemarthropathy changes ankle and subtalar joint kinematics [175, 176]. The reduction
of ABR and AJBR is often reported as an outcome in FFO intervention studies in people
with haemophilia. Jorge et al. (2006) reported the reduction of spontaneous ABR in their
total cohort; ABR reduced from 175 to 40 but traumatic ABR bleeds increased from 32
to 67 (P=0.004). The reasoning for increases in traumatic ABR has been reported in both
studies and attributed to increased physical activity [175, 176]. The use of FFO alone
may be counter-intuitive in people with haemophilia, therefore when activity increases
the mechanical load on the ankle increases in pharmacological treatment may be
required [178].
Tanaka et al. (1996) used similar casted orthoses constructed in 20mm EVA with a
silicone heel cup to investigate whether the casted orthoses would be of clinical benefit
to those with ankle haemarthropathy [179]. The casted orthoses were used in
combination with modified footwear (11 participants) and elastic support (n=8), ankle-
foot orthoses (AFO) (n=5) and above knee AFO (n=1). Allocation of the additional
intervention was based on the severity of haemarthropathy and radiological scoring.
Secondary outcomes consisted of the average frequency of haemarthrosis, ankle ROM,
and X-ray imaging scored using a modified DePalma classification score, a haemophilia
specific score of early (grade I) to late-stage (grade IV) joint pathology [180]. The use of
casted orthoses did not affect activities such as walking or occupation and total ROM
improved but without a significant change. A significant change in the frequency of
haemarthrosis occurred when elastic supports were used; a mean of 4.0 (0.4 SE) to 1.8
(0.4 SE) bleeds per month (p<0.05) was reported. Interpretation of the results does not
provide any insight into the use of casted orthoses in haemophilia. The use of a validated
PROM may have provided further insight. The variation of interventions used (casted
orthoses AFO, footwear modification) limit the ability to provide any insight into a specific
intervention effect. The significance of reductions in the frequency of ankle
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haemarthrosis suggests that casted orthoses in combination with elastic supports and
modified shoes reduce ankle haemarthrosis. In addition to their orthotic interventions,
patients and parents received education on CFC infusion, prophylaxis regime (interval
of treatment) and changes to CFC dose in patients who had an increase in the frequency
of ankle haemarthrosis suggesting that the reduced frequency of haemarthrosis may be
a result of improved treatment regimens and maintenance of haemostasis confounding
results [179].
The effect of AFOs on unilateral ankle pain in haemophilia has been investigated by
Oleson et al. (2017) [181]. Participants with haemarthropathy were recruited to compare
two different ankle supports (fracture boot & Carbon fibre AFO) for a reduction in ankle
pain when compared to the unaffected limb (within-participant comparison) wearing a
standard trainer. Temporal and spatial parameters and an 11-point numerical pain rating
scale (NPRS) were used to assess function and pain. NPRS was significantly reduced
when both devices were compared to a standard shoe (p<0.05), with no brace scoring
2.71 (0.47 SE), fracture boot (1.26 SE) and the carbon fibre 1.09 (0.32 SE). However,
no difference was detected between conditions (fracture boot & Carbon fibre AFO). The
fracture boot significantly (p<0.05) increased step time, cycle time, and swing time when
compared to non-brace conditions [181].  Reported differences in pain, whilst significant
provided little insight into the effect on pain, as there is no minimally important difference
to challenge the significance of pain change. Both devices show potential in the
management of ankle haemarthropathy and may be more appropriate at the chronic
stages of haemarthropathy where stabilisation of the ankle joint has the potential to
reduce pain. Likewise in the early stages of joint haemarthrosis, immobilisation with
prefabricated AFO may provide a splinting action. Further investigation with larger
cohorts and more sophisticated measures of gait, such as 3D gait analysis, and health-
related QoL outcomes may provide insight into the mechanical effect of the intervention
and the gains in QoL where function is impeded and QoL is impacted by pain [8, 182].
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Few studies have investigated the kinetic and kinematic effect of orthoses in haemophilia
and haemarthropathy. Lobet et al. (2012) explored the functional impact of casted
orthoses used in combination with standard and orthopaedic shoes [14]. A cohort of
adults (n=16) with ankle haemarthropathy was compared at baseline and a mean follow-
up of 17 (+/-5) weeks. Changes were reported for external foot progression of 3.1
degrees (p<0.001), an increase of 0.32 W kg-1 (P=0.004) in peak concentric power during
the push-off phase of gait. The improvements in external rotation and foot abduction
represent a potential correction of compensatory mechanisms such as foot pronation
that allows the body to progress over the foot during stance in pathological gait [183].
The correction of the frontal plane composition may therefore allow a more linear
contraction of the gastrocnemius and soleus complex with improvement in peak
concentric power, but the lack of foot and ankle kinetic and kinematic data limits any firm
conclusion. FFI-R scores were not significant between conditions, only the subscale of
pain decreased by nine points in those patients who were satisfied with their casted
orthoses. Overall, the biomechanical impact between those who were satisfied/ not
satisfied with their casted orthoses was similar [14].
Several review papers have reported the use of foot orthoses in the management of
haemophilia. More specifically changes associated with ankle haemarthrosis, pain,
physical impairment, changes in the axis of ankle joint, and as an aid to rehabilitation
[150, 184, 185]. The use of silicone heel cups, whilst not a true orthotic device, does
have the potential to change lower limb biomechanics. Seuser et al. (1997) found the
silicone heel cup caused instability at the ankle joint, though no reasoning for this
conclusion was provided [186]. In clinical practice, the soft silicone heel cups typically
deform rapidly under load, and therefore would not be a treatment choice for the
management of ankle pathology due to the potential to decrease stability at heel loading.
There is potential for increased variability in front and sagittal plane ROM and therefore
increase the risk of soft tissue trauma and pain, but this was not reported. A combined
approach to the provision of foot orthoses and footwear have produced significant
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reductions in patient-reported pain and disability, with excellent patient satisfaction [15].
The combined clinical benefit of FFO and footwear are yet to be established in ankle
haemarthropathy. Research to date lacks the methodological design to ascertain the true
mechanical effect of the interventions in part as they have been used with other devices
such as ankle braces. Several review articles include the use of orthotic devices, but lack
clarity in their application, often including the intervention as an adjunct to physical
therapy and appropriate CFC therapy.
2.3.6.2 Footwear
When the anatomical rocker mechanism is impeded by pathological changes, modified
footwear may substitute the ankle rocker at heel strike, through to toe-off during the
stance phase of the gait cycle [187, 188]. Modified footwear is commonly used in the
management of conditions such as diabetes and RA, to prevent ulceration and improve
mobility and function in several conditions associated with impaired walking and
orthopaedic deformity [188-190].
Rocker profile shoes and solid ankle cushioned heels (SACH) are regarded as two of
the most common footwear modifications [191]. The majority of research on rocker profile
footwear concentrates on the offloading and redistribution of pressure associated with
the occurrence of diabetic foot ulceration [188]. In ankle haemarthropathy, a rocker
profile shoe has the potential to compensate for the reduction in ankle ROM by providing
a mechanism for the body’s centre of mass to progress over the foot during the stance
phase [188]. A heel-toe rocker whereby a negative heel rocker is used in combination
with a forefoot rocker has been suggested as the most appropriate configuration in the
presence of ankle OA or where ankle ROM is impeded [188, 192]. A double rocker sole
has been shown to decrease plantarflexion moment at midstance through to toe-off with
an increase of dorsiflexion ROM at MS [187]. A decrease in dorsiflexion was also seen
at the late stance phase and initial swing phase whilst maintaining normal walking speed
when compared to a normal shoe in healthy adults (n=40) [187]. A smaller study (n=17)
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of healthy control participants by Arazpour et al. (2013) also reported a reduction in
terminal stance timings [187, 193]. The use of a heel-toe rocker shoe similar to the shoe
used by Long et al. (2007) increased dorsiflexion by 9.2° when compared to a standard
shoe. Both studies support the use of a double rocker, or heel-toe rocker in the
management of ankle OA and arthrodesis but at the sacrifice of frontal plane motion that
increased in both studies. Long et al. (2007) reported a decrease in loading at midstance
that could not be accounted for due to movement of the foot within the shoe between
footwear conditions (standard and rocker) that cannot be measured by shoe-mounted
markers [187]. Arazpour et el. (2013) found a significant increase (p 0.023) in inversion
and eversion angles during second double limb support between standard shoe (16.8°,
SD 4.8) and rocker (26.8, SD 4.4) conditions [193]. Whilst the findings are positive, true
estimates of ROM are not captured by the biomechanical methods used and therefore
rearfoot frontal plane ROM may be under-reported as the foot moves within the shoe.
The study used two different footwear types, and no analysis of the carryover effect was
performed which may have affected results if a period of adaptation to the footwear
condition was not observed. To date, no follow-up study has been performed in patients
with ankle arthrodesis so it remains to be seen whether findings translate to pathological
ankle disease. The findings from both studies highlight the potential benefit of footwear
to manage biomechanical changes at the ankle joint. Therefore application of footwear
modification to ankle haemarthropathy cohorts warrant further investigation [187, 188,
193].
Originally designed for use in amputees and prosthetics, the SACH modification is
designed to allow a normal heel strike during the stance phase of gait. When applied to
footwear, a SACH creates a pseudo-plantarflexion moment by deformation underload
forces and is made of a material softer than that of a solid sole unit. Wu et al. (2004)
observed the effect of a “spongy” SACH modification in combination with a forefoot
rocker at 60% of a shoe [194]. During level walking participants experienced increase
dorsiflexion/plantarflexion at the hindfoot in relation to the tibia (30.2° (5.9°SD) vs 24.2°
48
(3.0°SD)) when compared to a traditional shoe. The addition of the rocker profile at the
forefoot only decreased ROM when compared to a forefoot and hindfoot (18.4° (6.3°SD)
30.1° (4.6°SD) rocker. The effect of SACH has been suggested to produce a pseudo
plantarflexion moment rather than a kinematic effect, therefore reporting of ankle
kinematics may have been strengthened by the reporting of ankle kinetics [192]. Rapid
heel to toe movement with an increase in varus and valgus angles was reported at the
rearfoot, with a total 5° increase in ROM may suggest the material used in the spongy
SACH deformed too rapidly underload. Participants suggested the SACH did not provide
enough cushioning, nor did it feel thick enough. More detail on the material may provide
more insight into the condition, but suggests a material that gradually deforms may be
more suitable.
To date, there is little empirical evidence to support changes in practice, or management
guidelines [14]. No research study has been undertaken in haemophilia to understand
the mechanical effect of modified footwear in people with haemophilia. Therefore the
mechanical benefit of such modifications in conjunction with in-shoe orthoses must be
undertaken in ankle haemarthropathy before findings become part of standard clinical
practice in comprehensive haemophilia care.
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2.4 Health-related quality of life
The literature presented in section 2.4 provides an overview of health-related QoL
(HRQoL) measures, patient-reported outcome measures and joint heath measures.
Further detail in the relevant sections of chapter four titled (The impact of blood induced
ankle arthritis in patients with moderate and severe haemophilia A and B: The HAPII
study).
The physical burden of haemophilia and haemarthropathy is significant. HRQoL or the
measure of the mental and physical burden provide a deeper understanding of a patient’s
QoL [195]. Those with severe haemophilia report worse QoL when compared to
moderate and mild haemophilia and the general population. HRQoL differences have
been reported to decline in haemophilia dependant on the severity of the disease [11].
Moderate haemophilia is associated with less burden, less physical limitation and
therefore patients typically report better HRQoL than those with severe disease, but
worse than those with mild disease [196]. Changes in joint status caused by
haemarthrosis and haemarthropathy are a significant contributor to the burden of
haemophilia and the associated effect of HRQoL [197]. In a cohort of 381 American
patients with severe to mild haemophilia, Kempton et al. (2017) investigated the reliability
of PROMs in the assessment of pain and functional impairment. Adults with a history of
haemarthrosis, and joint pain, and in a non-bleed steady-state were assessed using
PROMs, joint ROM and concurrent HJHS scores [10]. Median (IQR) SF-36 were lower
for the physical domains of physical function (44.4 (29.7-52.8)) physical health (39.2
(29.5, 49.4)) and body pain (41.8 (37.2, 51.1)). The author also reported participant
problems with mobility, usual activities and pain/discomfort subscales of the EQ-5D-5L
increased. However, only the EQ-VAS (0-100 best health) of 80.0 (66.0, 90.0) were
reported which indicates patients perceived their health status was generally good
despite chronic pain and correlate with a similar evaluation of pain in haemophilia [198].
This study provides detail of the effect of joint pain and functional limitation on HRQoL in
patients with a history of haemarthrosis. The ankle, identified as the most painful joint,
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accounted for 37.4% of patients most painful joints, followed by the knees (23.7%) and
elbows (18.9%), although HJHS (v2.1) scores did not differ significantly (4.0, 4.0 and 6.0,
respectively). This study was performed in the USA where a private healthcare model
differs to that of the UK NHS, but patients still receive the same levels of CFC under the
comprehensive care model [199]. Regardless, those on treatment who were classed as
“steady or not bleeding”, still reported reduced HRQoL, low HJHS scores but a higher
incidence of pain. Understanding how haemarthrosis and haemarthropathy of the ankle
contribute to overall health may provide further insight to the HRQoL. Use of a disease
specific and region specific QoL outcome measures may provide information of the
contribution ankle pathology have in modern haemophilia treatment. To date, no study
has evaluated the impact of ankle haemarthrosis and haemarthropathy on the HRQoL in
those with moderate and severe haemophilia A and B.
2.4.1 Outcome measures
2.4.1.1 Haemo-QoL-A
The HAEMO-Qol-A is an HRQoL score developed by consensus agreement to measure
the QoL in adults with haemophilia. Originally developed for use in the paediatric
population (Haem-Qol) the HAEMO-Qol-A was adapted through the agreement of an
international group conducted across multiple sites (USA, Canada, Germany and Spain)
[200]. The HRQoL measure is made up of 41 questions and scored by subscales of
physical function, role function, worry, consequences of bleeding, emotional impact and
treatment concern [201]. Each of the 41 questions is scored on a six-point Likert-type
scale ranging from 0 (None of the time) to 5 (All of the time). A higher score indicates a
better HRQoL or less impairment of that particular subscale or raw scores can be
combined to produce a total score (0-100) [200]. The HAEMO-Qol-A has shown good
internal consistency (Cronbach’s a 0.95) and reliability for each subscale and overall total
scores over a four-week period. Field validation results strongly supported the use of the
HAEMO-QoL-A as a clinical and research PROM. Systematic reviews of outcome
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measures in haemophilia have identified that the HAEMO-QoL-A has strong content
validity but only moderate evidence of cross-cultural validity [202, 203]. When compared
to the generic QoL measure of the SF-36, the HAEMO-QoL-A displayed moderate to
strong correlation, with pain, social function and role limitations displaying the largest
correlations with the SF-36 [200]. Whilst limitations in test-retest reliability and hypothesis
testing of the HRQoL measure have been identified, the HAEMO-QoL-A is the most
widely used and clinical validated measure of HRQoL in haemophilia [202, 203].
2.4.1.2 Haemophilia health joint status (HJHS)
The HJHS is an internationally developed and standard assessment tool in haemophilia
comprehensive care. Developed by the International Prophylaxis Study Group, the HJHS
was aimed at providing a standardised clinical tool for identifying changes in joint function
in haemophilia for children and later adapted for young adults (14-30 years) on
prophylaxis factor replacement therapy evolving over three versions to its most recent
version 2.1 [204, 205]. The HJHS evaluates upper and lower limb joint swelling, duration
of joint swelling, axial alignment, muscle atrophy, crepitus and active ROM [206].
Reliability of the HJHS inter-rated and retest reliability has been undertaken in eight
haemophilia children (4-18 years). ICC overall inter-rater reliability was good (ICC=0.83)
as was the intra-rater reliability (ICC 0.89) [204]. When compared to the WFH produced
Gilbert score, the HJHS provided better sensitivity to early arthropathic changes. The
use of the HJHS may be limited in developing countries where factor treatment is not
available, or the burden of haemarthropathy is greater and access to medical
professionals is limited [203, 204]. Regardless, the HJHS is adopted globally, adapted in
several different languages and used frequently as a clinical outcome measure in
pharmacological and clinical research [204, 207]. Whilst there is some discussion about
its sensitivity in the early stages of arthropathic changes, the accumulative nature of the
score provides insight into individual and total joint health, but the HJHS is yet to be
validated in adults (>30 years) who have more established arthropathy [79, 208].
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The HJHS ability to measure joint health in early and late-stage haemarthropathy has
undergone sensitivity analysis to detect soft tissue and structural joint changes when
compared to radiological modalities (X-ray, MRI, US). In severe haemophilia and von
Willebrand’s disease good correlation has been reported in adolescence (15 years, 5-
17) with haemarthropathy (n=51) of varying levels of arthropathy measured by the
Pettersson radiological score [209]. Good correlation was reported between the
Pettersson score and HJHS (rs =0.66), and at the knee (rs = 0.75: 95% CI (0.58 to 0.85)
but only moderate correlation with the ankle joint [rs = 0.49: 95% CI (0.28 to 0.66)].
Therefore the HJHS may under-report actual ankle joint changes. When compared to
MRI and US, the HJHS was unable to identify pathological changes in joints that
appeared normal, but as the pathological state deteriorates, the HJHS may provide more
information in combination with radiographs. Poonnoose et al. (2016) concluded that
knee and ankle HJHS of less than three or ‘near normal’ joints may require the use of
additional US or MR imaging to determine arthropathic changes [209]. Where
haemarthropathy becomes more advanced, the use of the HJHS and radiographs
becomes more informative. Although limitations have been identified in ankle scores, it
is still the most widely used clinical score of joint health and currently, the HJHS score is
a clinical treatment requirement for all UK registered severe haemophilia A and B
patients for both children and adults with severe haemophilia [13].
2.4.1.3 Foot and ankle patient outcome measures
Whilst disease-specific and general QoL measures provide insight into current disease,
region-specific outcome measures allow the evaluation of the effect on specific MSK
areas such as the ankle and foot [210]. To date, only three measures of foot pain have
been used in clinical studies and service evaluation of haemarthropathy treatment and
management. The Manchester foot pain and disability index, FFI and the foot FFI-R short
form have been used to report differences in treatment and intervention studies [15, 19,
175]. Whilst all three PROMs are frequently used to measure foot pain, function,
psychosocial and QoL, in a condition characterised by haemarthrosis of the ankle joint,
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the language used i.e. foot pain may limit its use in understanding ankle pain and
disability. In clinical practice, patients distinguish foot pain and ankle pain as two
separate entities, therefore using PROMs that are specific to the ankle haemarthropathy
may provide more accurate information to ankle outcomes [211, 212]. The Manchester–
Oxford Foot Questionnaire (MOXFQ) (foot and ankle) was developed as an outcome of
foot and ankle surgery and more recently used in clinical trials of interventions such as
orthoses [213, 214]. The MOXFQ is a patient questionnaire consisting of 16-items related
to walking/standing, social interaction and pain, of the foot and later adapted to include
ankles (pain in your foot/ ankle) [214]. MOXFQ consist of three domains,
walking/standing (seven questions), pain (five questions) and social interactions (four
questions).
Evaluation of an index or total score created from the subscales of the MOXFQ yielded
greater precision when compared to the SF-36. Measurement properties of the MOXFQ,
originally tested in relationship to hallux valgus surgery performed well in patients
undergoing surgery and when compared to the generic 36-item Short Form Survey (SF-
36) and AOFAS [215]. Pre and 12-month postoperative scores of the outcome measures
identified that the MOXFQ effect size was greater than those obtained from the SF-36
and AOFAS, with satisfactory to optimal Cronbach’s alpha (>0.7, range 0.80-0.90)
representing internal validity of all MOXFQ subscales. Whilst the MOXFQ was
constructed of the three domains of walking/ standing, pain and social interaction a
summary score has been produced more recently to provide a single index measure that
reports an overall indication of the foot and ankle outcome [213]. The reliability of the
summary score assessed using Cronbach’s alpha was high (0.93) indicating internal
consistency of the three domains. Similarly, when compared to the SF-36 the summary
score attained moderate correlations (R* 0.34 to 0.70) with the relevant domains
(physical function, role physical, social function and energy/vitality) all of which were
clinically and statistically significant (P=<0.001) in the evaluation of overall impact and
support the validity of the index scores use. The findings of Morley et al. (2013) therefore
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support the validity of the index score in the assessment of the impact of foot and ankle
disease. The MOXFQ has been validated and widely used as a pre and post PROM of
foot and ankle surgery and more recently conservative intervention studies including
ankle-foot orthoses (AFO) [216]. In addition, the MOXFQ has been converted to multiple
languages and cross-cultural validation has been undertaken [217-219]. A recent
systematic review that investigated the measurement of PROMs in foot and ankle
disease concluded that the MOXFQ had the best overall, psychometric properties,
internal consistency, reliability, measurement error, structural, convergent, discriminant,
discriminative validity and responsiveness [220].
The MOXFQ is yet to be utilised in haemophilia clinical practice or research, but the
addition of the term ankle in questionnaire construct (pain in ankle/foot) lends itself to a
condition where pathology is predominantly the talocrural joint such as ankle
haemarthropathy.
2.5 Summary
Haemophilia is an X-linked recessive genetic disorder characterised by bleeding into soft
tissue and joints. In those with severe and moderate haemophilia CFC is used to halt or
reduce the risk of spontaneous and traumatic bleeding. Whilst prophylaxis has
decreased the burden of haemarthropathy, treatment is still sub-optimal across
European countries. Bleeding within the MSK system accounts for 90% of all bleed
incidents in haemophilia, with the ankle to date the most commonly affected joint,
previously identified as being the site for 20% of all MSK bleeds. The high incidence of
ankle haemarthropathy and changes to structure and function of the ankle joint can be
attributed to episodes of haemarthrosis. Changes to the joint initiated by synovitis,
synovial hypertrophy, cartilage, and bone damage lead to structural changes that can
result in loss of 80% ROM at the ankle by the third decade of life with significant patient-
reported pain and disability. Despite this, the true prevalence and impact of ankle
haemarthrosis and haemarthropathy are yet to be established. The structural and
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functional changes to the ankle joint result in pathological biomechanical changes in the
lower limbs. Footwear and functional foot orthoses have the potential to change patient
HRQoL, pain and disability but to date, there has been limited research of significant
academic quality to inform practice or change clinical guidelines. Orthotic devices such
as FFO and modified footwear have the potential to reduce the burden of ankle
haemarthropathy. Research to date is limited by methodological design and inadequate
sample sizes. Methods of functional analysis, such as kinetic and kinematic data
collection have become more sophisticated allowing more subtle understanding.
Investigating the mechanism of action of these interventions is required before wider use
in the haemophilia population.
Understanding the prevalence, impact of ankle haemarthrosis in moderate and
severe haemophilia will lead to a better understanding of the condition.
Establishing the mechanism of action of a potential intervention will enable future
research and targeted intervention in the management of ankle haemarthropathy.
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Chapter 3  - The prevalence of ankle haemarthrosis in moderate
and severe haemophilia A and B
This chapter describes the prevalence of ankle haemarthrosis in the UK adult population.
Data were obtained from the UKHCDO national haemophilia data analysis group to
establish the prevalence of haemarthrosis and levels of concurrent haemarthropathy at
the ankle and other commonly affected joints. The pathological process of
haemarthropathy has been discussed in the chapter two literature review, therefore this
introduction will provide a brief background of haemarthrosis and the current UK and
European trends.
3.1 Introduction
Haemarthrosis is an inherent clinical feature of severe haemophilia, a disease
characterised by spontaneous and traumatic bleeding. Musculoskeletal bleeding is the
most common haemorrhagic manifestation of severe haemophilia, with 90% of bleeds
occurring in muscles or joints [1]. The presence of blood products within the joint space
and the process of removal leads to synovial hypertrophy, haemosiderin deposition and
eventual arthropathic joint changes [46]. Over time the biological burden of repeated
haemarthrosis results in changes to cartilage, bone composition and progressive chronic
haemarthropathy [3, 4]. In joints, including the ankle, changes to the structures caused
by haemarthropathy inhibit joint function and are particularly prone to re-bleeding [59,
60]. The resultant haemarthropathy of affected joints is a cause of significant pain,
disability and detriment to health-related quality of life (HRQoL) [44, 46].
Regular treatment with replacement or bypassing clotting factor concentrates (CFC) are
termed prophylaxis [1]. The aim is to maintain a factor level or equivalent (bypassing
products) that halts spontaneous and traumatic incidence of bleeding. Primary
prophylaxis with CFC are the treatment regime of choice in the developed world and
form part of the treatment guidelines for the UKHCDO and World federation haemophilia
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[31, 221]. Standard factor treatment is effective at decreasing the frequency of bleeding.
Evidence in young children has shown that prophylaxis is effective at the prevention of
joint damage and bleeding events, but does not protect against all incidences of bleeding
[32-34]. Traditionally, prophylactic treatment in severe haemophilia aims to maintain
factor VIII (FVIII) or Factor IX (FIX) at a trough level >0.01 IU/ml. It is apparent that many
patients experience spontaneous as well as traumatic bleeds despite achieving trough
factor levels > 0.01 IU/ml. In recent years treatment options have improved dramatically
with the development of personalised treatment regimens with standard half-life (SHL)
products. Specialist laboratory testing and pharmacokinetic (PK) profiling has also been
shown to effectively predict CFC treatment effect and individual half-life profiles. PK
profiling, therefore, models the derogation of clotting factors and change dosing and
frequency [222, 223]. For example, if treatment is taken at night levels may drop to a
level that increases the risk of bleeding such as exercise or work-related activities the
following afternoon. Extended half-life products (EHL) have similarly been shown to
maintain trough levels by 1.6 to 1.8 times SHL products, but the treatment is yet to
definitively improve outcomes [49, 224-226].
Primary prophylaxis, the treatment of children for those age three years, without clinically
detectable joint damage was not a treatment option for many older adults with
haemophilia. Subsequent mistrust of treatment caused by contaminated blood products
meant those individuals adopted on-demand treatment by preference or only when
deemed necessary [227]. The introduction of recombinant clotting factor concentrates, a
synthetic (recombinant) factor replacement product and reduced treatment burden
(fewer infusions) have seen increased uptake in prophylaxis in older children and adults,
defined as secondary prophylaxis but multi-joint haemarthropathy is often a common
feature in this group [228]. In the presence of established haemarthropathy Collins et al.
(2010) investigated the efficacy and safety of secondary prophylaxis in adults aged 30-
45 years with severe haemophilia A. The authors reported a treatment dose of 20-40 IU
kg-1 three times per week led to a significant reduction in the incidence of haemarthrosis.
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Annual bleed rate (ABR) reductions and improvements in health-related QoL were
significant when compared to on-demand treatment. Whilst joint health stabilised no
definitive conclusions on the effect on joint health could be reported, but appropriately
dosed secondary prophylaxis treatment regimens are clearly beneficial were
haemarthropathy is present [2, 49].
Evaluation of real-world clinical treatment regimes in severe and moderate haemophilia
in the UK and Europe, have shown that despite adequate CFC availability, treatment is
still suboptimal. In 2015, data from the United Kingdom National Haemophilia Database
(NHD) reported median (IQR) ABR/ annualised joint bleed rates (AJBR) in children (0-
11y) and adolescents (12-18y) of 1.0 (0.0-0.5)/ 0.0 (0.0-1.0) and 2.0 (0.0-7.0)/ 1.0 (0.0-
3.0), respectively. ABR in adults with severe haemophilia A on prophylaxis were 2.0 (IQR
0.0-7.0) and AJBR were 1.0 (IQR 0.0-4.0) with only 29% bleed free and 34% joint bleed
free [4]. Similarly, European (Belgium, France, Germany, Italy, Spain, Sweden, and the
UK) data shows a median AJBR of 1.0 – 4.0. [3, 4]. However, data on the bleed frequency
and severity of haemarthropathy at an individual joint level is lacking. Likewise, the
reporting of Haemophilia Joint Health Score (HJHS) lacks the specificity to identify the
clinical impact on individual joint health and disability, especially the ankles that are often
more problematic [9, 18].
The main sites of haemarthrosis are the elbows, ankles and knees, with the shoulders,
wrists and hips less common affected and therefore not collated by the NHD or recorded
as part of the HJHS [9, 206]. The ankle has previously been cited as the most common
site of haemarthrosis in boys with severe haemophilia A and continues to be identified
as a problematic joint in the physical and pharmacological management of haemophilia
[9, 229]. The increased uptake of prophylaxis and new emerging treatments means the
prevalence of joint haemarthrosis, and incidence at each joint and joint health status of
interest is unknown. This study, therefore, aims to establish the current prevalence and
incidence of ankle joint haemarthrosis and its relationship to other commonly affected
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joints of the musculoskeletal system. Understanding the distribution, incidence and
prevalence of haemarthrosis and joint health in adults deemed compliant with
prophylaxis may provide direction for future pharmacological research and targeted
interventions; including non-pharmacological interventions and intra-articular therapies
commonly used in the management of MSK conditions.
3.2 Aims
This study aimed to identify the current prevalence and incidence of haemarthrosis in
the ankle and other commonly affected joints in adults with moderate and severe
haemophilia A and B. In addition, this study aimed to explore total and individual HJHS
a clinical measure of joint structure and function, therefore impact on the MSK system.
Exploration of the HJHS in combination with AJBR data will provide the current
prevalence and incidence of ankle haemarthrosis and the clinical impact on joint health
in the adult moderate and severe haemophilia population.
The specific aims of this study are as follows
I. To establish the prevalence and incidence of ankle haemarthrosis in adults
with moderate and severe haemophilia by obtaining UKHCDO, NHD data
from those deemed Haemtrack compliant.
II. To compare prevalence and incidence of ankle haemarthrosis to other
commonly affected joints of the musculoskeletal system.
III. To report HJHS concurrent joint health, the severity of haemarthropathy at
the ankle and other reported joints.
3.3 Participants and Methods
Ethical approval was obtained on 24th January 2017 (IRAS: 206141, R&D: PD16/227)
as part of the HAPII study investigating the prevalence and impact of ankle
haemarthrosis in severe and moderate haemophilia (Chapter Four). Once ethical
approval had been obtained, the application was submitted to the NHD Data Analysis
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Group to obtain NHD data. The application was considered on 14th June 2019, with
approval granted on the 12th of July 2019. Data were requested from all adult patients
(≥18 years) with severe (<0.01 IU/mL) and moderate (≥0.01, <0.05IU/mL) inhibitor and
non-inhibitor status with haemophilia A and B registered in 2018. Data from people with
moderate haemophilia did not meet the required numbers of participants for inclusion
and were subsequently excluded from the report.
prevalence, incidence and joint site data were collated retrospectively from Haemtrack
and HJHS from the NHD. Therefore, data were reported in adults aged 18 years and
above with severe haemophilia A and B (FVIII or FIX <0.01 IU/mL) without a current
inhibitor, issued with CFC in the UK between the 1st January and 31st December 2018.
Regular prophylaxis was defined for those using standard half-life (SHL) prophylaxis as
>=2 infusions per week for Haemophilia A, and >=1 infusions/week for haemophilia B.
For those using extended half-life (EHL) products, regular prophylaxis was defined as
>=1 infusions/week for haemophilia A, and >=1 infusion every two weeks for haemophilia
B for >45 weeks/year. Those included in the analysis were Haemtrack compliant (defined
as recorded use of ≥75% of received CFC) with a corresponding electronically recorded
HJHS Version 2.1. Haemtrack is a UK national online treatment diary whereby individual
patients regularly report details of treatments with CFC, including the reason for each
treatment such as prophylaxis or bleed treatment and the site of each bleed [230, 231].
The online diary records data on CFC delivered or collected from a patients
comprehensive care centre (CCC) or haemophilia treatment centre (HC). Once clotting
factor concentrates have been administered the patient should then record that particular
treatment episode using the Haemtrack app or website. The most recent UKHCDO
bleeding statistics report 2018-2019 reported median compliance at CCC and HC of 90%
and 93% respectively [232]. Whilst the compliance of record-keeping varies by patient
and centre the NHD require patient treatment delivered, or collected by the patient CCC
and HC. Treatment is recorded by a data manager for each CCC/HC, and uploaded to
the NHD quarterly. When the treatment has been self-administered by the patient they
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are then required to report each individual episode on Haemtrack. A >75% threshold of
treatment delivered or collected vs administered by the patient as the minimum inclusion
criteria and therefore available for data analysis [4, 231]. Data recorded in Haemtrack
are then integrated with NHD. Data is monitored to ensure the safety of treatment such
as ineffective treatment, or complications such as inhibitor development at the individual
centre and national level. The NHD use data to improve the care of patients with bleeding
disorders, NHS clinical treatment services and provide data that informs treatment
funding and safety [230].
The HJHS is used globally as a measure of joint health status in patients with severe
haemophilia and the UKHCDO haemophilia management guidelines recommend that
this is completed every 6-12 months [204, 233]. The HJHS is a standardised clinical
assessment tool developed to evaluate upper and lower limb joint health and status
[204]. Measures include joint swelling, alignment, range of motion, muscle atrophy and
crepitus; it has shown good inter-rater (ICC=0.83) and intra-related (ICC=0.89) related
reliability in children and young adults [205, 206, 220]. In the prediction of joint status,
the HJHS has shown a correlation with Pettersson radiological scores. Correlation is
reported as good at the knee (rs = 0.75: 95% CI (0.58-0.85) but only moderate with the
ankle joint (rs 0.49: 95% CI (0.28 – 0.66) [209]. Whilst limitations have been identified in
ankle scores, the HJHS is yet to be validated in adults (>30 years) but it is the most
widely used score of joint health in haemophilia. The HJHS Version 2.1 is collated as six
individual joint scores (0-20) and compiled with a global gait score (0-4) to a total score
(0-124), with higher HJHS representing worse joint health. Workshops have been
conducted in the UK to decrease inter-centre variability in HJHS scoring. Where HJHS
is recorded electronically by the local haemophilia centre, it is available to the NHD to
analyse and uploaded by a local data manager at CCC and HC. The prevalence of joint
bleeding was determined by the proportion of patients who reported haemarthrosis over
the 12 month study period. The incidence of new episodes of haemarthrosis at each joint
over the 12-month study period was captured by the AJBR. Joint bleed prevalence (%)
62
for adult patients AJBR incidence and HJHS were collated from Haemtrack and NHD.
Joint bleed prevalence, AJBR and HJHS are reported for all joints (total) and in each
joint.
3.4 Analysis
Analyses were undertaken by the NHD and a descriptive summary was produced as per
the NHD data reporting process. Data presented describes adult males (≥18 years) with
severe haemophilia A and B (FVIII or FIX <0.01 IU/mL) without a current inhibitor issued
with CFC between 1st January and the 31st December 2018. Participants were
Haemtrack compliant and had fully itemised HJHS during the study period. Data were
summarized by mean, standard deviation (SD) median, and interquartile range (IQR, 25-
75 percentiles) with age calculated at the midpoint of the study period. The primary
outcome of this study was haemarthrosis prevalence [n (%)]. AJBR incidence and HJHS
were reported for all joints as a total score (total), and at an individual joint level (ankle,
knee and elbow) by side (left/right).
3.5 Results
During 2018, 2338 individuals with severe haemophilia A (n=1889) and B (n=349)
without a current inhibitor were registered with the NHD and 1396 were registered with
Haemtrack. Simultaneous Haemtrack and electronically recorded fully itemised HJHS
data were available for 273 of which 176 individuals were adults (Table 1). 86.81%
(n=157) of the sample were patients with haemophilia A and 13.19% (n=19) were
patients with haemophilia B. Median (IQR) age in the haemophilia A sample was 40 (29;
50) and haemophilia B was 45 (25; 48) years.
Prophylaxis compliance as defined in section 3.1 was high, with 96% of haemophilia A
and all haemophilia B patients compliant with their individual treatment regime.
Treatment characteristics of those sampled using SHL and EHL products report that in
haemophilia A 23% (n=36) of adults used an EHL product and during the 12-month study
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duration 4% (n=6) switched from an SHL to EHL product with the remained treated by
SHL products (73%, n=115). In the cohort of Haemophilia B patients, 42% (n=8) used
an EHL product, 26% (n=5) switched from an SHL to an EHL product and the remainder
were treated with an SHL product (32%, n=6).
3.5.1 Joint bleed prevalence and annualised bleed rate
The combined total of joint bleed prevalence and AJBR and incidence by the site (Ankle,
knee, and elbow) and side (left and right) are presented in Table 1 by haemophilia type
(A and B). In this study prevalence of 59.9% and 42.1% were reported in haemophilia A
and B respectively, reporting at least one bleed over the 12 month study period.
Combined AJBR incidence is presented in Table 1 indicating ankles are the most
frequent site of haemarthrosis.
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Joint bleed prevalence n (%) 94 (59.9) 8 (42.1)
Annual joint bleed Rate
Mean (SD) 3.90 (7.00) 2.04 (3.59)
Median (IQR) 1.0 (0.0;4.4) 0.0 (0.0;3.5)
Right
Ankle
Joint bleed prevalence n (%) 27 (17.2) 2 (10.5)
Annual joint bleed Rate
Mean (SD) 0.38 (1.06) 0.16 (0.51)
Median (IQR) 0.0 (0.0;0.0) 0.0 (0.0;0.0)
Left ankle
Joint bleed prevalence n (%) 35 (22.3) 2 (10.5)
Annual joint bleed Rate
Mean (SD) 0.61 (1.98) 0.11 (0.33)
Median (IQR) 0.0 (0.0;0.0) 0.0 (0.0;0.0)
Right
knee
Joint bleed prevalence n (%) 27 (17.2) 2 (10.5)
Annual joint bleed Rate
Mean (SD) 0.41 (1.48) 0.53 (2.08)
Median (IQR) 0.0 (0.0;0.0) 0.0 (0.0;0.0)
Left knee
Joint bleed prevalence n (%) 24 (15.3) 2 (10.5)
Annual joint bleed Rate
Mean (SD) 0.29 (0.96) 0.21 (0.72)
Median (IQR) 0.0 (0.0;0.0) 0.0 (0.0;0.0)
Right
elbow
Joint bleed prevalence n (%) 29 (18.5) 3 (15.8)
Annual joint bleed Rate
Mean (SD) 0.39 (1.12) 0.28 (0.78)
Median (IQR) 0.0 (0.0;0.0) 0.0 (0.0;0.0)
Left elbow
Joint bleed prevalence n (%) 35 (22.3) 2 (10.5)
Annual joint bleed Rate
Mean (SD) 0.81 (2.38) 0.17 (0.53)
Median (IQR) 0.0 (0.0;0.0) 0.0 (0.0;0.0)
Joint bleed prevalence (%): Numerator= number of patients who had bleeds, Denominator= total cohort number. *Patients may have
reported bleeding at more than one joint over the 12 month study period
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3.5.2 Haemophilia joint health scores
HJHS are presented in Table 2 as all recorded joints combined (total), and individual
joint score by the site (ankle, knee, elbow), and side (left/right). In adults total median
(IQR) HJHS were higher in haemophilia A with a total HJHS of 18.0, (6.0; 31.0) when
compared to 11.0 (5.0; 24.0) for haemophilia B. At an individual joint level, both mean
and median ankle HJHS (3.8, 4.0) were higher than for the knee (2.9, 1.0) and elbow
(3.3, 1.0). Likewise, IQR was higher in the ankles (0; 8.0).





Mean (SD) 21.2 (16.8) 15.4 (15.1)
Median (IQR 18.0 (6.0;31.0) 11.0 (5.0;24.0)
Right Ankle
Mean (SD) 4.6 (4.2) 3.6 (4.1)
Median (IQR 4.0 (0.0;8.0) 2.0 (0.0;7.0)
Left ankle
Mean (SD) 4.6 (4.3) 4.8 (4.1)
Median (IQR) 4.0 (0.0;8.0) 4.0 (1.0;8.0)
Right knee
Mean (SD) 2.7 (3.9) 2.5 (4.6)
Median (IQR) 1.0 (0.0;4.0) 0.0 (0.0;1.0)
Left knee
Mean (SD) 2.9 (4.1) 1.3 (2.2)
Median (IQR) 1.00 (0.0;5.0) 0.0 (0.0-2.0)
Right elbow
Mean (SD) 3.3 (4.1) 1.3 (2.6)
Median (IQR) 1.0 (0.0;7.0) 0.0 (0.0;1.0)
Left elbow
Mean (SD) 3.2 (4.2) 2.1 (4.0)
Median (IQR) 1.0 (0.0;6.0) 0.0 (0.0;1.0)
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3.6 Discussion
This study aimed to examine the current joint bleed prevalence and incidence of
haemarthrosis, with a particular focus on the ankle in adults with severe haemophilia A
and B, without a current inhibitor. The impact of haemarthrosis on ankle health and its
relationship to other commonly affected joints were collated to provide insight into the
effect of haemarthrosis on joint health.
Data presented in this chapter identifies that despite prophylaxis, the prevalence of
haemarthrosis in those with severe haemophilia without a current inhibitor and compliant
with treatment has seen only minor reductions in the incidence of haemarthrosis despite
advances in treatment [4]. Whilst the incidence of haemarthrosis is evenly distrusted
amongst the most commonly affected joints of the upper and lower limbs, those CCC
and HC reporting concurrent HJHS indicate that the ankle joint is disproportionately
affected by haemarthropathy.
Mean and median AJBR totals (Table 1) were higher in people with haemophilia A than
haemophilia B. Total joint bleed prevalence of (Table 1) 60% and 41% respectively
indicate that those patients deemed the most compliant with recording treatment
experienced a minimum of one haemarthrosis over the 12 month study period. Study
results are consistent with published data that a higher prevalence of joint bleeding
occurs in haemophilia A [1, 4]. Those with haemophilia B have a less severe bleeding
phenotype, lower bleed frequency and better long term outcomes [234, 235]. Ultimately
haemophilia treatment aims to prevent all incidences of bleeding, but low rates of
haemarthrosis may be unavoidable with current haemophilia treatments [236].
Based on the haemarthrosis prevalence in 2018 a single incidence of joint bleeding may
have detrimental effects on joint cartilage, leading to the deterioration of joint health [237-
239]. Our study only reports data from a single year and cannot describe previous
haemarthrosis data in this cohort. Therefore we are unable to report the previous bleed
profiles of those included in this study or provide a direct causal effect of a single
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haemarthrosis. Relatively small volumes of blood have been shown to cause changes in
cartilage matrix properties and in vitro cartilage exposures of blood products as low as
10% cause irreversible damage at two days after exposure [62]. Furthermore, where
joint health continues to deteriorate the concept of low-level bleeding, micro-bleeding
and subclinical bleeding have been proposed as a mechanism by which joint health
continues to decline [46, 55]. Low-level incidence of clinical undetectable joint
haemarthrosis may be sufficient to initiate or maintain primary effects of blood exposure
by haemosiderin burden and pro-inflammatory markers causing secondary effects to
synovitis and pro-inflammatory cytokines and proteases. There is yet to be any definitive
study that supports clinical non-detectable haemarthrosis as a significant contributor to
the decline in joint health [52, 240]. The results of this study, whilst descriptive support
the notion that whilst bleed rates are low in established haemarthropathy and where
treatment compliance is high bleeding still occurs. In joints that are already burdened
with arthropathic changes, this single joint bleed event may be sufficient enough to
overload the joint with inflammatory markers, exceed the capacity of synovial removal of
haemosiderin and initiate further joint decline.
AJBR incidence presented in Table 2 are slightly lower than that of the THUNDER study
that, produced three years earlier from the same NHD database [4]. Scott et al. (2019)
identified that patients with severe haemophilia receiving prophylaxis and compliant with
Haemtrack (n=607) reported a median AJBR of 2.0 (0.0-6.0) of adults aged 19 and
above. The median AJBR is similar in our study cohort of 1.0 (0.0; 4.4) hence in the three
years between the THUNDER study there has only been a slight decrease in AJBR. In
this 2018 NHD cohort around a quarter of those sampled used EHL products with 96%
of those sampled compliant with prophylaxis which may provide insight to this chapter
finds as EHL were not commonly prescribed at the time of Scott et al. (2019) THUNDER
study. In addition, the THUNDER study did not include those with haemophilia B, which
as alluded to, display less severe AJBR, ABR and haemarthropathy. Lower rates of joint
deterioration and severity in the haemophilia B population may explain the slight
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decrease in our study data [235]. Direct comparisons between disease types are limited
and therefore requires further exploration to determine whether lower bleed rates and
better joint health in the haemophilia B cohort have external validity. Around 30% of the
participants sampled in this study used EHL treatment to manage their haemophilia. The
data collected in our study suggests EHL products make only slight differences to the
UK bleed rates. Studies of EHL factor VIII and IX levels report a 1.5 to 1.6 fold longer
drug half-life than standard products [241, 242]. In addition, ABR in patents on EHL
treatment are reported to decline by 20% to 50% with higher trough levels than SHL
products, but the data collected in this study does not support findings as the overall
effect on ABR were only slightly reduced in our study with 30% of participants on EHL
products [242]. A definitive study is yet to be undertaken to obtain the true efficacy and
effect of EHL products on ABR, AJBR and joint disease [241]. Longitudinal follow-up of
Dutch adults with severe haemophilia A and B (n=62) treated by prophylaxis reported
that over a 5-10 year period that median AJBR (IQR) of 0.0 (0.0-2.0). However, despite
the low incidence of haemarthrosis joint health continued to decline [243]. HJHS scores
increased by 4 points over the study period in 37.1% of patients, with the ankle joint the
most affected and accounting for 30.6% of the decline in overall joint health [243]. The
low AJBR and increased HJHS support the findings described in this chapter which
indicate that even with very low AJBR joint health declines despite controlled prophylaxis
treatment regimens.
Mean HJHS at the ankle joint were similar to the elbows followed by the knee indicating
the clinical impaction of haemarthrosis is evenly distributed amongst the most commonly
reported and affected joints. Interestingly the median scores at both the knee and elbow
(1.0) were lower than that of the ankle (4.0 (0.0; 8.0)) suggesting that there is worsening
ankle joint health when compared to other joints. It remains unclear as to why the ankle
joint is disproportionally affected by haemarthropathy. Structural and mechanical change
at the ankle contributes to abnormal loading forces during the stance phase of gait. In
combination with soft tissue changes, the ability to store and release energy from the
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gastro/soleus complex is compromised, therefore structural and functional changes
compromise ankle integrity [8, 166]. Similarly, where changes occur to the bone surfaces
of the talus and tibia, contact forces are greatly increased further adding to the detriment
of the joint [18]. While ABR and AJBR continue to decline higher levels of
haemarthropathy are still reported at the ankle joint. Increased frequency of ankle
haemarthropathy may be attributed to the complexities of the ankle joint complex and
biomechanical changes, although functional biomechanical changes may not present
until adulthood [8, 86, 229]. Moderate correlation of the HJHS with radiological scores at
the ankle joint warrants exploration of other markers that determine joint changes.
Physical assessment by HJHS lacks the sensitivity to identify active non-detectable
haemarthrosis at the ankle. Therefore additional measurements such as diagnostic and
point of care musculoskeletal ultrasound may be required to ascertain true ankle joint
status [209].
Haemarthrosis prevalence and joint health have been reported in children as per the
method described in section 3.3 [244]. A total of 97 children with haemophilia A (n=80)
and with haemophilia B (17) with a median (IQR) age of 10 (7; 13) and 12 (7; 14)
respectively were included with joint bleed prevalence and HJHS. Prevalence’s in the
paediatric cohort were lower than adult data with 32.5% of haemophilia A and 47% of
haemophilia B children recording at least one haemarthrosis over the 12 month study
period. Clinically detectable changes in joint structure and function were not detected by
the HJHS. Mean and median scores were 0.00 (0.00-0.00), therefore data suggest that
clinical signs of haemarthropathy are yet to occur in younger children, or is not detectable
using the HJHS in those compliant with treatment. Our study indicates the HJHS is not
sensitive to changes in children, or physical joint changes in children have not occurred.
This study supports the notion that HJHS measures the cumulative effect of
haemarthropathy, usually not clinically detectable until later years [240].
A limitation of this study is the relatively small number of patients registered on the UK
database who had full Haemtrack and concurrent itemised HJHS recorded at the time of
70
data collection. The NHD does not report bleed level data on patients who do not report
treatment using Haemtrack, thus limiting the sample size. Those patients included in the
analysis were self-reporting and therefore more likely to be compliant with treatment.
Bias may be introduced by the inability to include those not reporting treatment. Likewise
where HJHS were not reported electronically by CCC and HC, or itemised by total and
individual joint scores and therefore did not meet the NHD criteria for analysis. The small
sample size in our study highlights the need for the collation of HJHS by electronic
reporting across all UK centres, which would increase the sample size in future studies.
The sample of haemophilia B patients included in this analysis was small and therefore
clinical interpretation of joint bleed prevalence and HJHS between haemophilia A and B
should be interpreted with caution. Haemophilia A is associated with higher rates of
bleeding and studies of haemophilia B report lower bleed rates, fewer complications and
delayed progression and severity of haemarthropathy [234, 235]. Research with larger
samples of haemophilia B patients is required to understand whether the lower bleed
rates and lower levels of haemarthropathy reported in this study are generalisable to the
haemophilia B population. A further limitation is the variation of between-centre scoring
of the HJHS data. Different haemophilia centres may be subject to inter-centre scoring
variability, although regular workshops are conducted in the UK to decrease inter-centre
variability in HJHS scoring [245]. Furthermore, we are unable to confirm the influence of
other factors such as the presence of co-morbid musculoskeletal conditions on HJHS
data. UKHCDO NHD data was requested from those with a moderate disease type but
there was insufficient data to include in the analysis. Future comparison by disease




In the UK, joint bleed prevalence of incidence haemarthrosis has changed little in the
three years since the publication of the THUNDER study. In this 2018 cohort of severe
haemophilia patients without a current inhibitor, only 30% of adults remained
haemarthrosis free. Ankle joint haemarthrosis rates were comparable to that of the elbow
in haemophilia A, and the elbow was the most frequent joint affected in adults with
haemophilia B. However, higher HJHS were reported at the ankle joint compared to the
knee and elbow, confirming that the ankle joint is the most affected by haemarthropathy.
Understanding the impact of ankle haemarthrosis and subsequent haemarthropathy may
provide insight into the disparity between the ankle and other commonly affected joints
of the musculoskeletal system. Other contributing factors such as pain, treatment and
access to clinical services may provide future direction and research priorities. Future
clinical studies would benefit from understanding the bleeding profiles of those who do
not meet compliance or criteria for Haemtrack to obtain the true prevalence of
haemarthrosis. Current ankle joint bleed prevalence and associated impact on the
musculoskeletal system justifies the investigation of the impact on QoL and foot and
ankle specific outcomes in patients with ankle haemarthropathy across haemophilia
types, severity and treatment regimes.
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Chapter 4 - The impact of blood induced ankle
arthritis in patients with moderate and severe
haemophilia A and B: The HAPII study
This chapter investigates the impact of haemarthrosis and haemarthropathy of the ankle.
A cross-sectional questionnaire was used to establish the impact of blood induced ankle
arthritis in people with moderate and severe haemophilia A and B. Haemophilia
Consultants across the UK were also surveyed to provide a snapshot of services
available to those with haemophilia and haemarthrosis induced ankle arthritis.
A full review of literature has been undertaken in chapter two, therefore a brief
introduction will provide detail on the impact of blood induced ankle arthritis in moderate
and severe haemophilia A and B.
4.1 Introduction
Despite prophylaxis, adults with severe non-inhibitor haemophilia A and B still
experience haemarthrosis and develop haemarthropathy of the upper and lower limbs.
The data presented in Chapter Three identified that in patients with ≥75% adherence to
prophylaxis, most reported a minimum of one episode of haemarthrosis over 12 months
and a decline in joint health status. A single episode of haemarthrosis may be
unavoidable due to the balance of clinical effectiveness, risks and cost of treatment, with
treatment regimens aimed at trough levels similar to moderate haemophilia (0.01 to 0.05
IU/mL) that halt spontaneous haemarthrosis and minimise traumatic bleeding [4, 29].
European and UK studies report sub-optimal treatment regimens despite the availability
of clotting factor concentrates (CFC) in western medicine [4]. Data from individuals with
moderate haemophilia report a higher incidence of bleeding despite prophylaxis with an
annual bleed rate (ABR) ranging from 2.0 to 8.0 across Europe. In the UK, median (IQR)
ABR and annual joint bleed rate (AJBR) ranging from 3.0 (1.0 to 7.0) and 2.0 (2.0 to
73
15.3), respectively, in moderate haemophilia (n=154). In severe haemophilia, AJBR and
ABR are similar indicating that in the sample of moderate haemophilia patients treated
with prophylaxis 81% had a bleed and 72% had a minimum of one episode of
haemarthrosis [4]. This suggests that those with moderate haemophilia with a bleeding
phenotype are at risk of the same levels of joint damage seen in severe disease, yet
moderate factor levels have been a treatment target (>0.01 to <0.05 IU/mL) of severe
haemophilia for a number of years [221, 246]. AJBR of 3.5 (0.0 to 12.8) in patients treated
on-demand with severe haemophilia is without surprise higher than for those on
prophylaxis. Likewise in moderate on-demand treatment cases, AJBR is higher at 5.0
(2.0 to 15.3), exposing joints to worsening musculoskeletal health [4]. AJBR is a concern
across haemophilia severities and treatment regimens as a treatment target for
prophylaxis. Specifically, more than two bleeds within six months lead to the
development of target joints that are more prone to bleed and represents an indication
of under treatment [44]. It is clear that despite the availability of CFC, haemarthrosis
cannot be avoided. Measurement of ABR and AJBR outcomes by haemophilia type (A,
B), severity (severe, moderate) and treatment regime (prophylaxis/ on-demand) is
difficult, due to the reliance of patients reporting treatment and incidence of bleeding.
The UKHCDO NHD only report data on treatment ≥75% delivered vs recorded
treatments over 45 weeks, a minimum requirement for reporting “good data” [231]. Little
is reported therefore on patients who do not meet this ≥75% threshold and so a
significant proportion of the haemophilia population that may not be fully compliant with
treatment and/or report haemarthrosis are not included in analysis.  This therefore likely
underestimates the true clinical impact on musculoskeletal health in the UK [231] as joint
damage is likely to be worse in more poorly complaint patients than in the cases included
in NHD-based reports.
The physical and mental burden of haemarthropathy is great when compared to the
general population. Change to joint status is a significant contributor to the decline in
HRQoL as well as pain and functional impairment [10, 11]. The severity of haemophilia
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is associated with worse HRQoL, with people with severe haemophilia the worst affected
when compared to moderate and mild disease types [247]. A Dutch study of haemophilia
and social participation reported that adults with severe haemophilia (n=144) born before
the introduction of prophylaxis (30 to 65 years old) reported lower levels on the SF-36
HRQoL compared to the general population in all domains except mental health. Mean
(SD) scores (out of 100) physical function (45.9 (28.5), 84.0 (19.6)), role physical (67.4
(42.9), 81.6 (33.2)) and role emotional (67.4 (42.9), 81.6 (33.2)) respectively, were
particularly reduced compared to the general population. Those with severe haemophilia
born after the introduction of prophylaxis (15 to 30 years) reported higher scores than
older adults, but still lower than the general population, specifically in physical function
(82.2 (21.4) 93.1 (11.8)), role function (73.0 (38.0), 86.4 (27.6)) and general health 69.9
(22.2), 78.4 (17.3)) respectively. The sample of respondents with moderate and mild
levels of haemophilia (n=244) reported no differences in HRQoL compared to the general
population [247]. Low QoL appears to be associated with delayed prophylaxis and
associated haemarthropathy. Whilst overall QoL is informative, the inclusion of a joint
health measure such as the HJHS or factor treatment levels may provide further insight
to physical and pharmacological impact on HRQoL [247]. In a US study (n=381) of
haemophilia care, Kempton et al. (2017) explored the contribution of haemarthrosis, joint
pain and functional impairment on QoL in severe, moderate and mild haemophilia [10].
Median (IQR) SF-36 scores were lower for the four physical domains of physical function
(44.4 (29.7 to 52.8)), physical health (39.2 (29.5 to 49.4)), and body pain (41.8 (37.2 to
51.1)) thus indicating poor HRQoL. The absence of a control group make comparison to
the general US population difficult, but scores were similar to Plug et al. (2008) and
support the detrimental effect of haemarthrosis, haemarthropathy, functional impairment
and pain on the HRQoL across the range of haemophilia severities [10, 247].
Over 50% of people with haemophilia report acute and chronic joint pain related to
disability and impairment, a major factor in the determination of HRQoL [248, 249]. The
significance of pain to HRQoL has been examined by Wallny et al. (2001) who
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investigated the contribution of multi-joint severe haemarthropathy using a bespoke pain
questionnaire (n=71) [250]. The impact of HRQoL was significant, with difficulties
performing activities of daily living (ADL). Though mental health has been unaffected in
Dutch haemophilia cohorts Wallney et al. (2001) indicate that low mood contributed to
moderate levels of QoL [247]. Although little detail was provided on how QoL and ADLs
were measured the largest contributing factor was pain. The ankle joint (45.1%, n=32)
was the largest contributor to pain followed by the knee (39.4%, n=28), back (14.1%
n=10) and elbow (7.0%, n=5). Whist the authors provide no details on how
haemarthropathy was measured, the study reported 76.1% requiring analgesia daily to
alleviate pain [250].
The ankle is a problematic joint in the treatment and management of pain and
haemarthropathy in haemophilia [9, 19, 250]. Changes in structure, function and pain
suggest the ankle may disproportionally affect QoL, pain and disability compared to other
commonly affected joints, with the ankle joint often cited as the worst affected in terms
of function, higher levels of joint pain and the most frequent site of haemarthrosis [9, 19,
250]. Whilst prophylaxis reduces AJBR, ankle joint status continues to deteriorate even
where bleeding is not clinically apparent [46, 55]. In UK adults, the true impact of ankle
haemarthrosis and haemarthropathy on haemophilia type, severity and treatment
regimen is yet to be established.
4.2 Study aims
The primary aim of this study was to establish the impact of haemarthrosis and
associated haemarthropathy of the ankle joint in patients with moderate and severe
haemophilia A and B with and without a current inhibitor. Secondary aims were to
understand the effect of patient-reported pain, anatomical sites of haemarthropathy,
treatment regime, and patient-perceived access to clinical services. Finally, a consultant
survey provided a snapshot evaluation of clinical services relevant to the management
of haemarthropathy with a focus on the availability of foot and ankle services.
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4.3 Methods
Ethical approval was obtained on 24th January 2017 (IRAS: 206141, R&D: PD16/227).
Recruitment commenced on 13th April 2017 and ended on 31st August 2019.
Recruitment was across multiple sites across England, Scotland and Wales, with support
from the NIHR clinical research network (non-malignant haematology). A principal
investigator (PI) identified at each site oversaw implementation, approach, consent, and
data collection. Anonymised questionnaire data was returned to the primary site (Leeds)
for data entry and analysis.
4.3.1 Patient impact questionnaire (study one)
A cross-sectional multi-centre survey was conducted at 18 national sites, consisting of
13 haemophilia comprehensive care centres (CCC) and five associated haemophilia
treatment centres (HC) in England, Scotland and Wales. The survey aimed to explore
the association between ankle joint haemarthrosis and subsequent ankle
haemarthropathy on patient-reported QoL, ankle/foot pain and disability. The
questionnaire was divided into section A for patient completion and section B, clinical
details completed by the site PI or research staff member. Details related to weight,
height, surgical history, and ankle HJHS were collected (Appendix 1).
The questionnaire was administered by the participating centre’s doctor, nurse or allied
health professional (AHP). Patients were provided with a patient information sheet (PIS)
and given a minimum of 15 minutes to consider participation. Potential patients were
encouraged to ask questions about the study and advised to take the PIS home if they
required a longer period of consideration. Once participation was agreed, written,
informed consent was obtained and the questionnaire completed. Patients were
provided with a copy of the PIS and consent form. A copy of the consent form and PIS
were also either uploaded to or filed in the patient’s medical record.
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4.3.2 Inclusion/ exclusion criteria
Patients recruited to this study were required to have a consultant diagnosis of ankle
haemarthropathy with haemophilia A (factor VIII) or B (factor IX), with moderate (≥0.01
IU/mL) or severe (<0.01 IU/mL) levels of factor deficiency as defined by the International
Society on Thrombosis and Haemostasis (ISTH) [221]. The eligibility criteria are
summarised in  Table 3. Participants were male-only due to the X-linked recessive
inheritance nature of the disease. Similarly, participants were not aged-matched to other
disease types such as ankle OA owing to the early initiation of ankle joint disease. OA
cohorts typically 20 to 30 years older with the mechanism of injury is traumatic or
inflammatory in nature [251].
4.3.2.1 Patients use of clinical services
To obtain insight into the current care provision of those with ankle haemarthropathy,
patients were asked to provide detail on certain aspects of their clinical care related to
access to the following clinical specialists; physiotherapist, podiatrist/chiropodist for
musculoskeletal assessment and foot orthoses provision. Patients were asked if they
had access to a podiatrist/chiropodist for nail cutting and callus removal (routine podiatry
 Table 3: Inclusion/ exclusion criteria
Inclusion criteria Exclusion criteria
· Haemophilia A or B, moderate or
severe defined as a plasma factor
level of less than five percent (<5
IU dL-1)
· A consultant diagnosis of
haemarthrosis induced ankle
haemarthropathy
· Aged 16 or over
· Patients who can give informed
written consent
· Males
· Other bleeding disorders such as
Von Willebrand disease
· Mild haemophilia A and B
· Significant comorbidities such as
diabetes and inflammatory
arthritis that are associated with
lower limb vascular and
neurological defect leading to




treatment). Details of hospital or adapted shoes were recorded as were insole provision
and type (shop brought, NHS supplied, private podiatrist supplied).
4.3.2.2 Clinician reported participant details
Details of patient demographics (height, weight, and baseline factor levels), and
treatment (prophylaxis years, treatment trough level, product, product change in the past
12 months) were recorded. HJHS or ankles were reported as a single joint score per side
(left/right). Haemtrack participation status, ankle joint bleeds reported over the past 12
months and the imaging modality used to confirm haemarthropathy (US, MRI, X-ray)
were recorded. Finally, the history of ankle surgery by the site (left/right) and procedure
were collated.
4.3.3 Impact patient questionnaire
4.3.3.1 Haemophilia disease and management
Demographic data were collected for each patient consisting of haemophilia type (A or
B), severity (moderate or severe), treatment regime (prophylaxis or on-demand)
frequency of infusion, dose (IU/kg) and inhibitor status. Patients were also asked to
provide information on amounts of extra replacement CFC used per day when a bleed
occurred and on average how many extra days replacement therapy was taken following
a participant-perceived mild bleed or a severe bleed. A list of potential target joints,
defined in this study as those affected by haemarthropathy, were provided based on
affected joints by the site (ankle, knee, hip, wrist, elbow, shoulder) and side (left and
right). Patients were also asked to provide a self-reported number of ankle bleeds (left
and right) over the last 12 months and whether any ankle surgery had taken place (left
or right).
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4.3.3.2 Patient-reported outcome measures (PROMs)
To explore the impact of ankle haemarthropathy on health-related quality of life (HRQoL),
a disease-specific HAEMO-QoL-A and the foot-and-ankle-specific measure the
Manchester Oxford Foot and Ankle Questionnaire (MOXFQ) were collected. No other
HRQoL or PROM were used based on the burden of research questionnaire data
collection.
4.3.3.3 Haemophilia quality of life in Adults (HAEM-QoL-A)
This is a validated haemophilia specific HRQoL tool, consisting of 41 questions scored
in six subscales of functional activity, role function, worry, consequences of bleeding,
emotional impact, and treatment concerns [201, 252]. For each question, a six-point
Likert scale is used, ranging from 0 (None of the time) to 5 (All of the time) yielding a
domain score for each of the six subscales with a higher score indicating better health.
Raw scores are combined to produce a total score (0 to 100), with 0 indicating worse
possible health and 100 best possible health [200]. Whist limitations of the HAEMO-QoL-
A have been identified in cross-cultural validity, compared to generic QoL measures such
as the SF-36, the HAEMO-QoL-A displays moderate to strong correlation in pain, social
function, and role limitations [200, 202, 203]. Despite these limitations, the HAEMO-QoL-
A is the most widely used and clinically validated measure of HRQoL in haemophilia to
date [253].
4.3.3.4 Manchester Oxford Foot Questionnaire (foot and ankle) (MOXFQ)
The MOXFQ is a PROM used to evaluate foot and ankle pain, consisting of three
domains of walking/standing, pain and social interactions. A higher score (0 to 100)
indicate worse severity [213, 217-219]. The MOXFQ, when compared to other foot and
ankle PROMs, performed the best in psychometric properties, internal consistency,
reliability, measurement error, structural, convergent, discriminant, discriminative validity
and responsiveness [220]. The MOXFQ is yet to be utilised in haemophilia foot and ankle
research, but in a condition characterised primarily by the talocrural joint involvement,
the use of a MOXFQ outcome measure is appropriate.
80
4.3.3.5 Pain measures
Patients were asked to provide detail on how they would describe a joint bleed, whether
they took any medication for pain and what medications they currently took for joint pain.
Details of patient-reported pain were captured using an 11 point (0 to 10) numerical pain
rating scale (NPRS) and a Likert scale (discussed in section 4.3.3.3) to identify the
change in pain related to episodes of haemarthrosis and use of Factor treatment
following an acute, mild and severe haemarthrosis.
4.3.3.5.1 NPRS development
All pain measures were developed using the Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials (IMMPACT) guidelines for the management of chronic
pain and tested in a cohort of potential patients (n=12) in the initial questionnaire design
and final terminology used [254].
In this pilot pain questionnaire () participants were asked to rank three questions for each
outcome based on the best to worse relevance for “pain over the past six months”,
“thinking about ankles after an acute bleed” and “factor use after an episode of bleeding”.
The wording of each question was then ranked for relevance from 1= best and 3= worst.
The following responses were ranked as “best” by patients and most relevant in capturing
the effect of any ankle pain;
Pain in your ankle over the last six months
“How painful has your ankle been over the past six months?” (n=7, 58.3%)
Please think about your ankles after an acute bleed
How much pain do you have in your ankle straight after a bleed? (n=9, 75%)
Think about factor use when you have had a bleed?
You have had a bleed and treated it with factor. How much improvement do you have
in pain after your usual extra treatment period? (n=8, 66.6%)
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The patient selected questions were then included in the pain section of the HAPII patient
questionnaire and adapted to measure pain following an acute, mild and severe ankle
bleed (Appendix 2).
4.3.3.5.2 Final pain measures
Patients were asked to provide a score for ankle pain over the past six months, and pain
immediately following a bleed. Zero indicates no pain and 10 pain is as bad as you can
imagine. Picture mapping based on the Garrow et al. (2000) foot manikin was used to
identify common sites associated with ankle haemarthropathy [255]. Picture mapping
was provided as part of the questionnaire and patients were asked whether they had
experienced foot or ankle pain lasting at least one day during the past month. If the
participant shaded multiple diagrams across the picture mapping they were then required
to add an arrow indicating the most painful site.
4.3.4 Consultant online survey (study two)
A simultaneous online haemophilia consultant survey (Online surveys, Bristol, UK, Jisc
2021) was undertaken and distributed to all UKHCDO member haemophilia consultants
across the UK (Appendix 3). A description of the study was provided with the HRA
registration number and study team contact details in an approach email. Consent was
provided by participation and submission of the online survey for analysis.
4.3.4.1 Consultant survey
Consultant haematologists were assessed to provide details of the services provided at
their haemophilia CCC or HC related to the management of haemophilia, MSK disease
and UKHCDO care standards [12]. The following questions; access to core services of
foot and ankle orthopaedics, rheumatology, psychology, radioactive synovectomy, point
of care ultrasound (POCUS) and physiotherapy services. In addition, consultants were
asked to provide details specific to the management of the foot and ankle by orthotics
services, and podiatry for MSK assessment and provision of foot orthoses and access
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to podiatry for routine foot care for nail and skin (callus, corns) care. For each question,
the consultant was required to indicate whether access was available within their
haemophilia centre, externally via a general practitioner (GP) or did not have access.
4.4 Statistical methods
All data were entered into Statistical Package for the Social Sciences (SPSS) version 26
(Armonk, NY: IBM Corp). A recruitment target of 245 was set to allow the mean HAEM-
QoL-A to be estimated to be within ±2.5 units of the measurement scale, assuming a
between the patient standard deviation of 16.96 [200]. To predict participant disease
states, HRQoL and PROMs data were entered as outcomes into a linear regression
analysis, where the effect of participant haemophilia type (A or B), severity and treatment
regime (prophylaxis or on-demand) were added separately as indicators of direct
relationship. Clinical characteristics (severity, treatment etc.) were then added as
additional indicators. Complete cases were analysed under the assumption that any
missing data were missing completely at random. A 2-sided 5% significance level was
used throughout. Test of normality was undertaken to assess the skewness of data and
the appropriateness of the statistical methods used. Finally, regression analysis was
undertaken to determine whether there were direct relationships between clinical
characteristics and decline in HRQoL and PROM. Variable including numerical pain
rating scales, inhibitor status HJHS and treatment amount (IU/kg) were entered using
stepwise regression analysis to explore whether the clinical variables had a direct
relationship to decline in HRQoL and PROM. Parametric data are presented as mean
and standard deviation (SD); non-parametric data as the median and interquartile range




At the close of recruitment, 250 response sets had been received. Data from seven
patients were excluded from the analysis due to the incompleteness of the primary
outcome measures (HAEMO-QoL-A and MOXFQ), leaving 243 for primary and
secondary analysis.
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4.5.1.1 Haemophilia disease and management
Overall, 214 (88.1%) patients had severe and 29 (11.9%) had moderate haemophilia.
Participant characteristics by haemophilia type and severity are presented in Table 4.
Those with severe haemophilia A made up the largest proportion of patients. Age, height
and weight were similar across haemophilia type and severity. BMI was similar across
haemophilia types, with the majority of patients classed as over-weight.
4.5.1.1.1 Prophylaxis regimes
Details of prophylaxis, treatment frequency and those who treat on-demand are listed in
Table 5. Overall, 242 out of 243 patients provided detail. The most common treatment
regimens were alternate day prophylaxis, followed by daily treatment across haemophilia
types.
Table 4: Study participant characteristics
Severity and treatment Haemophilia A Haemophilia B
Severe
Mean (SD)
Number 184/ 75.7% 30/ 12.3%
Mean (SD) age 42.4 (13.1) 47.3 (11.5)
Prophylaxis 164 / 67.5% 27/ 11.1%
On-demand 20/ 8.2% 3/ 1.2%
Current inhibitor 16/ 6.6% 1/ 0.4%
Height (cm) 176.9 (7.4) 177.6 (7.3)
Weight (Kg) 84.1 (18.3) 89.4 (19.9)
BMI (Kg/m2) 26.7 (5.3) 27.8 (7.1)
Moderate
Number 25/ 10.3% 4/ 1.7%
 Age 48.9 (15.9) 46.6 (18.1)
Prophylaxis 11/ 4.5% 3/ 1.2%
On-demand 14/ 5.8% 1/ 0.4%
Current inhibitor 1/ 0.4% 0
Height (cm) 177.2 (7.9) 180.6 (9.6)
Weight (Kg) 85.0 (16.2) 98.4 (18.9)
BMI (Kg/m2) 26.8 (4.4) 30.1 (4.5)
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4.5.1.1.2 Treatment products
Patients receiving standard half-life (SHL) CFC treatment were exclusive to haemophilia
A, with 107 (45.3%) patients receiving this. Extended half-life (EHL) products were used
by 88 (37.38%) and 32 (13.55%) patients with haemophilia A and B respectively. Nine
(3.8%) patients used a bispecific monoclonal antibody (BsMAb), which at the time of this
study, were used exclusively in the management of haemophilia A with a current
inhibitor.
Table 5: Prophylaxis treatment characteristics
Severity and treatment frequency Haemophilia A Haemophilia B
Severe
(n=213)
Daily 24 (9.9% ) 0
Alternative days 93 (38.4%) 4 (1.7%)
Five times per week 2 (0.8%) 0
Three times per week 6 (2.5%) 0
Twice per week 26 (10.7%) 5 (2.1%)
Once per week 4 (1.7%) 18 (7.4%)
BsMAb 9 (3.7%) n/a
On-demand 20 (8.3%) 3 (1.2%)
Moderate
(n=29)
Daily 0 1 (0.4%)
Alternative day 7 (2.9%) 1 (0.4%)
Five times per week 0 0
Three times per week 0 1 (0.4%)
Twice per week 2 (0.8%) 0
Once per week 2 (0.8%) 0
On-demand 14 (5.8%) 1 (0.4%)
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4.5.1.1.3 Prophylactic treatment of haemophilia
Complete and detailed treatment data was only available for 213 out of 243 patients.
CFC treatment characteristics are presented in Table 6. Median (IQR) treatment dose
by IU/kg was similar across haemophilia types but in both haemophilia, A and B higher
doses were reported in those with moderate disease types.
Table 6: Clotting factor concentrate treatment characteristics
Type Haemophilia A Haemophilia B

































30.5 (-) 28.4 (-) -
Prop= prophylaxis, OD= on demand *= ≤3
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4.5.1.1.4 Treatment of haemarthrosis
The characteristics of haemarthrosis treatment are presented in Table 7. Median (IQR)
treatment characteristics are presented and are representative of participant treatment
habits for the management of haemarthrosis. The patient’s IU/kg of CFC treatment
increased by 5.2 IU/kg and 5.4 IU/kg in severe haemophilia A prophylaxis and on-
demand treatment respectively. The number of extra treatment days was similar across
groups for mild (1 to 2) and severe (3 to 4) bleeds. Participants’ ankle AJBR were
generally higher in the moderate haemophilia groups, but again similar across treatment
types.
Table 7: Characteristics of haemarthrosis treatment
Type Haemophilia A Haemophilia B































40.7 (-) 28.4 (-) -
Treatment days - mild
bleed
1 (1; 2) 1 (1; 2) 2 (2; 3) 2 (-)
1.0 (1;
2)
2.0 (-) 2.0 (-) -
Treatment days –
severe bleed
3 (2; 4) 3 (2; 4) 4 (4; 7) 3 (-)
3.0 (3;
5)
4.5 (-) 6.0 (-) -
Right ankle bleeds last
12 months
1 (0; 3) 0 (0; 2) 1 (0; 1) 0 (-) 0 (0; 1) 0.5 (0.7) 1 (-) -
Left ankle bleed last 12
months
0 (0; 2) 0 (0; 2) 1 (0; 3) 4.0 (-) 1 (0; 2) 1.5 (-) 3.0 (-) -
Prop= prophylaxis, OD= on demand *= ≤3 treatment doses are presented as medians to represent clinical treatment
doses, ie drug is supplied to the patient in 500ui vials.
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4.5.1.2 Pain
4.5.1.2.1 Ankle pain characteristics
Ankle pain characteristics are presented in Table 8 as mean (SD) with data available for
220 out of 243 patients. Ankle pain severity experienced over the last six months was
consistent across haemophilia type and severity regardless of treatment type. Pain
experienced following an acute bleed was also consistent with a 1 to 2 point increase in
pain following an acute episode of bleeding. Patients reporting use of CFC treatment
following a severe or mild bleed report “much improved” pain for both incidence of mild
and severe haemarthrosis.
Table 8: Pain characteristics
Type Haemophilia A Haemophilia B



















Ankle pain in the
past six month
(NPRS 0-10)
5.1 (2.6) 5.5 (3.0) 5.8 (2.6) 4.8 (2.7) 5.3 (2.3) 5.0 (0.0)* 6.0 (3.6) 5.2 (0.0)
Ankle pain after an
acute bleed (NPRS
0-10)
7.1 (2.0) 6.9 (2.8) 6.9 (2.2) 6.6 (1.4) 7.4 (1.9) 9.5 (0.7) 7.0 (3.0) 9.5 (0.0)
Ankle pain response
to factor – Mild
bleed (n=225)
1.2 (0.8) 1.3 (0.9) 1.0 (0.5) 1.3 (0.7) 1.1 (1.1) 1.0 (0.0) 0.7 (0.6) -
Ankle pain response
to factor – Severe
bleed (n=223)
1.5 (0.8) 1.5 (.7) 1.3 (0.7) 1.5 (0.5) 1.5 (1.3) 2.0 (0) 1.0 (0.6) -
Prop= prophylaxis, OD= on demand *= ≤3
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4.5.1.2.2 Pain medication
Complete data on pain medication was available for 233 out of 243 patients. Overall, 131
(56.2%) patients did not take regular pain medication, and 102 (43.7%) patients used
regular pain medication. The most commonly used analgesics were paracetamol and
COX2 inhibitors (see Table 9). The most common combination of medications were
paracetamol and opioid analgesics (n=8) followed by opioids, COX2 (n=2) and NSAIDs
(n=2) respectively.
Table 9: Pain medication
Medication Regular medication (n=102) Additional medication (n=16)
Paracetamol 31 (13.3%) 2 (0.8%
NSAIDs 10 (4.1%) 1 (0.4%)
COX2 Inhibitors 25 (10.3%) 0
Co-Codomol 15 (6.2%) 0
Opioids 18 (7.4%) 13 (5.4%)
Medicinal 1 (0.4%) 0
Other 2 (0.8%) 0
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4.5.1.2.3 Participant reported haemarthropathy
The site and distribution of patient-reported haemarthropathy are presented in Figure 8.
Patient-perceived haemarthropathy was reported by all 243 patients.
Figure 8: Distribution of patient-reported arthropathy
The distribution of patient-reported arthropathy was similar across the left and right sides
of the body. Left and right ankles were the most commonly affected joints, followed by
elbows and knees. At the ankle, 117 (48.5%) patients reported bilateral ankle
arthropathy, 29 (11.9%) bilateral elbows, followed by 10 (4.1%) wrists and four (1.6%)















Ankle HJHS was available for 202 and 199 patients for the left and right ankles
respectively and are presented in Table 10. Median HJHS at the ankle were higher in
severe haemophilia A patients. Across both haemophilia severities, patients treated on-
demand had higher scores, indicating worse ankle haemarthropathy. Moderate
prophylaxis groups had higher HJHS, although the haemophilia B group had low
numbers of patients. Median on-demand treatment in moderate haemophilia A was
relatively low indicating less effect of treatment on the regime in the management of
moderate disease.
Table 10: Ankle HJHS
Type Haemophilia A Haemophilia B



























2.0 (0;3) 6.0 (4; 10) 7.5 (-)* 10.0 (-)* 7.5 (-)*
Right ankle
(n=199)
5.0 (2.0; 9.0) 7.5 (4; 12) 5.0 (0; 11) 1.0 (0;1) 3.0 (1; 6) 6.0 (-)* 7.0 (-)* 6.5 (-)*
Prop= prophylaxis, OD= on demand *= ≤3 (n=left ankle/right ankle)
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4.5.1.2.5 Ankle pain-specific location
Ankle pain-specific location was reported by all 243 patients. Across disease, severity,
and treatment type, the most common site of pain was the left lateral ankle, with 143
(60.9%) and right lateral ankle 125 (51%), patients indicating pain. Right medial ankle
110 (45%), left medial ankle 118 (48.5%), left posterior ankle 80 (32.9%), right posterior
83 (34.2%), and anterior ankles, right 115 (47.3%) and left 125 (51.3%). Where both left
and right ankle pain were pooled by site, the lateral ankles (81, 33.3%) were the most
common site of ankle pain followed by anterior, (74, 30.5%) medial (72, 29.6%) and
posterior (54, 22.2%) ankles.
4.5.1.2.6 Ankle surgery
Ankle surgery was reported in 95 out of 243 patients. The surgery site was evenly
distributed by left (30, 31.6%), right (29, 30.5%) and bilateral ankle surgery (31, 32.6%).
Five patients (5.3%) did not indicate side. The most common unilateral procedure was
ankle fusion (52, 54.7%), followed by arthroscopic debridement (11, 11.6%), osteophyte
removal (4, 3.8%) and open ankle debridement (n 4, 3.8%). Radioactive synovectomy
subtalar joint fusion and total ankle replacement were performed each in two patients.
An Achilles lengthening z-plasty was reported by one participant. Secondary surgical
procedures were recorded in 23 (24.0%) patients. Contralateral ankle fusions were
indicated in 14 (61.9%) patients and subtalar joint fusion in three (13.0%) patients.
Contralateral ankle surgical procedures; arthroscopic debridement: total ankle




4.5.1.3.1 Consultant survey and patient questionnaire responses
Overall, 41 responses were collected from 28 CCC and 13 haemophilia treatment
centres (HC) across the UK. Specialist services consultant survey responses are
reported in Figure 9. Concerning the specifics of access to clinical care, both consultant
survey and patient questionnaire responses are compared in Figures 10-12. Consultant-
reported access to specialist services at haemophilia centres was indicated either
directly or indirectly in all settings for rheumatology and orthopaedics. Point of care
diagnostic US was minimally available, with a total of 19 (43%) centres reporting no
access (11 CCC, 8 HC). Consultants at seven (17%) centres had no access to
radioactive synovectomy services (3 CCC, 4 HC). Finally, four (9%) centres (3 CCC, 1
HC) had no access to psychology. A total of 13 (31.7%) centres (8 CCC, 3 HC) had no
access to two services (US, RS, physiology, routine podiatry), with only one (2.4%) HC
without access to three clinical services (routine podiatry, US, RS).
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Figure 9: Consultant access to specialist services
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Consultant survey (n=42, 100%) and patient questionnaire (n=215, 89%) responses
reported access to physiotherapy (Figure 10) at haemophilia centres either directly or
indirectly, but 26 (11%) patient questionnaire responses report no access. Access to
orthotic services for the provision of devices such as braces and AFOs, commonly used
in the management of ankle pathology, were again reported in the consultant survey
(n=42, 100%) as accessible either by direct or indirect referral at all haemophilia centres.
In comparison, a high proportion of the patient questionnaire responders did not use
specialist footwear (n=211, 88%) or foot orthoses (n=117, 51%). Therefore, whilst
services are available, patients were either unaware or chose not to access orthotic
services.
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Figure 10: Consultant and participant access to physiotherapy and
orthotic services
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Access to musculoskeletal podiatry services is presented in Figure 11. A large proportion
of the questionnaire patients reported no access to a podiatrist (n=139, 58%). In the
proportion that indicated access, 81 patients (34%) were supplied with orthoses. When
asked the specifics of what was provided (n=116 responses), 73 patients (63%) obtained
their orthoses from the NHS, but 36 patients (31%) used shop-bought devices. A small
proportion was supplied by a private podiatrist (n=7, 6%).
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Figure 11: Consultant and patient-reported access to podiatry
musculoskeletal services
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Access to podiatry for routine foot care is presented in Figure 12. Only four HC reported
no access to routine podiatry care, while 133 (57%) patients in the impact questionnaire
suggest the need for routine foot care is not a requirement. Only 20 (8%) questionnaire
patients received routine foot care.
Figure 12: Consultant and participant access to podiatry routine foot care
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4.5.1.4 Patient-reported outcome measures
4.5.1.4.1 HAEMO-QoL-A
Total and individual domain scores of the HAEMO-QoL-A are presented in Table 11. The
total scores were generally low (100=best health), indicating poor HRQoL associated
with ankle haemarthropathy, regardless of haemophilia type, severity or treatment
regime.
Table 11: Individual and total HAEMO-QoL-A
Type Haemophilia A Haemophilia B



























































































































Prop= prophylaxis, OD= on demand
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4.5.1.4.2 MOXFQ
Total and individual domain scores of the MOXFQ are presented in Table 12. Total
scores were similarly high across all haemophilia types and treatment regimens (50 to
59), indicating worsening pain and function, except for those with moderate haemophilia
B (n=4).
Table 12: MOXFQ (foot and ankle)
Type Haemophilia A Haemophilia B















































Social 5.9 (4.1) 7.5 (3.5)
6.6
(4.2)

















Prop= prophylaxis, OD= on demand
4.5.1.5 Regression analysis
In line with the hypothesis of this chapter, haemophilia characteristics of type, severity
and treatment type were not directly linked to worse HRQoL or foot and ankle PROMs.
4.5.1.5.1 HAEMO-QoL-A
When analysed, neither haemophilia type nor treatment type was independently
associated with HAEMO-QoL-A total scores, nor were any of the domain scores (Table
13). Haemophilia severity was associated with poorer physical function but was not
independently associated with differences in any other domain, and not with the HAEMO-
QoL-A total score.
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Haemophilia type -0.42 0.598 -1.94 1.10
Treatment type -0.18 0.817 -1.73 1.37
Severity 0.06 0.950 -1.75 1.86
Physical
function
Haemophilia type -0.15 0.177 -0.36 0.07
Treatment type 0.13 0.224 -0.08 0.35
Severity 0.38 0.004 0.12 0.63
Role function
Haemophilia type -0.06 0.769 0.83 1.84
Treatment type -0.03 0.877 -0.49 0.36
Severity 0.27 0.293 -0.46 0.40
Worry
Haemophilia type -0.09 0.707 -0.55 0.37
Treatment type -0.27 0.255 -0.75 0.199
Severity -0.06 0.825 -0.61 0.49
Bleeding
Haemophilia type 0.05 0.831 -0.40 0.49
Treatment type 0.07 0.769 -0.38 0.52
Severity -0.05 0.848 -0.58 0.48
Emotion
Haemophilia type -0.05 0.769 -0.40 0.29
Treatment type 0.08 0.670 -0.27 0.42
Severity -0.10 0.615 -0.51 0.30
Treatment
Haemophilia type -0.12 0.617 -0.58 0.35
Treatment type -0.15 0.531 -0.63 0.32
Severity -0.37 0.187 -0.93 0.18
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4.5.1.5.2 MOXFQ (foot and ankle)
Again haemophilia type, treatment type or severity grading were not independently
associated with MOXFQ scores (Table 14).







Lower bound Upper bound
MOXFQ Total
score
Haemophilia type 2.10 0.642 -6.79 10.99
Treatment type 0.10 0.983 -8.97 9.16
Severity 5.21 0.332 -5.36 15.78
Walking/ standing
Haemophilia type 0.79 0.596 -2.13 3.71
Treatment type 0.08 0.956 -2.89 3.06
Severity 2.02 0.252 -1.45 5.50
Pain
Haemophilia type 0.73 0.421 -1.05 2.50
Treatment type -0.53 0.563 -2.34 1.28
Severity 0.32 0.763 -1.79 2.44
Social
Haemophilia type -0.17 0.824 -1.66 1.32
Treatment type 0.51 0.508 -1.01 2.03
Severity 0.99 0.273 -0.78 2.76
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4.5.1.5.3 Stepwise regression analysis
4.5.1.5.4 Regression analysis stepwise effect
The final regression models are reported in Table 15. Stepwise regression led to the
exclusion of HJHS for left and right ankles for the HAEMO-QoL-A total scores. Treatment
IU/kg, HJHS for the left ankle, HJHS for the right ankle and factor product were also
excluded from the final MOXFQ model. In the HAEMO-QoL-A NPRS model accounted
for 52% of the R-square proportion of variance, where all were significant. In the MOXFQ
total scores model, R-square was 73%. In both total scores models, pain over the past
6 months was a significant predictor of worse HRQoL, as was inhibitor status.
4.5.1.5.5 Sensitivity analysis
A sensitivity analysis of the subscales of both the HAEMO-QoL-A and MOXFQ was
undertaken to establish whether individual domains of the HAEMO-QoL-A and MOXFQ
were directly linked to HRQoL and foot and ankle outcomes. Results of the HAEMO-
QoL-A and MOXFQ are presented in Table 16 and Table 17 respectively. NPRS over
six months was found to be directly linked to all HAEMO-QoL-A and MOXFQ sub-scales
indicating NPRS over six months may be a useful indicator of overall HRQoL and
worsening foot and ankle outcomes. Specifically, the interpretation indicates that decline













NPRS six months 0.76 <0.001 0.56 0.98
Inhibitor status 4.14 0.001 1.68 6.55
MOXFQ  Total
score
NPRS six months 6.84 <0.001 5.88 7.80
Inhibitor status 11.39 0.048 0.12 22.65
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in HRQoL is mostly driven by pain in haemophilia. Inhibitor status (current inhibitor) had
a significant effect on role function, worry, bleeding and treatment. This indicates that the
presence of an inhibitor, and the associated risk of bleeding, are a significant burden on
HRQoL. On-demand treatment and physical subscales were also significantly
associated with outcomes, indicating that treatment choice directly affects physical
function, a known consequence of treatment regime (on-demand vs prophylaxis).












Lower bound Upper bound
Physical
function
NPRS six months 0.05 0.003 0.02 0.09
Factor product -0.50 0.009 -0.08 -0.01
On demand
treatment
0.31 0.013 0.07 0.56
Role
function
NPRS six months 0.22 <0.001 0.16 0.28
Inhibitor status 0.85 0.018 0.15 1.55
Worry
NPRS six months 0.24 <0.001 0.18 0.31
Inhibitor status 0.79 0.041 0.03 1.55
Bleeding
NPRS six months 0.19 <0.001 0.12 0.25
Inhibitor status 1.04 0.005 0.30 1.79
Emotion NPRS six months -0.11 <0.001 -0.162 -0.06
Treatment
NPRS six months 0.17 <0.001 0.10 0.24
Inhibitor status 1.36 0.002 0.52 2.21
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4.6 Discussion
This study used the HRQoL questionnaire and foot and ankle PROMs to understand the
impact of haemarthrosis and ankle haemarthropathy in a cohort of severely and
moderately affected haemophiliac adults. In addition, a consultant survey was
undertaken to understand current access to clinical services within the UK that provide
the MDT management of ankle haemarthropathy. This large multicentre study has
identified that across the UK, patients with moderate and severe haemophilia A and B
have poor HRQoL, and foot and ankle specific health outcomes, regardless of
haemophilia type, severity or treatment regime. Findings suggest that pain may be a
significant driver of poor HRQoL, physical function and the risk of bleeding, a significant
worry to those with an active inhibitor. The management of ankle haemarthropathy is
further blighted by the disparity between consultant perceived access to clinical MDT
services and patients own experience of access and use.









Lower bound Upper bound
Walking/
standing
NPRS six months 1.85 <0.001 1.50 2.20
HJHS right 0.23 0.021 0.04 0.43
Pain NPRS six months 1.40 <0.001 1.22 1.59
Worry
Social
NPRS six months 1.05 <0.001 0.89 1.24




Demographics of the patients were representative of the severe adult haemophilia
population with higher numbers of haemophilia A and B patients. The sample of
moderate haemophilia patients (n=29) whilst small provides insight into the effect of
haemarthrosis and levels of ankle haemarthropathy. Patients with moderate haemophilia
are required to use prophylaxis CFC treatment, only when they experience regular
haemarthrosis, however, this sample of patients were near equally split between on-
demand (n=15) and prophylaxis (n=14) treatment [29]. Whilst this sample is small it does
provide context to an emerging trend that moderate haemophilia, once considered the
treatment target for severe disease is associated with high levels of haemarthropathy
[29, 256]. The age of patients would class the cohort as older adults, therefore patients
would be more likely to have established haemarthropathy. Associated changes in joint
function and structure are related to the length of disease and changing approaches to
CFC prophylaxis regimes [2, 33, 257].
The BMI scores in this cohort were above the upper limit of normal (25 Kg/m2) and
therefore the majority of patients fell into the overweight category [258]. In people with
haemophilia, as well as the general population, there is a rise in the prevalence of obesity
with the World Health Organisation estimating a one-third increase in prevalence since
1975 and 39% of adults classed as overweight [258]. In people with haemophilia, being
overweight and obese is thought to increase the burden of disease, as well as having an
impact on pharmacokinetic CFC dosing [259]. Reduced plasma volume in adipose tissue
is thought to reduce the effectiveness of CFC treatment, though exploration of body
weight and CFC treatment has been shown to make no difference to FVIII levels or
treatment half-life [260]. Although BMI is the most widely recommended method of
reporting the incidence of weight and obesity, it does not discriminate between body fat
percentage and lean mass [261]. This is particularly relevant in haemophilia were
changes in body composition, muscle atrophy and disability limit activities and muscle
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bulk [262]. Population studies in haemophilia have identified that those with arthropathic
joint and soft tissue changes tend to avoid exercise due to the inherent risk of bleeding,
but those who are overweight may compromise joint function and are at a higher risk of
bleeding [262, 263]. This chapter broadly supports this notion, but it is unclear whether
higher body mass causes worsening haemarthropathy or physical impairment caused by
haemarthropathy leads to increased body mass. Regardless, it is clear that addressing
weight gain, lifestyle modifications and dietary changes may reduce the impact of
haemarthropathy and long term health at the ankle and other commonly affected joints
[259].
4.6.1.2 Multi-joint arthropathy
Multi-joint haemarthropathy was a common feature in the cohort, with the ankle most
commonly reported followed by the elbow and knee. These findings are not unexpected
as this chapter aimed to recruit patients with known ankle haemarthropathy and the
distribution at the knee and elbow is cited in multiple studies [9, 53]; these outcomes are
similar to those reported in Chapter Three: prevalence study. Patient-reported sites of
arthropathy (Figure 8) indicate similar rates of arthropathy to large cohort studies of OA
at the shoulders hands and hips with prevalence (95% CI) per 1000 people of 6.74 (2.19,
11.29), 7.13 (2.51, 11.75) and 6.42 (1.93, 10.91) respectively [251]. The age range of
respondents in the Keenan et al. (2006) population study was older (aged 55-65) than
this cohort but with a similar distribution of joint OA. The age of this cohort (42-49 years)
suggests that in haemophilia the incidence of OA at other joints occurs at a younger age
than that of the general population. Whilst self-reported patient data can be unreliable, it
is unclear whether reported younger onset is a result of haemarthrosis specifically, or
the indirect effect of changes in the structure and function of multiple joints caused by
haemarthropathy at the ankle elbow and knee [9]. This is an important consideration as
the focus is generally placed on the common sites of haemarthrosis of the ankles, knees
and elbows. This may not be directly related to haemarthrosis, but rather the
109
consequences of proximal and distal functional and structural joint changes that cause
early initiation of joint disease and multi-joint OA [251].
4.6.1.3 Ankle joint haemarthropathy
The clinically detectable changes at the ankle measured using the HJHS indicate
advancing haemarthropathy across all haemophilia disease types with the exception of
moderate haemophilia A treating on-demand (Table 10). Whilst there is no consensus
on the level of haemarthropathy indicated by the HJHS, one radiological study, has
explored concurrent HJHS in patients with severe haemophilia A who reported left and
right ankle HJHS of 5.0/6.0. When compared to the Pettersson score, a measure of joint
damage in haemophilia, an HJHS of 5.0 to 6.0 correlates to moderate to severe levels
of haemarthropathy [209]. Whilst HJHS at the ankle joint is only moderately correlated
with joint changes, as haemarthropathy progresses the clinical manifestation of ankle
joint damage becomes more apparent [209]. High ankle HJHS were reported in the
cohort of haemophilia B patients with mean scores ranging from 3.0-10.0 across disease
severity and treatment types. Haemophilia B treated by prophylaxis ankle HJHS were
comparable to in those with severe haemophilia A, suggesting that ankles are equally
affected in terms of clinically detectable haemarthropathy, but findings are limited by
sample size. As discussed in Chapter Two, studies of people with haemophilia B report
lower incidence of haemarthrosis with fewer complications of joint haemarthropathy
[235]. This cohort appears to differ from other cited studies, but again the small sample
size (n=34) limits any firm conclusions. Haemarthropathy has been observed in 17% to
77% of patients with moderate haemophilia in population studies in the Netherlands [5,
264]. Low HJHS in moderate haemophilia treated using an on-demand regime are a
reflection of current evidence on the effect of bleeding and the need for treatment In the
UK [4]. Total HJHS in moderate haemophilia A are similar to those in severe haemophilia
A, but no formal observations were made owing to the sample size (n=122); A large
proportion of patients did not have an HJHS, limiting the generalisability of the study [4].
Whilst the Scott et al. (2019) study reported total HJHS and the cohort in this study only
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reported HJHS for the ankles, it does provide support to the case that there are emerging
trends of joint disease in the moderate haemophilia population [4, 256, 265]. Prophylaxis
regimes are yet to be formally adopted in the treatment of moderate haemophilia. den
Uijl et al. (2009) recommended that those with moderate haemophilia should start
prophylaxis if they have a trough level of less than three and following their first joint
bleed up to the age of five [29]. The effect of haemarthrosis at the ankle and subsequent
haemarthropathy in this cohort highlights the level of haemarthropathy across all disease
characteristics. In moderate haemophilia, there is a need for a better understanding of
the population and the potential effect of detectable and non-detectable episodes of
haemarthrosis, which results in a decline of joint health.
4.6.2 Impact of ankle haemarthropathy
The primary aim of this study was to identify the impact of ankle haemarthropathy on
HRQoL and foot and ankle PROMs. The results indicate that HRQoL and foot and ankle
PROM scores are poor in the presence of ankle haemarthropathy in people with
haemophilia. Patient characteristics of haemophilia type, severity and treatment regime
did not affect HRQoL, with poor total and domain scores of the HAEMO-QoL-A across
all patient characteristics. When patient characteristics were analysed as independent
predictors of decline in HRQoL, only haemophilia severity in the domain of physical
function was significant (0.004, CI .24; 0.629). Therefore having a direct relationship of
severe haemophilia and impaired physical function. Findings in this study are similar to
other studies of multi-joint haemarthropathy where severity is associated with worse
HRQoL. Higher levels of disability associated with loss of joint function and structural
change at the ankles, knees and elbows have been reported in severe disease with
patients experiencing the worst outcomes related to bleeding, pain and HRQoL [19, 250,
266]. However, patients with moderate and mild disease with lower levels of joint disease
have been reported to be less affected [221, 246]. This was not the case in the current
study where people with moderate disease were equally affected as those who have
severe haemophilia. Although the 29 moderate cases in the current study is a relatively
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small sample (n=29) the findings are similar to De Juili et al. (2014), who in a much larger
sample (n=75) identified that whilst the majority of those with moderate haemophilia have
few bleeds or complications of bleeding, a proportion are severely affected by
haemarthrosis disability and reduced QoL [29]. In our cohort of moderate haemophilia A,
patients treated by prophylaxis reported higher HJHS (Table 10) than those using on-
demand treatment. This study suggests that those treating with prophylaxis do so
because of a history of spontaneous or traumatic bleed similar to the bleeding profile of
severe haemophilia A [5]. Those treated on demand may have fewer clinically detectable
joint bleeds or fewer serious ankle haemarthrosis events. Closer monitoring of moderate
haemophilia is emerging as a recommendation for this group of patients, leading to
changes in treatment regimens [4, 196, 256]. Whist drawing inference from this small
sample is done with caution, these findings support the notion that moderate haemophilia
should be closely monitored and treated, especially in children with musculoskeletal
immaturity exposing joints to a higher risk of long-term complications, including the
decline in HRQoL, increased pain and disability [29].
Similar conclusions can be drawn from this sample of haemophilia B patients who were
impacted as much as those with haemophilia A in both HRQoL and foot and ankle
PROMs. This chapter contradicts reports that people with haemophilia B present with a
less severe bleeding phenotype, lower incidence of haemarthropathy and fewer
complications [234, 256]. Specifically, haemophilia B is reported to have a lower
incidence of bleeding and less joint damage [256]. In this chapter, HJHS of patients with
haemophilia B patients were similar to haemophilia A (severity and treatment type) which
would suggest that clinical measures of ankle haemarthropathy are the same regardless
of haemophilia type. Whilst our results are again to be interpreted with caution owing to
the sample size (n=34) It is apparent that where the physical manifestations of ankle
haemarthropathy are moderate to severe, the impact on HRQoL is equivalent across
disease type and severity. It remains to be established at what point arthropathic joint
changes lead to a decline in HRQoL. This chapter has highlighted that measurement of
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the physical manifestation of ankle joint disease alone does not fully capture the impact
on the patient. Therefore the use of an HRQoL measure such as the HAEMO-QoL-A in
clinical practice may help identify a decline in physical health where clinical measures
are limited by presentation and examination.
Similar results were reported in the foot and ankle specific total and domain scores of
the MOXFQ. Total scores, reported in Table 12 were between 50.1 and 58.9 with higher
scores (100 = worst health) across the total domain scores for walking/ standing pain
and social interactions. Similarly haemophilia type, treatment and severity were not
independent predictors of foot and ankle outcomes, indicating a systemic effect of ankle
haemarthropathy. These findings show ankle haemarthropathy directly affects foot and
ankle PROMs across the domains of walking/standing and social interaction, regardless
of cohort characteristics. Patients with moderate haemophilia treating on-demand
HRQoL were less affected (HAEMO-QoL-A total scores 35.5, SD 22.6) for reasons which
have been discussed previously. This is the first study to report foot and ankle specific
PROMs using the MOXFQ and therefore direct comparison with another haemophilia
population is not available. There is limited research that includes foot and ankle specific
outcomes in haemophilia studies. Intervention studies assessing the impact of foot
orthoses and footwear in the management of ankle haemarthropathy have used the foot
function index (FFI) and FFI revised (FFI-R) [14, 175]. In patients with varying levels of
ankle haemarthropathy, low to moderate effects of foot orthoses have been reported on
pain, activities and disability [175]. The study lacked detail, with a small study sample
(n=16) and no clinical measure of haemarthropathy, limiting the comparison to this
chapter’s findings [175]. Investigation of foot orthoses and footwear effect by Lobet et al.
(2009) identified low to moderate levels of impact of the interventions using the FFI-R
[14]. In both studies, foot orthoses and footwear produced significant reductions in pain
[14, 175]. Neither study provided mean data on the FFI domain or total index scores, but
both studies reported pre-intervention scores of 22 and 29-32 (FFI-R) respectively
indicating low to moderate levels of foot and ankle impact. This is lower than findings in
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this chapter (Table 12), but direct comparisons are limited by poor methodology, data
reporting and sample size. Studies of preoperative ankle OA have reported MOXFQ
scores of 55-60 out of 100, with higher scores indicating worsening foot and ankle pain,
walking/standing problems, and social interaction issues as a direct effect of ankle OA
[267]. Outcomes in this chapter’s cohort are similar indicating people with haemophilia
experience foot and ankle outcomes equivalent to people with ankle OA who have ankle
fusions and TAR surgery [267]. This chapter has identified that foot and ankle outcomes
in people with haemophilia who have ankle haemarthropathy have significant levels of
pain and disability equivalent to people with OA immediately before surgery for foot and
ankle disease. This thesis chapter aimed to understand the impact of ankle
haemarthropathy, and therefore all patients had a consultant diagnosis of ankle
haemarthropathy confirmed by diagnostic imaging (x-ray/ MRI). Ankle HJHS scores
(Table 10) were between 3.0 to 10.0, but mean SD were as high as 17 indicating
advanced end-stage haemarthropathy associated with chronic pain and disability [76].
Whilst there is no agreement as to the level of haemarthropathy indicated by HJHS when
compared with radiological scores of joint disease the mean HJHS in this chapter would
suggest moderate to severe levels of haemarthropathy [209]. These results show that
the presence of moderate to severe levels of ankle haemarthropathy severely impacts
foot and ankle outcomes that are driven by high levels of patient-reported pain.
Inhibitor status was significantly associated with the decline in HAEMO-QoL-A and
MOXFQ total scores (Table 15). The findings of this chapter suggest that the presence
of an inhibitor is a significant predictor of declining HRQoL and foot and ankle outcomes.
The development of inhibitors is a major complication of haemophilia and clinically
difficult to manage both physically and psychologically [39, 42, 268]. Immune response
to CFC significantly reduces drug half-life making standard treatments ineffective
resulting in an increased risk of bleeding [39]. The presence of inhibitors is also
associated with increased levels of joint arthropathy, chronic pain, long periods of
hospitalisation, absenteeism from work and decline in QoL compared to non-inhibitor
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patients [268]. Inhibitor status should therefore highlight not only the physical risk of
bleeding and disability to the patient but also the potential for a decline in HRQoL and
foot and ankle outcomes. Findings indicate that the impact of ankle haemarthropathy is
multi-factorial, in the presence of ankle pain and persistent joint bleeding that does not
respond to CFC treatment, inhibitor status should be closely monitored to prevent or
delay ankle haemarthropathy.
HAEMO-QoL-A physical function domain and on-demand treatment (P=0.13 CI, -0.087;
-0.01) were both independent predictors of declining HRQoL. Physical function is
severely impacted in the presence of ankle joint haemarthropathy. The walking and
standing domain of the MOXFQ and right ankle HJHS were also significant (P=0.021 CI,
0.035; 0.429) with higher HJHS a predictor of decline in the walking and standing domain
scores. Data suggests that on-demand treatment directly impacts physical function and
consequence of adherence to treatment and regime (prophylaxis, on-demand).
Numerous publications have reported the efficacy of prophylaxis on reducing ABR and
AJBR and the reduction of haemarthropathy development so the low AJBR in this study
is not unexpected [33-36]. Increased bleeding events are associated with increased pain,
disability and rapid decline in joint health [33, 36, 246, 257, 269]. Direct correlation
between regular prophylaxis and decline in joint health deterioration has also been
shown to improve physical and radiological joint changes [270]. Results are consistent
with primary and secondary prophylaxis studies that have shown physical function
declines at a much faster rate if treated by on-demand CFC. In a large cohort study
(n=903) exploring QoL in patients receiving different treatment regimens, significant
differences (p<0.02) in SF-36 physical domain scores are reported when on-demand
treatment (68.4 SE1.54) is compared to prophylaxis (73.5 SE1.95) [11]. In comparison,
Collins et al. (2010) seminal study of secondary prophylaxis and on-demand treatment
in adults (n=22) identified significant reductions in ABR and AJBR but did not find
significant differences in total HAEMO-QoL-A scores. Individual domains including
physical function improved on prophylaxis but were not significant. Whilst specific scores
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were not reported there were reported improvements in those treated by prophylaxis
compared to on-demand [2]. Findings in this study indicate that the impact on ankle
haemarthropathy is significantly higher when using on-demand treatment and is an
independent predictor of reduced HRQoL and foot and ankle physical function. The
majority of patients on treatment in the UK are now taking regular prophylaxis, but our
results suggest that those who start secondary prophylaxis are more at risk of decline in
physical function and therefore should be closely monitored to reduce the impact of ankle
haemarthropathy [232].
The significance of right ankle HJHS as an independent predictor of decline in the
walking and standing domain of the MOXFQ is consistent with moderate and severe
levels of ankle haemarthropathy reported in this chapter. It is unclear why the right HJHS
was significant as scores were similar between left and right HJHS, this could be related
to limb dominance or could be a data artefact. Difficulties in undertaking ADL where ankle
joint haemarthropathy is established is associated with loss of ROM and chronic joint
diseases [113]. Functional limitations associated with basic (walking/ standing) and
complex (running/ jumping) lower extremity activities have been associated with an
increase in age and loss of ROM but not with pain, however, the subgroup was younger
than the cohort of patients in this chapter and may not have had the same level of joint
changes seen in the impact chapter patients [266]. This contradicts this chapter’s
findings that ankle pain is significant in the presence of ankle haemarthropathy. The
patients sampled in the aforementioned study were classed as arthropathic based on
the radiological Pettersson (x-ray) score only, whereas the impact questionnaire patients
were recruited based on a consultant diagnosis. Therefore the clinical signs and
symptoms of ankle joint haemarthropathy and previous medical history such as episodes
of haemarthrosis and pain management would have been considered.
Ankle pain was the most impactful feature across all haemophilia disease characteristics.
Measurement of ankle pain using NPRS over six months is an independent predictor
(Table 15) of total and individual domains of both primary outcome measures the
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HAEMO-QoL-A and MOXFQ and is a significant predictor of decline in HRQoL (P=0.00
CI .559; .978) (Table 16) and foot and ankle outcomes (P=0.00 CI 5.87; 7.79) (Table 17).
In this chapter, patients with ankle pain reported over the past six months using NPRS
scores between 4.8 and 6.0 on an 11 point scale (0-10) reported in Table 8. Our NPRS
ranged from 4.8 to 6.0 across the cohort which is similar to that seen in studies of severe
haemarthropathy. A large US survey of the pain experience (n=764) in people with
haemophilia who have haemarthropathy reported pain with average persistent pain NPR
scores of 4.32/10 (SD, 2.53) in moderate and 4.25/10 (SD, 1.90) in severe haemophilia.
Pain was also the most significant contribution to the decline in QoL [271]. The level of
haemarthropathy was not reported and whilst the health care models of both countries
differ, scores were slightly lower than those reported in this cohort, suggesting this data
is representative of severe haemophilia in both chronic and acute pain driven by synovitis
and chronic joint disease [271].
These findings, therefore, indicate that the use of NPRS to measure ankle pain over six
months may predict worsening outcomes. Pain at the ankle has been identified as the
largest contributor to the decline in HRQoL; decline in ADLs associated with multi-joint
haemarthropathy accounting for 45.1% of all joint pain when compared to other
commonly affected joints [250]. Details of pain at other joints were not recorded in this
study, but the patient-reported distribution of haemarthropathy (Figure 8) was similar to
other studies where multiple joints are affected, and the prevalence data was reported in
Chapter Three. Ankle pain is often problematic in clinical practice, unlike other affected
joints the complexities of ankle joint biomechanics means the ankle is subjected to high
forces with ground reaction forces up to five times the body weight during the stance
phase of gait and restrictions in ankle ROM make offloading the ankle during ADL difficult
[14, 72]. The level of ankle pain highlights the effect of chronic ankle joint pain and the
impact on HRQoL and foot and ankle specific outcomes. Pain is the most significant
feature of ankle joint haemarthropathy and it is clear pain is a significant indicator of
worsening HRQoL and foot and ankle specific PROMs. Both the prevalence data
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presented in Chapter Three and the primary outcome data presented in this chapter
highlight that the ankle is the most impacted joint by haemarthropathy and the effect on
HRQOL and foot and ankle outcomes are significant.
4.6.3 Management of ankle haemarthropathy
4.6.3.1 Pharmacological management
The use of CFC for the treatment of mild and severe ankle haemarthrosis resulted in
very much improved/much-improved pain following mild and severe joint bleeds
respectively (Table 7). Infusion of CFC following haemarthrosis is known to result in rapid
bleed resolution and the reduction of pain [272]. The complexities of pain in haemophilia
are acknowledged [266], specifically the ability to differentiate between acute
haemarthrosis and chronic pain. Patients have been reported to treat episodes of joint
pain with CFC as the physical manifestation of joint bleeding declines and chronic joint
haemarthropathy and associated pain increase [221]. It is unclear whether the patients
in this chapter were treating haemarthrosis or musculoskeletal pain. A period of rest
following a suspected haemarthrosis resulting in a reduction in pain is often an indicator
of chronic OA pain in haemophilia, but this becomes more difficult to differentiate as
haemarthropathy progress [221]. Clinically patients often treat an incidence of joint pain
as a suspected joint bleed with extra CFC treatment; if in doubt as to whether a bleed
has occurred treatment should be initiated [272]. Patient questionnaire responses to
ankle pain response to CFC treatment for a mild and severe bleed were much improved
for both mild and severe bleeding, suggesting that in the presence of moderate to severe
ankle haemarthropathy it is still possible to differentiate haemarthrosis, and CFC
treatment is effective at reducing symptoms [221].
Regular use of pain medication was only reported in 43.7% of patients despite acute and
chronic pain being a key feature of our ankle haemarthropathy cohort. These results
indicate much lower levels of pharmacological pain management than that of Wallny et
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al. (2001) who reported 76% of patients took daily medication for chronic joint pain [250].
Paracetamol, Non-steroidal Anti Inflammatory Drugs (NSAIDs) and COX2 selective
inhibitors were the most commonly reported form of analgesia. Paracetamol followed by
traditional NSAIDs and COX2 inhibitors are recommended as the first and second-line
treatment of pain, but with gastrointestinal and cardiovascular comorbidity risk
respectively, caution is advised [53]. Strong opioid analgesics for chronic pain in people
with haemophilia are recommended were moderate to severe pain persists for up to six
months in duration, and with consideration to tolerance and dependency [140]. Opioid
analgesics were only used by a small number of patients (Table 9) in this study
suggesting opioids are used sparingly. This is in contrast to a recent US study that
reported 56% of adults with haemophilia used opioid analgesics for pain. However, US
prescribing practices differ greatly from the UK with emerging evidence of over-
prescription of opioids and dependency in US cohorts [249, 273]. It is unclear why the
other 56% of patients did not use pain medication despite similar NPRS scores. The
explanation may lie in the complexities of pain and other contributing factors such as
perception, experience and response to pain [272]. It is beyond the scope of this chapter
to discuss the complexities of pain, but patients are known to experience pain differently,
develop coping strategies to deal with pain such as exercises, massage and physical
therapy and distraction techniques or ignoring pain to combat symptoms [268, 272].
4.6.3.2 Surgical management
Ankle fusion surgery was reported in 59 patients with bilateral fusion reported in 14
patients. Rates of surgical fusion of the ankle joint are similar to those reported in other
studies of end-stage ankle haemarthropathy [79, 150, 274]. Pain is a significant driver of
the decision to undergo joint fusion surgery with significant improvement in pain, QoL
and function reported in several small studies [275-277]. Medium to long term follow-up
(six to 10 years) studies of joint fusion have reported a favourable outcome in people
with haemophilia who report low levels of pain and low complication rates [167, 174].
Medium to long term outcomes studies of haemophilia and ankle joint fusion (n=57)
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report VAS of 0.75 (1.3SD) after a mean of 6.6 years (range 1-18 years) post-surgery
indicating good pain outcomes [76]. Similarly, assessment of outcomes at 9.4 years post
ankle and subtalar fusion report favourable symptoms scores of 94.9 (of 100) [74]. Whilst
we could not confirm any specifics of the time of fusion or post-operative complications,
the findings of this chapter question the contribution of fusion surgery to pain
improvement and QoL. The patients in this chapter may have additional changes to the
joint around the ankle such as the subtalar joint, talonavicular and calcaneocuboid which
have been impacted by the changes to talocrural ROM. Radiological studies of OA ankle
fusion report arthritis at the hindfoot and midfoot with subtalar joint the most common
and severely affected (77.5%) therefore the joints adjacent to the fused ankle may
decline and become symptomatic [278]. In haemophilia, the subtalar joint is reported to
be affected in 50% of cases, therefore, providing context to results [77]. The fusion may
have also caused an additional burden to the contralateral ankle which may further
explain levels of chronic ankle pain. The biomechanical consequences of fusion are yet
to be established, or the effect on lower limb kinetics and kinematics of the contralateral
ankle, which may explain findings in this study that ankle pain and decrease in HRQoL
are unaffected by fusion surgery. Further exploration of long term outcomes in large
haemophilia cohorts is required to ascertain the impact of ankle fusion in the UK.
TAR was only reported by one patient and whilst TAR failure rates in haemophilia are
similar to the general population, patients with haemophilia require surgery at a much
younger age owing to the decline in joint health [64]. Therefore the complication of
revision surgery, potential for conversion to fusion and pharmacological treatment
complications make TAR a less favourable procedure in haemophilia and not commonly
performed [171]. Emerging pharmacological treatments such as EHL and BsMAbs may
improve long term joint health but their long term effect is yet to be established [225, 226,
241]. Reductions in ankle haemarthropathy and improvements in treatment may
therefore allow joint sparing surgery such as osteophyte or arthroscopic debridement.
Current ankle surgery procedures require additional treatment and high CFC treatment
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levels during and after the procedure increases the risk of complications [8]. Therefore
at the ankle, haemarthropathy surgical options remain limited.
4.6.3.3 Pharmacological treatment
Patients were asked to provide characteristics of treatment dose and regime.
Prophylactic regimens were used by a large proportion of patients with only 15.7% (n=38)
using on-demand treatment, of whom 6.2% (n=15) had moderate haemophilia. It is
unclear whether primary or secondary prophylaxis was initiated by patients in this
chapter and details were not collected as part of the patient questionnaire. The mean
age of patients indicates it would be more likely that prophylaxis was started after the
second joint bleed or over the age of five, increasing the likelihood of worsening
arthropathic joint changes [31, 246]. Secondary prophylaxis in adults has been shown to
significantly reduce ABR and AJBR. Collins et al. (2010) reported that in adults who were
previously treated on-demand, the initiation of secondary prophylaxis over 12 months
resulted in significant reductions in joint bleeds (15.0 (11-26) to 0 (0-3)) [2]. Therefore
starting prophylaxis in adulthood is still effective at reducing haemarthrosis. In this
chapter, ankle joint bleeding with low ankle AJBRs was reported across all disease types.
The presence of established joint haemarthropathy has been reported to “burn out” as
the levels of joint disease become chronic and the rates of joint haemarthrosis decline
[23]. Therefore the level of haemarthropathy in the prophylaxis group explains the low
levels of haemarthrosis in this chapter. Reporting of historical AJBR and ABR at the ankle
or other commonly affected joints were beyond the scope of this chapter.
Treatment doses per kg were within the UKHCDO recommendation for prophylaxis, but
studies of European and UK treatment regimens have suggested that lower IU/kg may
indicate under treatment [3, 4]. It is difficult to draw inference from our data due to the
absence of trough levels which provide a measure of the participant’s empty level before
CFC treatment [1]. Centres were asked to provide trough levels, but how trough levels
are taken before treatment, or “empty” may not have been consistent and therefore
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misinterpreted. SHL treatment was used by 45.3% (n=107) of haemophilia A patients
and a larger proportion of all patients used EHL (50.93%, n=120) in our cohort than the
previously reported data in prevalence chapter three of 30%. Our data was collected
over a longer period (2018-2020) than the chapter three prevalence data (2018) and
therefore the likelihood of access to EHL would be higher, with more patients moving
onto EHL products. The use of EHL products has been reported to increase trough levels
by 1.6 to 1.8 times that of an SHL and increase trough levels by 20% to 50% with higher
trough levels [242], therefore reduce treatment burden and improve HRQoL but this
chapters data does not support this, nor the improvement of patient outcomes [49, 224-
226].
Treatment of joint bleeds in our cohort presented in Table 6 was within UKHCDO
guidelines on acute and chronic joint bleeding of 25-30 IU/kg for haemophilia A SHL and
EHL products and 40-60 IU/kg for haemophilia B [13, 43]. The number of days treated
was relatively low for both mild and severe incidents, with treatment days of 1-2 for a
mild bleed and 3-6 for a severe bleed. During a suspected joint bleed, patients are
clinically advised to continue CFC treatment until the pain subsides [43]. Our findings
suggest that this is a relatively short period for mild and severe joint haemarthrosis.
Diagnostic studies of MSK ultrasound have shown that blood within the joint is present
for several days after the initial pain has subsided [145]. Even low levels of blood
contained within the joint continues to cause a decline in joint health as well as the
inflammatory effects of haemosiderin burden and pro-inflammatory cytokines and
proteases [53]. Whist our cohort had moderate to severe ankle haemarthropathy, the
use of pain as a marker for treatment of joint haemarthrosis may lead to CFC under
treatment. Likewise, it is a balancing act between the effective use of bleed dose CFC
and the long term consequence of under-treatment of haemarthrosis. Low-level bleeding
has been proposed as a mechanism by which joint health continues to decline [52, 240].
Whilst our study did not ask specifically about treatment following the subsidence of pain,
122
the treatment length does raise concerns around patient perceptions of treatment length
and the risk of ongoing joint damage despite adequate treatment regimes.
4.6.3.4 Access to clinical services
Consultant survey data identified general access to all complementary MSK services
associated with the management of haemophilia and joint pathology. Orthopaedics,
rheumatology, and AHP services were by direct or indirect referral within haemophilia
centres nationally. Only a small number of centres were unable to access specific
services (Figure 9) such as point of care ultrasound, radioactive synovectomy and
psychology services. This is consistent with data recently published in the Care Quality
Review of Inherited and Acquired haemophilia and other Bleeding Disorders  Programme
2019/2020 on behalf of the UKHCDO [12]. Access to diagnostic and point of care MSK
ultrasound was the most common service with limited or no access by consultants at
participating centres. This finding is of particular importance as the emergence of new
pharmacological treatments reports better haemostasis and declining AJBR and ABR
[241, 279]. It is unclear as to the impact these pharmacological treatments will have on
early and established haemarthropathy, however, MSK ultrasound has the potential to
monitor joint health as a potential treatment outcome [280, 281]. MSK ultrasound is
particularly sensitive to detecting soft tissue pathology associated with haemarthropathy,
but at the talocrural joint is limited by access to the joint and the inability to detect
subchondral bone changes [282, 283] Whilst limitations are acknowledged, in the
monitoring of early disease synovial changes and cartilage make ultrasound a cheap
and reliable method of monitoring of joint health and use in clinical practice may improve
patient outcomes as well as decrease the impact of disease by timely assessment of
joint pain and disability [280].
The consultant survey reported direct or indirect access to orthotics, physiotherapy and
podiatry services, but patient responses in the impact study were somewhat different.
Access to physiotherapy forms part of the UKHCDO management guidelines [12, 13]. In
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the consultant survey, physiotherapy access was reported at all centres, but 11% (n=26)
of the impact patients reported no access to a physiotherapist. Despite access
improvements, there are still centres that have no full time access to a haemophilia
specific physiotherapist and therefore patients may not feel they have access to
specialist physical therapy. Physical therapy in haemophilia has been shown to reduce
pain and provide expertise in the management of bleeding disorders [284]. Access to
adapted footwear and foot orthoses by patients were vastly different to service access
indicated by the consultants (Figure 10). Adapted footwear and foot orthoses were not
worn by 88% and 51% of patients respectively. Lobet et al. (2012) reported good patient
satisfaction when using bespoke footwear and casted foot orthoses but failed to identify
specifics of the satisfaction questionnaire which may have provided details of
contributing factors such as comfort, compliance and acceptability [14]. Patient
satisfaction has been identified as high when accessing combined podiatry and
physiotherapy services for the provision of footwear [15, 16]. The combined approach to
the management of haemarthropathy is positivity associated with improvement in pain,
reduction in AJBR and improvement in QoL [15]. Access to a podiatrist was again
reported either by direct or indirect referral in UK CCC and HC (Figure 11). Findings
indicate that common MSK services provided by a podiatrist are not accessed by patients
with ankle haemarthropathy. Access was limited to less than half of patients, with only
34% of patients supplied with foot orthoses. Specifics of foot orthoses provision also
indicate that the majority of patients were supplied with foot orthoses by NHS services,
but 31% used shop brought orthoses. It is unclear as to why patients used shop brought
insoles. Access to orthotic services by either podiatry or orthotics might not be available
or poor satisfaction from previous interventions with patients often attending clinics with
a bag of previously issued foot orthoses. It may simply be that over the counter orthoses
often found on the high street exert their action by providing a cushioning effect and this
is enough to provide some form of comfort. The use of combined podiatry and
physiotherapy services have shown good patient satisfaction in the management of
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ankle haemarthropathy and the provision of foot orthoses in the UK haemophilia cohorts
[15, 16]. The clinical needs of patients with ankle haemarthropathy and multi-joint
haemarthropathy however are unknown and require further investigation.
Although access to routine podiatry foot care services was available at HC (90%, n=38
centres) for callus debridement and nail cutting, a large proportion of patients (57%,
n=133) deemed access as not applicable. Findings suggest that the requirement for
routine foot care is not a priority for those with ankle haemarthropathy with only 8% of
patients receiving regular foot care. There is no published evidence for the need for foot
care in haemophilia, but the progressive plantarflexion deformity and evidence of
increased forefoot pressures combined with axial joint deformity at the elbows and knees
may limit the ability to self-care [176]. This is typically seen in people with RA where the
loss of hand strength and deformity prevent self-care and foot deformity result in the
build-up of painful callosities [210, 285]. Whilst multi-joint haemarthropathy is a common
feature of the disease, findings suggest that the level of disability reported in this cohort
is not sufficient to limit self-care, or may indicate that patients rely on family members to
provide foot care.
Research in RA and OA have shown that patient education, regular foot assessment and
foot care services improve pain and QoL but to date, there is no published data in
haemophilia cohorts [286, 287]. Findings from this study highlight the need for further
research to determine the provision of routine and musculoskeletal foot and ankle care
required in the management of ankle haemarthropathy. Both modified footwear and foot
orthoses have the potential to improve HRQoL and foot and ankle PROMs. However, in
a condition characterised by haemarthrosis and bleeding, the mechanism by which the
intervention exerts its clinical effect should be established before a full randomised
control trial in the haemophilia population.
125
4.6.1 Limitations
The limitations of this study are acknowledged. Self-reported data has been cited as
unreliable with the potential to overestimate specific joint pathology. It relies on patients’
interpretation of their condition, however, data presented here is similar to other studies
of multi-joint OA and HRQoL in haemophilia and therefore provides assurances to the
quality of data [5, 251]. Haemophilia is a life-long condition, therefore they are typically
aware of their joint health. Efforts were made to reduce over-reporting by providing
details for both the patient and clinician to complete. The small number of patients with
haemophilia B and moderate haemophilia included in this study means specific results
should be interpreted with caution. This is a difficulty in rare diseases and whilst the
number of patients is small, it does highlight emerging issues in the impact of ankle
haemarthropathy outside of severe haemophilia A. The small number of moderate
haemophilia patients provides further evidence to the effect of moderate haemophilia on
joint health status, recently reported in haemophilia literature [5, 29, 265]. Recent
advances in treatment have seen people with severe haemophilia without inhibitors grant
access to the uses of BsMAb treatment with equivalent factor levels of 20-30% and show
promising reductions in ABR, AJBR and treatment burden [225]. Treatment is not
currently licenced for use in those with moderate haemophilia, but those affected by high




In the presence of ankle haemarthropathy HRQoL is poor and foot and ankle PROMs
are significantly affected regardless of haemophilia type, severity or treatment regime.
Pain is the main driver for decline and those with ankle haemarthropathy have high levels
of chronic pain. Findings from this study indicate that the assessment of ankle pain using
NPRS over six months is directly linked with worsening HRQoL and foot and ankle
PROMs. The management of ankle haemarthropathy appears to be inadequate with the
disparity in the pharmacological management of pain and bleeding events and non-
pharmacological management. Whilst UK CCC report access to a range of MSK
services, patients’ engagement with mechanical interventions such as footwear and foot
orthoses is very low. Further research is needed to understand contributors to decline in
HRQoL, management of pain and better quality research to understand how mechanical
interventions such as modified footwear and foot orthoses may improve HRQoL. The
multi-joint nature of haemarthropathy means that understanding the effect of an
intervention on the ankle could potentially lead to unwanted proximal compensation in
kinetics and kinematics. Likewise, where modifications to footwear are multi-faceted the
effect of individual and combined components provides insight to effect. Therefore before
future studies in a haemophilia population, the mechanism of action of interventions
should be undertaken in healthy patients to reduce risk to joint health.
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Chapter 5 - A mechanism of action study to explore
the individual and combined components of the
Leeds Ankle Stabilising Enhanced Rocker (LASER)
intervention
This chapter establishes the mechanism of action of the LASER intervention. Gait
analysis was used to quantify the kinetic and kinematic effect of footwear on the lower
limb. Modified footwear can change the kinetic and kinematic profile of the ankle and
lower limb joints during gait. The kinetic and kinematic effect of the LASER intervention
on the ankle and other lower limb joints was explored in terms of it its individual
components and all components combined.  The mechanical effects of the intervention
on the ankle joint moment of force and range of motion (ROM) were measured in a
normal healthy population to avoid exposing patients at risk of joint bleeds to poorly
understood mechanical forces.
5.1 Introduction
Ankle pain and osteoarthritis (OA) affect 12% and 4%, respectively in the UK population
[288]. Whilst primary OA is uncommon, post-traumatic OA accounts for 70% of
symptomatic ankle arthritis, caused by a malleolar fracture and ligamentous injury [288].
Less common causes include inflammatory and crystal, infection and neuropathic
arthropathy [288, 289]. In contrast, patients with severe haemophilia have a population
incidence of 20% of ankle OA and significant patient-reported pain and disability related
to the incidence of haemarthrosis [9, 248]. A single significant episode of haemarthrosis
or repeated minor incidents leads to joint health damage by means of reactive synovitis,
cartilage haemosiderin deposition and changes to the subchondral bone resulting in
permanent damage and structural change and haemarthropathy [60, 69, 290]. The ankle
is the most common site of joint health decline and pain as identified in Chapters Two
and Three. Pathological changes to the ankle joint result in lower joint stress tolerance
when walking as ankle joint haemarthropathy progress [136]. Recently a small study
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(n=3) conducted by Talbott et al. (2020) investigated changes in contact pressures of the
talus using non-weight-bearing MRI with the segmentation of bone, cartilage (n=14
images) and bone cysts. Cyst formation in the talus increased contact pressures by 66%
in the talus and 16% in overlying cartilage. If both the tibia and talus are affected then
forces are shown to increase by 125% and 120% respectively with a 140% increase in
pressure exerted on cartilage [70]. This study, whilst small and experimental rather than
definitive, provides context to the functional and structural changes observed clinically at
the ankle joint [70]. Sub-optimal condition of bone caused by damage to the articular
cartilage and subchondral bone cyst formation results in instability and ultimately joint
failure, with those patients in the third decade of life reporting a reduction of 80% ankle
joint range of motion (ROM) and significant pain and disability [290]. Ultimately the failure
of the ankle joint leads to changes in the ability to continue activities of daily living (ADL)
and significantly impacted health-related quality of life (HRQoL) and foot and ankle
outcomes identified in Chapter Three.
Progressive destruction of the ankle joint leads to changes in the kinetic and kinematic
profile of the lower limbs [18]. During the gait cycle, the foot makes contact with the
ground, the ankle joint acting as a fulcrum to allow forward progression of the limb; a
process referred to as the ‘anatomical rocker’ [92]. In haemarthrosis of the ankle, gait
changes occur at all phases of the anatomical rocker, resulting in a significant reduction
in ROM, and gait efficiency [18]. Typically changes in joint structure and function
described above and loss of ankle dorsiflexion required for normal walking leads to
gradual loss of the normal rocker function of the ankle, significant disability and changes
to kinetics and kinematics of the proximal joints of the lower limb. When the anatomical
rockers of the heel, ankle and forefoot are impeded by pathological changes such as the
structure and function changes reported in ankle haemarthropathy, modified footwear
may substitute to facilitate movement during the stance phase of the gait cycle [187,
188]. Modified footwear is commonly used in the management of conditions such as
diabetes and RA, to prevent ulceration and improve mobility and function in several
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conditions associated with impaired walking and orthopaedic deformity [188-190].
However, there is little published data on the benefit of modified footwear in haemophilia
and ankle haemarthropathy, despite the ankle being the most affected joint [14].
Rocker profile shoes are the most common footwear modification used in the
management of diseases of the foot and ankle to facilitate motion and redistribute foot
pressures [194, 291]. The majority of research on rocker profile footwear concentrates
on the offloading and redistribution of pressure associated with the occurrence of diabetic
foot ulceration [188]. In the management of ankle OA, the use of rocker profiled shoes
has been shown to facilitate change in sagittal plane kinematics by reducing the plantar/
dorsiflexion at the ankle joint where the function is either impeded by pathology or lost
by fusion [115, 188, 292]. In haemarthrosis, a rocker profile shoe has the potential to
compensate for the reduction in ankle ROM [188]. A heel-toe rocker whereby a negative
heel rocker is used in combination with a forefoot rocker has been suggested as the most
appropriate configuration in the presence of ankle OA or where ankle ROM is impeded
[188, 192]. Kinetic and kinematic changes have been observed at the ankle joint when
using a double rocker (rearfoot and forefoot) shoe.
The study by Long et al. (2009) of rocker soled footwear in healthy controls (n=40)
reports that use of a double rocker sole increased dorsiflexion at midstance, but as the
ankle rocker progressed to through to the third ankle rocker, dorsiflexion was significantly
reduced, although the reductions reported were between 0.61 and 1.25 degrees
(P=0.05) calling into question the clinical relevance of the ROM change [187]. The
change reported in dorsiflexion was small, but in ankle haemarthropathy, this small
change may reduce the risk of further trauma to the joint and pain associated with
osteophyte formation and synovial hypertrophy at the joint margins [293].
Whilst the results should be interpreted with caution owing to the use of a single marker
to calculate ankle kinetics, Long et al. (2009) did report reductions in plantarflexion
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moment from midstance through to toe-off (P=0.01) [187]. Findings indicate the potential
to reduce the mechanical burden at the ankle joint by reducing the ROM and moments
during all three ankle rockers. This is particularly relevant to ankle haemarthropathy
where the gradual loss of ankle ROM in combination with joint pathology exposes the
joint to the risk of trauma, haemarthrosis and pain [293]. [135]. Evidence supports the
benefit of a double rocker shoe especially in ankle haemarthropathy where changes in
both ankle kinetics and kinematics occur ankle joint disease progresses [135].
A smaller study (n=17) of healthy controls investigated a double rocker soled shoe, but
with a different short rocker apex point (50% vs 60%). Arazopour et al. (2013) [193]
reported a reduction in terminal stance dorsiflexion of 9.2 degrees when compared to a
standard shoe and a sagittal plane ROM change of 9 degrees. Arazopour et al. (2013)
[193] found a significant change (p0.023) in the inversion of the ankle by a mean of 10
degrees (SD  4.4) during second double limb support. Likewise, a significant increase of
1.25% (P=<0.05) was reported for external foot rotation. Both studies support the use of
a double rocker or heel-toe rocker in the management of ankle OA and arthrodesis, but
at the sacrifice of frontal plane motion which increased in both studies. Whist, it is unclear
how these finds translate to a pathological cohort, they have potential implications for
use in clinical practice, although the authors acknowledge this may lead to instability and
a reduction in balance and changes in foot pressures. Both studies acknowledge
limitations in methodology and the recommendations for further investigation. Firstly, the
collection of in-shoe kinematics to include markers attached directly to the foot or
videofluoroscopy to quantify movement of the foot with the shoe. Secondly, the use of a
rocker sole in combination with additional modifications such as the SACH [187, 188,
193]. The use of a rocker sole appears to have the potential to change ankle kinetics and
kinematics, but the lack of cited research on the effect of modified footwear in the
management of those with haemophilia and ankle haemarthropathy indicates a need for
further investigation of the mechanical effect in combination with other footwear
modifications.
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The solid ankle cushioned heel (SACH) modification is designed to allow a normal heel
strike during the stance phase creating a pseudo-plantarflexion moment by deformation
under loading forces. This is particularly beneficial where ankle ROM is impeded such
as talocrural joint OA [192]. The benefits of a SACH have been reported by Wu et al.
(2004) when using a “spongy” SACH in combination with a forefoot rocker at 60% of a
shoe in healthy males [194]. The SACH increased dorsiflexion/plantarflexion at the
hindfoot in relation to the tibia (30.2° (SD 5.9°) vs 24.2° (SD3.0°)) when compared to a
traditional shoe. The five-degree increase in ROM was identified as mechanically
beneficial for patients with ankle pathology or arthrodesis where ankle ROM is impeded.
An increase in eversion angle of 3.8° occurred in the frontal plane, a potential
compensatory effect that led to a rapid increase in peak plantarflexion at the hindfoot
during stance. The author reported that participants thought that the SACH did not
provide enough cushioning, nor did it feel thick enough, although no formal PROMs were
included. Large magnitudes in the rearfoot inversion may suggest the material used in
the spongy SACH deformed too rapidly under load. Details of the SACH material were
not reported and may provide more insight, but comments and results suggest a material
that gradually deforms under load may be more suitable.
The use of modified footwear has the potential to delay mechanical joint changes,
improve reported pain, QoL, kinetic and kinematics in patients with haemophilia and
associated ankle haemarthropathy. To date, there is little evidence to support changes
in practice or management guidelines. Therefore research in ankle haemarthropathy
must establish the mechanical benefit of such adapted footwear before clinical trials. In
clinical practice, modified footwear is rarely used in isolation, with foot orthoses used in
parallel to also control how the foot interacts with the shoe [188].
In-shoe orthoses, casted insoles and functional foot orthoses (FFO) describe devices
that exert or change forces and pressures at the shoe foot interface [113]. Evidence
supports the use of in-shoe foot orthoses and FFO in the prevention of foot deformity
and provides stabilisation in inflammatory arthritis and the management of the diabetic
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foot, but evidence in ankle haemarthropathy is lacking [17-19]. The research was
undertaken by Slattery & Tinley (2001) reports significant improvement in foot pain and
reduced incidence of bleeding in a group of 16 haemophilia A patients using FFO [294].
Likewise, the use of heel cushion insoles has been reported to improve patient-reported
pain and disability, but provide no functional control and where instability of the ankle
joint occurs [179]. Jorge et al. (2006) reported that the use of FFO produced a significant
reduction in spontaneous joint bleeding (P=<0.001), though the type of FFO used
provided cushioning action only and was investigated in combination with an ankle brace,
potentially confounding the individual effect of the cushioning orthoses [176]. Few studies
have investigated the kinetic and kinematic effect of FFOs in haemophilia and blood
induced ankle arthritis. Lobet et al. (2012) reported little effect of casted high-density
polyethene anti-pronatory casted orthoses on ankle biomechanics in patients with
haemophilia and ankle haemarthropathy. When orthopaedic insoles were prescribed in
combination with a bespoke orthopaedic shoe, little effect was reported either with or
without the insole but kinematics were measured using markers mounted on the outside
of the shoe, not the skin, a known source of error in gait analysis [295]. Studies have
now shown that shoe-mounted markers lead to an underestimate of the ankle kinematics
which is essential to calculating joint kinetics [129, 296]. Specifically, comparisons of in-
shoe vs shoe-mounted markers have reported significant (P=<0.001) under-reporting of
the calcaneal ROM of 5.9 degrees in the sagittal plane, and 1.6 degrees in the transverse
planes [125]. Similarly, a comparison of shoe-mounted vs skin mounted markers have
reported significantly greater (p<0.05) coronal plane peak ROM (3.16°) and peak
eversion magnitude (5.11 degrees s-1) [124]. Further investigation using in-shoe
measuring techniques such as those described by Bishop et al. (2015) is required to
appreciate the mechanical effect of FFOs and orthoses in combination with modified
footwear in the management of ankle haemarthropathy [126].
In the management of ankle pathology, the LASER intervention, a modified military boot,
with a rocker sole and SACH (details described in 5.3.5.3) has been used clinically at
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the Leeds CCC to manage ankle haemarthropathy for the past 12 years. Audit data
obtained from eight adults diagnosed with haemophilia using the LASER intervention
reported an improvement in patient-reported pain and disability scores by 18.5%, and a
reduced incidence of ankle bleeds from 11.4 to 2.2 per patient over 12 months [15, 297].
Whilst the individual and combined boot modification and FFO have been investigated,
the design of the LASER intervention use of a modified SACH heel in combination with
a “heel-toe” rocker profile and a military boot has yet to be explored. Therefore before a
study is undertaken in a pathological patient group such as blood induced ankle arthritis
ankle the kinetic and kinematic effect of the individual and combined components of the
LASER intervention requires the establishment of the mechanism of action.
5.1.1 Study aims
The specific aims of this chapter are:
i. To determine whether a bespoke cluster marker wand is suitable for the
collection of in-shoe foot and ankle kinematics.
ii. To compare the accuracy of foot vs boot-mounted gait markers in the collection
and reporting of kinematic gait data.
iii. To investigate the biomechanical properties of the LASER intervention when
compared to a standard sports trainer in normal volunteers.
iv. To investigate the effect of the LASER intervention on the kinetic and kinematic
profile of the lower limb in normal volunteers.
5.2 Pilot study
A pilot study was performed to determine the most appropriate data collection methods
for acquiring lower limb kinematics whilst participants wore a military boot used as part
of the LASER intervention.
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5.2.1 Introduction
The use of carefully modified shoes in biomechanical research has shown comparable
repeatability to studies employing barefoot conditions with the advantage of a more
realistic clinical application in the collection of multi-segment foot kinematics using
surface-mounted markers in healthy volunteers [127, 131]. The bespoke shoes used in
past research for in-shoe, skin mounted markers are minimal in the structure of the upper
and sole units, a limitation in both studies. The military boot used in the LASER
intervention is however a semi-rigid military boot that fastens above the ankle, and
therefore significantly more structured than previously investigated footwear [127, 131].
The collection of foot and ankle kinematics requires the use of boot-mounted markers or
foot mounted cluster wands, therefore the comparison is required to determine the
accuracy of data collection techniques and identify the most reliable method.
5.2.2 Aims
This pilot study aimed to determine the following;
I. Whether a cluster “wand” is suitable for the collection of foot mounted in-boot
kinematics.
II. Whether differences in ankle kinematic data are reported between boot-
mounted markers set vs foot mounted cluster wand marker set, and which
approach should be undertaken in a LASER intervention mechanism of
action study.
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5.2.3 Pilot study part one: Cluster wand development
Details on in-shoe foot kinematics have been presented in the review in section
2.2.1.1.3, therefore an overview only is presented in this section.
5.2.3.1 Introduction
The measurement of shod 3D kinematics have until recently been captured by shoe-
mounted marker sets, but there is emerging evidence that external footwear markers
makes assumptions about the movement of the foot within the shoe and therefore
incorporates error to kinematics [123]. In a deep shoe such as a military boot, a marker
cluster wand is yet to be utilised in-shoe. Cluster wands have been used to obtain
hindfoot kinematics in-shoe, however, there are no commercially available marker
clusters [20, 131]. It was, therefore, necessary to develop a bespoke cluster wand that
can sit on the foot through a window within the shoe. The use of rigid clusters with three
or more attached passive markers allows the generation of a virtual marker on the skin
surface that can then be tracked during data collection (Figure 13) [298]. A virtual marker
can be generated at the cluster wand origin (Figure 13b) using offsets obtained from the
known dimensions of the wand.
5.2.3.2 Methods
A cluster wand was created using a 3D printer (3D HUBS, Chicago, US) with 6mm
reflective markers placed at the anterior, posterior and superior projections displayed in
figure 1a. Three individual kinematic cluster wand positional trials were collected at zero,
five and 10 degrees of lateral tilt (Figure 14) using a 10 camera Vicon system (Vicon MX;
Oxford Metrics, UK). The cluster wand, measuring 27mm from origin to base was placed
in insolation at the gait laboratory origin (Figure 13a) at the Chapel Allerton Hospital
(CAH) gait analysis laboratory. Markers were labelled in Vicon Nexus software version
2.6.1 (Vicon, Oxford UK) and exported into Visual 3D software (C-Motion, Germantown,
USA). A virtual marker or “landmark” was created by using the three physical markers
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on the cluster wand identified as the anterior, posterior and superior markers (Figure
13a). The virtual marker was generated between the anterior (A) and posterior (P)
marker within Visual 3D (Figure 13b). A “landmark” was generated defined as the origin
marker (O) between the anterior and posterior markers (0.5). A segment was then
generated by the anterior, posterior and superior markers with the landmark defined as
the centre and another landmark generated at the cluster wand base (B) using methods
described in the C-Motion WIKI tutorial [299].
Figure 13a Figure 13b
Figure 13: Cluster wand
The marker used and landmark locations of the generated origin marker point and
projected. Figure 13b. Generated virtual markers at origin (O) and base (B) in Visual 3d
software (C-Motion, Germantown, USA). Anterior (A), superior (S) and posterior (P) =
technical marker position on cluster wand (Figure 13a) and corresponding markers on
in Visual 3D software (Figure 13b)
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5.2.3.3 Results
When a bespoke cluster wand was positioned at zero, five and 10 degrees the base
virtual mark maintained a position of 27mm about the origin marker (Figure 14). In
addition, the displacement of the base marker maintained its coordinates of <0.007mm
within the margin of error of the Vicon data collection system.
a
Zero degrees Five degrees Ten degrees
X:0.007002 X:0.007413 X: 0.004348
Y: 0.003032 Y: 0.002661 Y: 0.001870
Z: 0.003113 Z: 0.003770 Z: 0.004918
Figure 14: Cluster wand testing
Cluster wand orientation at gait laboratory base marker displacement from laboratory
origin in the XY and Z
5.2.3.4 Conclusion
The findings from this pilot study indicate that the bespoke cluster wand is suitable for
projecting a virtual marker for the collection of In-shoe kinematics. Findings justify the
use of cluster wands to define the placement of the anatomical markers at the lateral
calcaneus, first and fifth metatarsal heads and in turn, the generation of a virtual foot
segment.
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5.2.4 Pilot study part two: Boot and skin mounted kinematic
comparison
5.2.4.1 Introduction
The collection of in-shoe kinematic and kinetic data can be problematic due to movement
of the foot within the shoe and marker placement misrepresentation when placed on the
shoe surface [127]. Shoe mounted markers have been used in the collection of kinematic
data with a recent study using 3D printed wand markers reporting reliable data collection
in-shoe [131]. The use of shoes with windows cut into mesh uppers to allow skin
mounting of markers has also been reported, but in both instances, large portions of the
shoe were removed and lacked the structural integrity of the military boot required as
part of the LASER intervention [127, 131]. This second pilot study aimed to compare in-
shoe ankle kinematics using foot-mounted cluster wands (actual) compared to markers
mounted on the external surface of the boot, to determine whether the extra complexity
of wand-based markers could be warranted and to finalise which method was to be
employed in the LASER intervention study.
5.2.4.2  Method
Based on the rules of thumb for the recommended sample size for conducting pilot
studies [300], 12 healthy participants were recruited from department staff. A 10 camera
infrared passive marker motion capturing system operating at a frequency of 100Hz
(Vicon MX, Oxford metrics, UK) was integrated with two force plates (AMTI, Watertown,
MA) capturing force data at 1000Hz and arranged in succession allowing simultaneous
collection of concurrent left and right side gait events. Lower limb kinematic data were
collected using skin mounted nine millimetre (mm) reflective markers (Vicon MX, Oxford
metrics, UK). Markers were placed following the CAST protocol marker set that tracks
lower limb segment kinematics with six degrees of freedom [301]. Justifications for use
of the CAST protocol have been presented in the Chapter Two literature review (Section
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2.2.1.1.1: Lower limb models). Tracking marker clusters were placed on the sacrum,
lateral thighs, and lateral shanks.
Figure 15: marker setup
a, Anterior view b, Posterior view
Gait data were collected for the left limb with both a shoe-mounted marker set and with
in-shoe 3D printed cluster wands placed at the lateral calcaneus, 1st metatarsal
phalangeal (MTP) joint and 5th MTP joint through 25 mm holes pictured in Figure 16
[126]. Each participant wore tight-fitting shorts to allow the fixation of reflective 9mm
markers over anatomical landmarks to define joint centres at the hip, knee and ankle.
Hip joint centres were calculated based on the embedded anatomical frame of the pelvis
based on the recommendation of Bell et al. (1999) [302]. Reflective markers were placed
on the left and right anterior superior iliac spine, and right and left posterior superior iliac
spine. The knee joint centre was defined by marker placement at the condyles of the
femur and the ankle medial and lateral malleolus [301].
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Figure 16: Pilot Military boot with foot and boot-mounted marker sets
A static calibration was captured at the beginning of each footwear condition, a reference
frame for the dynamic trials. If markers were lost or moved during a dynamic trial the
marker or tracking pad was repositioned and another static trial was then collected for
the subsequent trials. After an acclimatisation period of five minutes between footwear
conditions, participants were instructed to walk, at a self-selected walking speed, up and
down a 12-metre walkway. Measurement occurred within a 5m3 capture volume with gait
events defined using two adjacent integrated AMTI force plates (Watertown, MA, USA).
Each participant undertook a static reference trial followed by five representative walking
trials. A trial was deemed acceptable if the participant made clean contact with either
foot on the force plate during the participant’s normal cadence. All static and dynamic
trial markers were labelled and dynamic trials gap-filled using the spline fill function up
to 10 frames using Vicon Nexus software 2.7.1(Vicon MX, Oxford metrics, UK). Labelled
kinematic markers trajectories and kinetic data were exported to Visual 3D (C-Motion,
Germantown, USA) for further analysis.
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A biomechanical model was created using the methods described in the c-motion six
degrees of freedom model that links segments of the pelvis, right and left thigh, right and
left and right shank and left and right foot [303]. Linked segments were then used to
calculate the kinematics and kinetics of the hip (pelvis and thigh), knee (thigh and shank)
and ankle (shank and foot).
The biomechanical model was applied to the static trial with associated dynamic trials
paired, based on the methods for building a six degrees of freedom model tutorial motion
wiki (C-Motion, Germantown, USA) [303]. Kinematic data were interpolated to fill any
gaps up to a maximum of 10 frames within Visual 3D (C-Motion, Germantown, USA)
[304] and was filtered using a low pass Butterworth filter at a cut of frequency of below
6Hz. Ground reaction forces (GRF) were filtered using a low pass Butterworth filter at
25Hz with toe-on and toe-off above 20 N at heel strike and below 20 N for toe-off using
thresholds from the GRF data [128, 305]. Calculations of ankle joint kinematics were
derived using a single segment foot model with the proximal segment defined by the
medial and lateral malleolus and the distal segment defined by the medial and lateral
malleolar markers and foot markers used to track the segment. Ankle kinematics were
calculated based on the C-motion ‘foot model two’ and calculated based on the knee
markers (medial and lateral epicondyle) as the proximal segment and ankle, the distal
segment (medial and lateral malleolus) tracked using the calcaneus, 1st metatarsal and
5th metatarsal markers. The use of foot model two calculates the ankle joint angle as
zero in standing regardless to actual anatomical position [304]. This pragmatic approach
was taken in preparation for use and comparison in a pathological cohort of patients with
ankle haemarthropathy, where the foot is often affected by plantarflexion deformity and
would not be captured faithfully using other methods [304, 306].
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5.2.4.3 Analysis
Processed kinematic data was exported at 101 data points of the stance phase of gait
for the ankle in the sagittal and frontal planes (X, Y) as mean values into a Microsoft
excel 2018 worksheet. Specific time points of stance; initial contact (IC), midstance (MS)
and toe-off (TO) were compared between conditions based on the anatomical points
associated with the ankle rocker during the stance phase of gait and the theoretical
concept that the LASER intervention will affect these points in the gait cycle [88].
Statistical analyses of the sagittal (X-axis) plane ROM at IC, MS and TO were undertaken
to test for differences between conditions. ROM was calculated from the peak joint
angles during the stance phase of gait for peak plantarflexion and peak dorsiflexion for
ankle sagittal plane ROM and peak inversion and peak eversion. Ankle joint angles at
IC, MS and TO were taken from 1%, 50% and 100% of the stance phase of gait.
Statistical analysis of the sagittal plane kinematics (x-axis) was chosen for comparison
between the LASER intervention, trainer and secondary outcomes due to its importance
in the calculation of ankle kinetics and change in ROM observed in the sagittal, frontal
and transverse planes [91]. Mean joint angles at IC, MS and TO were compared between
conditions in the Y (coronal plane) and Z-axis (transverse plane) of the ankle joint. To
assess the reliability of the foot-mounted (FM) and boot-mounted (BM) datasets
intraclass correlations (ICC) were calculated using two way, mixed effect consistency,
single rater (ICC 3,1) ICCs to report agreement between marker sets [307]. Root mean
square error (RMSE) and a paired 2 tailed t-test was undertaken to assess error between
measurements and explore for systematic differences in mean ROM in the sagittal plane
(x-axis), respectively. Statistical analysis was carried out using IBM Statistical Package
for Social Sciences (SPSS) version 21.
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5.2.4.4 Results
Descriptive ankle joint kinematics in the sagittal, frontal and transverse planes are
presented in Table 18. The largest variation between marker set measurements occurred
in the frontal plane at IC, sagittal plane in MS and TO. In sagittal plane gait events, the
boot-mounted marker set over-reported ankle joint angles when compared to the in-shoe
foot model kinematics. In the frontal plane, the boot-mounted marker set over reported
at TO and under-reported transverse plane kinematics at IC and TO.
Table 18: Ankle joint kinematics (degrees)
Plane Sagittal (X) Frontal (Y) Transverse (Z)
Footwear
Condition
FM BM FM BM FM BM
IC
Mean -1.30 -1.59 1.58 3.67 1.87 1.73
SD 1.65 2.18 1.27 3.39 2.29 2.38
Minimum -4.18 -5.45 0.02 -2.20 -3.00 -2.73
Maximum 1.41 2.72 3.92 10.22 4.77 4.49
MS
Mean 2.39 4.29 -3.90 -3.41 -0.31 -0.40
SD 1.14 1.17 1.22 1.75 3.02 2.91
Minimum 0.57 2.55 -6.32 -6.28 -7.13 -7.33
Maximum 4.93 7.13 -2.27 -0.82 5.15 5.49
TO
Mean -7.78 -10.57 1.93 3.23 5.37 5.72
SD 2.21 2.98 2.18 3.54 4.89 4.67
Minimum -11.03 -16.49 -0.96 -1.36 -1.71 -1.37
Maximum -2.69 -3.71 5.94 10.70 14.06 13.30
FM= foot markers, BM= boot markers, SD= standard deviation. Stance phase gait events; IC= initial contact,
MS= midstance, TO= toe-off.
Mean sagittal plane ankle kinematic profiles are presented in Figure 17, with the boot
condition demonstrating greater magnitudes of dorsiflexion at MS, and increased
plantarflexion at TO. Ankle inversion/eversion in the frontal plane Figure 18 shows the
boot-mounted markers larger variation in measurement at IC, but little difference was
reported in foot angles between conditions.
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Figure 17: Mean ankle kinematics in the sagittal plane
A red kinematic profile represents foot mounted marker set; a black kinematic
profile represents a boot-mounted marker set. Stance phase gait events; 0%=
initial contact (IC), 50%= midstance (MS), 100%= toe-off (TO)
Figure 18: Mean ankle kinematics in the frontal plane
Red = foot mounted marker set, black = boot-mounted marker set. Stance phase
gait events; 0%= initial contact (IC), 50%= midstance (MS), 100%= toe-off (TO)
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Figure 19: Mean ankle-foot progression ankle in the transverse plane
Red = foot mounted marker set, black = boot-mounted marker set. Stance phase
gait events; 0% =initial contact, 50% = midstance, 100%= toe-off
ICC of sagittal plane ankle joint angles between FM and BM at IC, MS and TO are
presented in Table 19. ICC at IC (.961), MS (.979) and TO (.981) report excellent
correlation.
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Stance phase gait events; IC= initial contact, MS= midstance, TO= toe-off.
 Table 19: Intraclass Correlation Coefficients of sagittal plane kinematics




Lower Bound Upper Bound
IC
Single Measures .925a .761 .978
Average Measures .961c .864 .989
MS
Single Measures .959a .864 .988
Average Measures .979c .927 .994
TO
Single Measures .849a .558 .954
Average Measures .918c .716 .976
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RSME are presented in Table 20. The greatest RSME was reported at IC 1.01 degrees
with MS at 0.71 and TO 0.29.
Paired t tests were performed (Table 21) to compare the mean values between maker
sets. A significant increase in mean difference was reported in the boot marker set with
increased ROM reported in the sagittal plane at MS (p<.0001) and TO (p<.0001).










IC 0.29 0.78 0.23 -0.21 0.79 1.28 0.23
MS -1.90 0.35 0.10 -2.12 -1.68 -19.03 0.00
TO 2.79 1.51 0.43 1.83 3.75 6.42 0.00
SD= standard deviation, SE= standard error
 Table 20: Root mean square error (RMSE) of sagittal plane kinematic









IC 0.66 1.02 1.01
MS 1.90 0.51 0.71
TO 5.31 0.08 0.29
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5.2.4.5 Conclusion
A pilot study was undertaken to determine the appropriateness of shoe-mounted marker
placement versus an in-shoe marker set generated by cluster wands placed on the foot
to calculate ankle joint kinematics during normal walking. Results indicate that the BM
set over-report ankle kinematics research that shoe-mounted marker sets that report
significant discrepancies in ankle kinematics using shoe-mounted marker sets [124,
125]. The finding of this study is contrary to previously cite research that boot-mounted
marker sets under-report kinematics, as the boot marker set in this pilot study over
reported kinematics in the sagittal at all stance phase gait events, MS in the transverse
plane and all three planes (X, Y, Z) at TO.
An explanation for our finds can be found in several reasons. Previously cited research
has used inferior lower limb biomechanical modelling to obtain kinematic data which are
known to incorporate error in the measurement of ankle kinematics (see section
2.2.1.1.1). The use of a military boot in this study is significantly more rigid than the
trainers cited in other marker set comparisons the rigid structure may therefore not of
been subjected to the same levels of movement artefact on the shoe. Graphical profiles
(Figure 17-19) were similar between conditions, with ICC and RMSE showing high
agreement between marker sets. Therefore it could be suggested the use of the boot
marker set would be an acceptable method of data capture and significantly easier to
undertake. However, the significant differences in sagittal plane kinematics at MS and
TO may lead to the over estimation of sagittal plane kinematics, potentially resulting in
significant levels of error in the proposed main study (Section 5.3). In addition to the
primary finding of the study, the cluster wand successfully collected foot mounted
kinematics without fouling the cluster wands during dynamic trials. The foot segment was
generated by three marker clusters and therefore used only three 25mm holes which
minimised the loss of shoe integrity. Therefore the methods presented in this pilot study
represent a robust “gold standard” approach to the investigation of ankle kinematics and
footwear evaluation.
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5.3 The effect of the LASER intervention on the kinetic and
kinematic profile of the lower limb
5.3.1 Background
The LASER intervention, a combination of the LASER boot and an FFO is used clinically
in the management of ankle haemarthropathy at the Leeds haemophilia comprehensive
care centre (CCC). Historical audit data for Leeds CCC indicates that footwear and FFO,
including the LASER intervention, reduce bleeding foot and ankle pain and function [15].
However, only a small number of studies have investigated the use of footwear and FFO
or other modified footwear interventions in ankle haemarthropathy [188, 308]. The use
of FFO has been investigated in patients with haemophilia, but low-level evidence is
quasi-experimental, and non-randomised studies limit reported benefits that FFOs
reduced pain and disability. The reduction of episodes of bleeding and additional clotting
factor concentrate (CFC) are similarly reported, but to date, no definitive trial has been
undertaken [175, 294]. Footwear worn by patients with ankle haemarthropathy can have
a significant effect on forces acting on the ankle joint [188]. The mechanism by which the
LASER intervention alters lower limb kinetics and kinematics remain unclear despite
positive clinical observations [15]. Therefore before undertaking a biomechanical study
in the haemophilia population, who may be at risk when exposed to altered joint forces,
investigating the effect of the LASER intervention on the ankle and lower limb kinetics
and kinematics of healthy adult males is appropriate. Investigating the individual and
combined components of the LASER intervention will establish the mechanism of action,
and allow refinement of the design prior to future testing in a pathological haemophilia
cohort and a future RCT.
It is hypothesised that the LASER intervention will reduce the mechanical demand on
the ankle joint moment of force (Nm.kg) in the sagittal and frontal planes. The
modification of a double rocker sole and SACH on a military boot in combination with an
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FFO (LASER intervention) will substitute for the movement normally required of the ankle
during walking.
5.3.2 Participants and methods
5.3.2.1 Aims and Objectives
This study aimed to investigate the mechanism of action of the LASER intervention using
3D gait analysis to understand the effect of the LASER boot modifications and FFO on
kinetics and kinematics of the ankle and proximal joints of the lower limb.
Analysis in biomechanical studies have historically received criticism for the use of small
sample sizes and the use of multiple statistical tests of dependant variables from the
same dataset, which increase the risk of type I error [309, 310]. To prevent this in the
current study predetermined and limited set of the most likely clinically and functionally
meaningful variables were defined before testing of the LASER intervention. To test the
mechanical effect of each footwear condition, outcomes were agreed by RAW and
research supervisors (AR, GC) based on the proposed mechanical effect of each
footwear condition as described in section 5.3.5.3. Primary, secondary and experimental
biomechanical outcomes were produced to obtain unbiased condition effects and
improve the validity of the data reported [309].
5.3.2.1.1 Primary objective
To determine the effect of the LASER interventions individual and the combined effect
on internal ankle plantar/dorsiflexion and inversion/eversion moments of force (Nm.kg)
when compared to a standard training shoe acting as a control shod condition.
5.3.2.1.2 Secondary objectives
To compare the individual and combined components of the LASER intervention on
lower limb kinetics and kinematics. Specific secondary objectives are as follows:
· The kinematic effect on the ankle in the sagittal and frontal planes.
· The kinetic effect on the knee and hip in the sagittal and frontal planes.
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· Observation of vertical, anterior/posterior and medial/lateral (Z, X, Y) ground
reaction forces (GRF).
· Temporal and spatial parameters differences of walking speed, cadence, step
length and double support.
5.3.2.1.3 Exploratory objectives
To investigate the mechanical effect of individual components of the LASER intervention
compared to a standard training shoe.
5.3.2.1.4 Footwear condition-specific conditions
Comparisons will be based on the individual footwear modifications incorporated into the
LASER boot (described in methods) and their proposed mechanical effect, providing
clinical context to results. A pre-defined set of measures were selected to compare the
effect of LASER intervention modifications to a standard trainer.
The following comparisons will be undertaken:
· The effect of the military boot on ROM at the ankle joint.
· The effect of a military boot with a SACH on peak plantarflexion ROM.
· The effect of a military boot with a rearfoot and forefoot rocker on the progression
of GRF centre of foot progression (CoP).
· The effect of the LASER boot with and without an FFO on the kinetics and
kinematics of the ankle joint.
5.3.3 Primary Hypothesis
A combination of the LASER boot and FFO will reduce the mechanical demand on the





In accordance with the Declaration of Helsinki, seventh revision [311] local ethical
approval was obtained from the University of Leeds, School of Medicine Research Ethics
committee (MREC16-087).
5.3.5.1 Study Design
A single-centre, six-period, six-treatment, Williams Latin-Square cross-over design
(within-participant comparison) was used to investigate the individual and combined
components of the LASER intervention. The Williams design is suitable where there are
more than two treatments/ conditions in a trial, and is a type of Latin square [312, 313].
Unlike a traditional Latin square, the Williams design is balanced for the carryover effect.
Therefore the participant receives the same interventions in a randomised order.
Participants were randomised to a sequence of interventions and control in a 6-period
Williams Latin Square design [54, 55].  A 6 by 6 Williams Latin square was generated
(Table 22) where each condition is represented once only per sequence. The table was
repeated six times to generate the total participant number and balance the number of
sequences that were randomised to each participant.
Table 22: Williams Latin square six by six sequence
Participant ORDER OF CONDITION
1 A B C D E F
2 B D A F C E
3 C A E B F D
4 D F B E A C
5 E C F A D B
6 F E D C B A
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Individual sequences were randomly allocated by study number (0-36) to a sealed brown
envelope by a research officer (LC). To avoid allocation bias the research officer
randomised the sequences using an online random sequence generator (random.org).
A record of the randomisation was then recorded on a database by the research officer
to allow an audit of the sequence throughout the study. On the day of data collection, the
research officer then allocated an envelope containing the sequence in ascending order
at the point of data collection and participant consent.
5.3.5.2 Participants
Thirty-six healthy adult male participants were recruited from the University of Leeds
Alumni group and the University of Leeds staff. All participants had no history of lower
limb surgery or co-morbidities associated with foot and ankle pathology such as diabetes
and inflammatory arthritis. Healthy participants were recruited to observe the
biomechanical effects of footwear conditions in the absence of pathology. Inclusion
exclusion criteria are presented in Table 23.
Table 23: Inclusion/ exclusion criteria
Inclusion criteria Exclusion criteria
· Male
· Aged 16 to
· Free from musculoskeletal and
neurological disease
· Able to give informed written
consent
· A normal foot posture (defined
as a Foot Posture Index score
between +1 to +6)
· Ability to walk unaided
· The ability to read and
understand English
· Under 16 years of age
· Females (only 1 in 25million
females are affected by
haemophilia)
· A history of below-knee surgery and
significant comorbidities where
changes to the mechanical function
of the ankle joint alter the
biomechanics of the foot
· Extremes of foot posture (FPI-6
more than +8 (low arched) and
below 0 (high arched)
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Before enrolment, potential participants were screened for a “normal” foot posture
defined by the foot posture index 6 (FPI-6) with normal defined as neither supinated nor
pronated [314]. If the participant's foot posture was deemed normal (FPI-6 score of 1-6)
and they had no other comorbidities that may affect gait then they consented following
good clinical practice guidelines [315]. The participant was asked to identify their
dominant foot (left/ right) thereafter known as the study limb, and footwear size.
Participants enrolled in the study attended a one-time visit to the Chapel Allerton Hospital




The six footwear conditions are summarised in Table 24 with descriptions provided in
section 5.3.5.3.1. All adaptions were undertaken by a single technician by Steeper’s
group (Steeper Inc, Leeds, UK).
Table 24: Footwear experimental conditions
A: Standard trainer, no
adaptation
B: Military boot, No
adaptation
C: Military boot with SACH
D: Military boot with
rearfoot and forefoot
rocker sole
E: LASER boot F: LASER boot with FFO
SACH= Solid ankle cushion heel, FFO = functional foot orthoses. Holes in boot depict data collection
windows for cluster wand placement.
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5.3.5.3.1 LASER boot design
The LASER boot was developed and used in clinical practice by Lee Short, Extended
Scope Practitioner podiatrist at the Leeds CCC. The design was later standardised by
Richard Wilkins. The design of the LASER boot came about due to an unmet clinical
need for the management of ankle haemarthropathy, poor compliance with footwear
supplied by orthotic services and a more functional approach to the management of
ankle joint kinetics and kinematics as opposed to the accommodation of structural
deformity. The LASER boot (Figure 20) is designed to reduce the mechanical demand
on the ankle joint in the presence of haemarthrosis and haemarthropathy in patients with
haemophilia and other bleeding disorders associated with blood induced ankle arthritis
such as type III Von Willebrand’s diseases. The LASER boot comprises different
components that are commonly used in footwear adaptations consisting of a ‘heel-toe
rocker sole, modified SACH heel and military-style boot.
Figure 20 Leeds Ankle Stabilising Enhanced Rocker (LASER) boot
A= rearfoot rocker, B= SACH heel, C= 8mm EVA, D= forefoot rocker position (60% of
boot)
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5.3.5.3.2 Military boot (Condition B)
The military-style boots, SWAT 8” force side zip boot (Original S.W.A.T, Morristown, TN)
were used for adaptation. The military-style boot is designed to provide a solid base of
support and provide a platform for adaptation. The upper shaft of the boot in combination
with lacing and side zip fastening provide fixation around the ankle joint and lower shank.
In the military where a multitude of terrain provides a challenge to preserving a level of
adaptation whilst preventing injury such as ankle sprain by providing a level of fixation at
the ankle joint [316].
5.3.5.3.3 Rocker sole (Condition C)
The rocker sole consists of a rearfoot (Figure 20a) and forefoot rocker (Figure 20d)
manufactured by the addition of an 8mm high-density Ethylene-vinyl acetate (EVA) full
length raise to a military boot. The EVA is then grinded down (Figure 20c) to
accommodate the rocker profile adaptation. The rocker profile allows forward
progression of the body’s centre of mass over the foot during the stance phase of the
gait cycle [187]. The forefoot rocker is positioned at 60% of the shoe (Figure 20d) and is
reported to be the optimal position in the management of forefoot pressures and facilitate
movement where ankle ROM is limited [188].
5.3.5.3.4 SACH heel (Condition D)
Traditional SACH heels are used in prosthetics using a soft material that deforms under
load. The SACH is made up of nora® Lunalastik (nora® SYSTEMS, GMBH) material
with a shore rating of A25, specifically designed for use in the manufacturing of footwear.
A Shore rating of A25 was chosen to allow gradual deformation under load whilst
maintaining a level of stability as the rearfoot is loaded up to the midstance of gait. The
traditional length of the SACH heel is around 1cm but is extended to 2cm to control the
acceptance of load and decrease the risk of instability [194].
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5.3.5.3.5 Functional foot orthoses
An X-Line standard (Healthystep, Manchester, UK) FFO without adaptation was used to
assess the effect of the FFO in combination with the LASER boot (condition F). Changes
in foot pressure and foot deformity are associated with ankle haemarthropathy in
haemophilia [176]. The X-Line standard consists of a heel cradle and midfoot contoured
support, metatarsal support and a 1st MTP joint depression providing rearfoot control,
and midfoot support to stabilise the foot then loaded. The x-line standard is currently
used clinically in haemophilia at the Leeds CCC. Nationwide, x-line FFOs are used in
FFO trials and is the most widely used FFO in the NHS [317-319].
5.3.5.3.6 Trainer (condition A)
A standard trainer, the ASICS patriot 8 (ASICS Oceania Pty Ltd, USA) consists of a
single EVA sole unit and laced upper. A trainer was chosen for comparison as the type
of footwear recommended in clinical practice and did not contain any additional
mechanical effect such as a medial or laterally posted rearfoot seen in other running
footwear.
5.3.5.3.7 Outcomes
A predefined set of outcomes were chosen before data collection, based on the proposed
mechanism of action of the LASER intervention (condition F) compared to a standard
trainer (condition A). Secondary biomechanical outcomes were chosen to analyse the
effect on ankle ROM and explore the biomechanical effects of the intervention on the
knee and hip.
Primary outcome; LASER boot plus orthoses vs trainer
· Peak plantarflexion/dorsiflexion moment (Nm.kg) in the sagittal (X) and frontal
(Y) plane as a measure of mechanical demand at the ankle joint.
Secondary outcomes; LASER boot and FFO vs trainer
· Peak knee and hip moments in the sagittal and frontal planes
· Total ROM, maximum plantarflexion and dorsiflexion at the ankle joint
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· Total ROM, maximum flexion and extension at the knee and hip
· Maximum and minimum GRF X/Y/Z (observational)
· Temporal and spatial parameters: walking speed, cadence, step length, double
support
Exploratory
Footwear condition-specific vs a trainer (condition A)
· Military boot: sagittal and frontal plane ankle joint ROM (condition B)
· SACH heel: ankle joint peak plantarflexion moment (condition C)
· Rocker sole: GRF centre of progression width and length (condition D)
· LASER boot only: as per primary comparisons (condition E)
· FFO effect: Laser boot only vs LASER intervention (condition E, F)
5.3.5.4 Data collection
As described previously, a 10 camera infrared passive marker motion capturing system
operating at a frequency of 100Hz (Vicon MX, Oxford metrics, UK) integrated with two
force plates (AMTI, Watertown, MA) capturing kinetic data at 1000Hz and arrange in
succession allowed simultaneous collection of concurrent gait events. Lower limb kinetic
and kinematic data were collected using skin mounted nine millimetre (mm) reflective
markers (Vicon MX, Oxford metrics, UK). Markers were placed in accordance with the
CAST model details of which are provided in section 5.2.4.2 [301]. Study limb in-footwear
gait data were collected using 3D printed clusters wands placed at the lateral calcaneus,
1st MTP  joint  and  5th MTP joint through 25 mm holes pictured in Figure 21 [126].
Additionally, markers were placed on the proximal joints and segments. The cluster
wands were used to define the study limb foot. The contralateral “non-dominant” foot
was defined with footwear mounted markers at the 1st, 2nd and 5th MTP joints and the
posterior calcaneus using the same skin mounted 9mm reflective lower limb markers.
Following the collection of data for each footwear condition (A-F) ankle and foot markers
were removed to allow for footwear change and were reapplied once the footwear was
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secured. Proximal markers and tracking pads were repositioned carefully by an
experienced MSK podiatrist (RAW) to ensure correct anatomical position and maximise
the accuracy of the data.
Figure 21: Cluster wand placement
Right foot cluster wand placement on the A, lateral calcaneus, B, 5th metatarsal head
and C, 1st metatarsal head. Left foot corresponding boot-mounted marker set.
5.3.6 Data Capture and processing
36 participants undertook gait analysis using the methods described in section 5.2.4.2.
Participants were asked to place the boot on each foot and lace-up using all eyelets to
the top of the boot. Once the boot was laced, participants were asked to fasten the side
zip of the boot so the boot felt “secure, but not uncomfortable”. Details of the processing
of static and dynamic trials are provided in section 5.2.4.2. Data was exported to excel
2018 as the mean minimum and maximum kinetics and kinematics of the five
representative gait trials of each condition and each footwear condition (A to F).
5.3.7 Sample size
A sample size of 36 participants provided 80% power to detect a standardised effect size
of 0.5, assuming a 2-sided 5% significance level. Equal numbers of participants were





number of participants needed to power the trial is a multiple of the condition times by
itself. Replicating the design six times required 36 participants [313].
5.3.8 Statistical analysis
Data were analysed graphically for each of the primary, secondary and exploratory
outcomes by exporting data into Microsoft excel 2018 worksheet. Motion time curves
were generated as mean for each individual segment (ankle, knee and hip) in the
specified anatomical plane for the kinetic (X, Y) and kinematic (X, Y, Z) variable. Grand
means were then exported for analysis. Descriptive statistics were produced using SPSS
version 26 (Armonk, NY: IBM Corp). The mean, standard deviation (SD) and 95%
confidence interval (95% CI) are presented for all primary, secondary and exploratory
outcomes.  To compare outcomes between conditions, a linear mixed model was fitted
using Statistical Analysis Software SAS version 9.4 (North Carolina, USA: SAS Institute
Inc.). Fixed effects were included for sequence, period, condition and prior condition, and
random effects for participants within sequences, using PROC MIXED. Differences in
the least-square means were extracted for conditions and prior conditions using
LSMEAN. As the same participant acts as their own control, within-subject rather than
between-subject differences were tested [320]. A two-sided significance level of 5% was
used throughout, using type III tests of fixed effects. Overall effects are presented as
statistic (F), degrees of freedom (DF) and significance (p-value). Treatment effects are
reported as estimates, standard error, t value and significance (p-value). Estimation of
parameters was undertaken using restricted maximum likelihood (REML). Finally, linear
mixed model regression analysis was undertaken using the SAS Kenward-Roger
method to model the relationship between exploratory conditions against the standard




A total of 36 male participants consented to take part in the study with a mean age of
participants of 31.1 years (SD, 7.9). Mean (SD) FPI-6 was 2.8 (SD 1.55) for the left foot
and 2.89 (SD 1.35) for the right foot, which is within the normal foot posture range (neither
supinated nor pronated). Participant mean weight of 82.2 kg (SD, 12.5) and height of
179cm (SD, 7) produced body mass index (BMI) measures of 25.5kg/m2 (SD, 3.4).
5.4.2 Primary outcome
Ankle Kinetics
Comparison of ankle moment data between the LASER intervention and trainer is
presented in Table 25. The LASER intervention reduced internal ankle plantarflexion,
therefore reducing the rotational force at the ankle as the foot moves from the ankle to
forefoot rocker, opposed to the plantarflexor musculature of the ankle. The internal
plantarflexion moment was reduced by 0.18Nm.kg compared to the trainer which was
statistically significant (P=<0.0001). Increase in peak internal dorsiflexion moment is
caused by the LASER intervention as the heel makes contact with the floor (heel rocker)
and is opposed by the dorsiflexor musculature of the ankle. The increase in internal
dorsiflexion moment was small in magnitude (0.06Nm.kg), however significant
(P=<0.0001).
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Table 25: Ankle kinetic effect of the LASER intervention when



















0.055 0.010 5.09 <.0001
Peak ankle inversion
moment
0.15 (0.07) 0.15 (0.07)
-0.002 0.010 -0.26 0.798
Peak ankle eversion
moment
-0.13 (0.07) -0.12 (0.04)
-0.007 0.007 -0.99 0.322
A= trainer condition (control), F= LASER boot intervention. Significance level <0.05 (bold figures =
significance)
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Test of fixed effect
Type III tests of overall effects were undertaken to test the significance of sequence,
period, condition, and prior condition (Table 26) on primary outcomes. The peak moment
of ankle joint plantarflexion was significant for treatment only. Peak dorsiflexion was
significant for treatment and period indicating some carryover effect of the previous
intervention. Neither prior condition nor sequence was important, indicating no first-order
carryover effects for any of the ankle joint kinetic parameters.
Table 26: Ankle kinetics type III tests of fixed effects




Sequence 5 30 0.17 0.970
Period 4 165 0.59 0.670
Treatment 5 165 50.86 <0.0001




Sequence 5 30.2 0.65 0.662
Period 4 165 2.51 0.044
Treatment 5 165 28.08 <0.0001
Prior treatment 5 165 1.62 0.156
Ankle inversion
moment
Sequence 5 30.1 1.01 0.427
Period 4 165 0.52 0.724
Treatment 5 165 0.76 0.581
Prior treatment 5 165 1.16 0.329
Ankle eversion
moment
Sequence 5 30.4 0.68 0.638
Period 4 165 0.93 0.447
Treatment 5 165 1.61 0.159
Prior treatment 5 165 1.55 0.178
Bold text= significance (p <= 0.05)
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5.4.3 Secondary outcome measures
5.4.3.1 Ankle kinematics
Secondary comparisons of ankle kinematics are presented in Table 27. In the sagittal
plane, the LASER intervention reduced total ROM by 4.6 degrees (P=<,0001). The
largest change was in the reduction of peak plantarflexion (3.4 degrees, P=<0.0001),
with a reduction of dorsiflexion of 1.6 degrees (P=0.0007). Peak inversion was reduced
by 3.7 degrees for the LASER intervention, however, a small increase in peak eversion
ROM (1.0 degrees) was observed. Both inversion and eversion peak ROM were
significant.

















26.3 (3.9) 21.7 (3.7) 4.5 0.3 15.2 <.0001
Sagittal plane peak
plantarflexion
-17.8 (4.4) -14.4 (3.3) -3.2 0.4 -7.3 <.0001
Sagittal plane peak
dorsiflexion
8.5 (3.7) 7.3 (3.1)
1.3 0.4 3.5 0.0007
Frontal plane
Ankle total ROM
11.0 (2.1) 8.5 (1.8)
2.5 0.3 8.5 <.0001
Frontal plane peak
inversion
11.1 (4.0) 7.4 (3.5)
1.2 0.3 3.8 0.0002
Frontal plane peak
eversion
0.1 (3.5) -1.1 (3.4)
3.6 0.4 9.5 <.0001
SD standard deviation
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Comparison of total ROM at the ankle are present in Figure 22 and Figure 23. Ankle
ROM in the sagittal plane (Figure 22) were 21.71° (SD, 3.77 95% CI: 20.44 to 22.99) and
26.31° (SD, 3.90 95% CI 24.99 to 27.63) in the LASER intervention and trainer
respectively. Total ROM was reduced by the LASER intervention, with the most notable
difference occurring towards the end of stance with a reduction in dorsiflexion and less
plantarflexion at TO.
Figure 22: Ankle sagittal plane kinematics
The black line represents control A and Red line represents condition F
(intervention)
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Frontal plane ROM (Figure 23) yielded similar results with a mean reduction of total
ROM in the LASER intervention of 8.5° (SD 1.84, 95% CI: 7.9, 9.2) compared to that of
the trainer (mean 11.0° SD 2.1 95% CI: 10.3, 11.7).
Figure 23: Ankle frontal plane kinematics
The black line indicated control A, Red line equals condition F (intervention)
Test of fixed effect
Test of fixed effect for ankle kinematics reported significance in treatment for all ankle
kinematic outcome measures in the sagittal and frontal planes (P=<0.0001). Only peak
ankle dorsiflexion and plantarflexion reported the significance of P=0.0032 (f value 3.7)
and P=0.0211 (f value 2.7) respectively for prior treatment indicating a significant
carryover effect in both parameters.
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5.4.3.2 Knee and hip kinetics
Knee and hip kinetics are reported in Table 28. Knee extension moment in the LASER
intervention (1.21 SD0.23 Nm.kg) vs trainer (1.16 SD0.29 Nm.kg) were not significant
(P=0.0706).  . Observations at the knee report an increase in knee adduction moment of
-03 Nm.kg (P=<0.0001) at the hip both peak extension and adduction moments were
also increased by 0.15 (P=<0.0001) and 0.03 Nm.kg respectively.
Table 28: LASER boot with a foot orthoses effect on Knee and hip















(0.13) -0.38 (0.14) 0.0132 0.013 0.98 0.328
Peak knee extension
moment





-0.11 (0.06) 0.028 0.006 4.39 <.0001
Peak knee abduction
moment





-1.14 (0.22) 0.010 0.022 0.47 0.6394
Peak hip extension
moment





-0.16 (0.09) 0.029 0.010 2.88 0.0045
Peak hip abduction
moment
1.12 (0.17) 1.14 (0.16) -0.021 0.0166 -1.27 0.2049
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5.4.3.3 Knee and hip kinematics
Knee and hip kinematic graphs over the stance phase of gait are presented in Figure 24.
In the trainer condition, peak knee flexion was increased by a 3.2° (SD 3.9) and
movement toward extension was decreased by 2.2° (SD 3.4) and remained in a more
flexed position. Peak movement towards knee extension fall outside of the CI (LASER
intervention, 49.8 to 52.4, Trainer 52.7 to 56.0) therefore representing a systematic
difference. ROM at the hip was similar between conditions with only less than 0.3°
between conditions in all parameters. Total knee and hip kinematics during the stance
phase of gait are presented in Table 29.
a b
c d
Figure 24: Knee and hip kinematics
Sagittal (a and c) and frontal plane (b and d) Black line indicated control A, Red line
equals condition F (intervention)
Differences in the knee and hip kinematics are presented in Table 29. Sagittal plane
ROM was significantly increased (P=<0.001) by mean 5.3° (SE, 0.3) in the LASER
intervention compared to the trainer. Increases in ROM were attributed to significant
increases in peak knee flexion (mean 3.3°), and peak knee extension (mean 1.9°,




























kinematics were not found. Changes in total hip ROM were not significant in either the
sagittal or frontal plane for the LASER intervention, therefore little proximal effect
occurred at the hip during the stance phase of gait, indicating that the main effects
occurred in the knee and ankle.
Table 29: LASER intervention effect on the knee and hip kinematics when













sagittal plane 45.1 (3.8) 44.5 (3.5)
0.7 0.4 2.2 0.032
Peak knee flexion 54.3 (4.8) 51.3 (3.9) 3.3 0.4 8.1 <.0001
Peak knee
extension 8.6 (3.7)* 6.9 (3.1)
1.9 0.3 6.1 <.0001
Frontal plane knee
total ROM 3.7 (1.9) 4.7 (2.5)
0.1 0.3 0.4 0.652
Peak knee
adduction 1.1 (3.6) 1.2 (3.1)
0.01 0.3 0.3 0.767
Peak knee
abduction -3.9 (4.1) -3.5 (4.1)
-0.3 0.3 -0.8 0.410
Hip total ROM
sagittal plane 40.3 (5.4) 38.9 (5.2)
0.5 0.3 1.7 0.093
Peak hip flexion
31.7 (8.7) 31.3 (7.5)
0.5 0.7 0.6 0.544
Peak hip extension
-9.0 (7.9) -9.2 (7.1)
0.3 0.7 0.4 0.689
Hip total ROM
frontal plane 9.7 (2.5) 11.4 (2.6)
0.4 0.2 1.7 0.095
Peak hip adduction
6.5 (3.8) 6.4 (4.1)
0.1 0.4 0.3 0.7896
Peak hip abduction
-5.4 (3.2) -5.1 (3.1)
-0.3 0.4 -0.8 0.453
* Positive values indicate knee flexion
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Tested of fixed effect
Secondary kinematic outcome measures tests of fixed effects were significant (p<0.001)
for treatment for all knee outcome measures, indicating that treatment effects were
independent of the period, sequence and prior treatment. Similarly at the hip, the
treatment effect had a significant effect on total sagittal plane total ROM (P=<0.0001)
and peak hip flexion (P=<0.01). In the frontal plane, there was a significant treatment
effect for total hip ROM (P=<0.0001) and prior treatment (P=0.004) whilst there was a
significant period effect for peak hip adduction (P=0.04).
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5.4.3.4 Ground reaction forces
GRF graphs are presented in Figure 25. Few differences were apparent in
anterior/posterior (Figure 25c) and vertical GRF (Figure 25a). Less variation in





Figure 25: Ground reaction forces
The black line indicates control A, red line condition F (intervention)
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Comparisons of the LASER intervention and trainer are presented in Table 30.
Significant increases in minimum and maximum medial GRF and a decrease in posterior
GRF were reported in the LASER intervention when compared to the trainer. Vertical
GRF was also significantly increased.












T value P value
Maximum vertical
GRF
1.24 (0.09) 1.27 (0.08) -0.030 0.008752 -3.44 0.0007
Maximum medial
GRF
0.07 (0.02) 0.08 (0.02) -0.006 0.002 -2.7 0.007
Minimum lateral
GRF
-0.04 (0.02) -0.05 (0.02) 0.013 0.002 5.93 <.0001
Maximum anterior
GRF
0.22 (0.04) 0.20 (0.04) 0.017 0.002 6.35 <.0001
Minimum posterior
GRF
-0.23 (0.04) -0.24 (0.04) 0.006 0.004368 1.51 0.132
Test of fixed effect
Treatment had a significant fixed effect (P=<0.002) on all GRF outcomes in all planes
(X, Y, Z) with the exception of minimum anterior/ posterior GRF that also reported
significance in prior treatment (P=0.05). No fixed effect of sequence or prior treatment
were reported in any of the GRF parameters.
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5.4.4 Temporal and spatial parameters
Temporal and spatial parameters
Temporal and spatial parameters are a measure of overall function, therefore walking
speed, cadence, step length and double support were compared between the LASER
intervention and trainer. Descriptive analyses of temporal and spatial parameters are
presented in Table 31. Walking speed, cadence and double support was significantly
lower in the LASER intervention, but step length was unaffected.
Table 31: Changes in temporal and spatial parameters between the












T value P value
Walking speed
(meters/sec)




108.96 (6.4) 2.16 0.61 3.55 0.0005
Step length (cm) 0.79 (0.06) 0.79 (0.05) 0 0 0.79 0.433
Double support (% of
stance)
0.23 (0.05) 0.22 (0.05) 0.01 0 3.63 0.0004
Test of fixed effect
Test of fixed effected reported significance in temporal and spatial parameters for
treatment only (p<0.01) in all temporal and spatial outcome measures. There were no
significant effects of sequence of intervention, period and prior treatment on any temporal
and spatial parameters.
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5.4.5 Exploratory outcome measures
5.4.5.1 Descriptive statistics
To investigate the specific mechanical effect of the individual components of the LASER
boot (conditions B, C, and D), each condition was compared individually to the control
intervention (condition A). The effect of the LASER boot with (condition F) and without
(condition E) FFO were compared to understand the effect of the FFO. Specific
measures were chosen before analysis that represents the proposed clinical effect of
each condition (discussed in section 5.3.2.1.4).
Test of fixed effect
The test of fixed effect was significant for all footwear conditions for treatment only
(<0.001). Therefore no period, carryover or sequence effect was observed.
5.4.5.1.1 Footwear component effect
Military boot (Condition B)
Ankle ROM (X and Y) comparisons of the military boot and trainer are presented in Figure
26 as sagittal plane (Figure 26a) and frontal plane (Figure 26b) over the stance phase
of gait. A systematic reduction in ankle ROM was reported in both the sagittal and frontal
planes in the military boot. In the sagittal plane, the ROM (Figure 26a) were 26.3° (SD,
3.9 95% CI: 25.0, 27.6) for the trainer and 22.8° (SD, 3.3 95% CI: 21.7, 23.9) for the
military boot. In the frontal plane (Figure 26b) the ROM of the trainer was 11.0° (SD 2.1,
95% CI: 10.3, 11.7) and for the military boot, 9.1° (SD, 1.9 95% CI: 8.5, 9.8). In both
sagittal and frontal planes, CIs for the ROM in the boot lay outside of the boundary of the
relevant Cis for the trainer. Statistical analysis (Table 32) indicates significance for these
differences in both the sagittal and frontal planes, with total sagittal and frontal ROM




Figure 26: Ankle range of motion of exploratory conditions
Black line = trainer, green line = military boot. Ankle ROM during the stance phase of
gait. 5a, sagittal plane ROM (dorsiflexion/plantarflexion). 5b, frontal plane ROM
eversion/inversion.
Table 32: Effect of a military boot on the total ROM at the ankle in the













26.3 (3.9)  22.8 (3.3)
3.51 0.29 11.85 <.0001
Ankle total ROM
frontal plane
11.0° (2.1) 9.1 (1.9)
1.92 0.29 6.63 <.0001
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SACH heel modification (condition C)
Compared to a trainer, the SACH modification (Table 33) leads to a significant decrease
in peak plantarflexion moment of 0.145 Nm.kg from 1.55 to 1.40 Nm.kg (P<0.0001).
Table 33: Effect of a SACH on peak plantarflexion moment (Nm.kg)
when compared to a trainer
Moment (Nm.kg)
Mean (SD)
Trainer (A) SACH (C)




T value P value
Peak plantarflexion
moment
1.55 (0.170) 1.40 (0.148) 0.145 0.013 10.8 <.0001
Forefoot and rearfoot “rocker bottom” sole (condition D)
Descriptive and inferential statistics for centre of pressure data presented in Table 34
revealed the rocker bottom sole reduced the minimum width of the GRF CoP progression
by 0.011cm (P=<0.001), however maximum width was increased by 0.010cm
(P=<0.0001). GRF CoP maximum length was increased by 0.001cm, and whilst very
small in change was significant (P=0.01) indicating the rocker soled shoe increased the
surface in contact with the floor when compared to the trainer.
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Table 34: Exploration of the rocker sole effect on GRF centre of


































0.231 (0.014) 0.003 0.001 2.35 0.0199
5.4.5.1.2 Foot orthoses effect
LASER boot and foot orthoses effect (conditions E and F)
The LASER boot with FFO (LASER intervention) produced a reduction in plantarflexion
moment of 0.03 Nm.kg (P=0.043) when compared to the LASER boot alone (Table 35).
No differences were reported in ankle dorsiflexion moments and the FFO produced a
small increase in eversion moment (0.01 Nm.kg) which was not significant.
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T value P value
Ankle plantarflexion
moment
1.40 (0.17) 1.37 (0.17) 0.03 0.013 2.03 0.043
Ankle inversion
moment










-0.12 (0.04) 0.011 0.007 1.48 0.140
Comparison of the LASER boot without an FFO identified a systematic reduction in all
ankle moments when compared to a trainer (Table 36). The LASER boot reduced
plantarflexion moment (0.15 Nm.kg, P=<0.001), eversion moment (0.02, P=0.01) and
treads towards decrease for inversion moment (0.01 Nm.kg, P=0.61). However,
reductions were offset by an increase in dorsiflexion moment of 0.06 Nm.kg which was
significant (P=<0.0001).
Table 36: Exploration of ankle kinetic effect of the LASER boot without a













1.55 (0.17) 1.40 (0.17) 0.15 0.013 11.31 <.0001
Ankle inversion
moment










-0.11 (0.03) -0.02 0.008 -2.47 0.0144
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Test of fixed effect
Comparison of the LASER boot and trainer and the LASER boot with and without an
FFO test of fixed effect was significant for treatment (P=<0.0001). In addition, the ankle
dorsiflexion moment period was significant (P=0.04). Sequence and prior treatment did
not affect any of the outcome measures.
5.5 Discussion
This study used 3D gait analysis to establish the mechanism of action of the LASER
interventions individual and combined components when compared to a standard trainer
in a cohort of non-pathological males. In this Williams Latin square designed to study the
primary outcome, ankle moments of force were significantly reduced. The LASER
intervention appears to exert its main effect on kinetics and kinematics of the ankle joint
in the sagittal plane and to a lesser extent at the knee and the hip. Establishing the
mechanical effect in a healthy cohort has identified the main effect of the LASER
intervention as well as identified parameters that may be affected in pathological cohort
with ankle haemarthropathy. These findings support future research in haemophilia as
well as other pathological conditions of the ankle joint.
5.5.1 Ankle joint kinetics and kinematics
The primary aim of this study was to determine whether the LASER intervention reduced
the mechanical demand on the ankle joint when compared to a standard trainer. The
results of this study demonstrated statistically significant changes in ankle joint kinetics
and kinematics. The effect of the LASER intervention at the ankle occurred
predominantly within the sagittal plane with a significant reduction in plantarflexion
moment and a small increase in dorsiflexion moment, therefore decreasing the overall
mechanical demand on the ankle joint.
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5.5.1.1 Kinetics
The reduction of plantarflexion moment of the LASER intervention (1.37 Nm.kg (SD
0.17)) in comparison to a standard trainer (1.55 Nm.kg (SD 0.17) indicate the
combination of the individual components of the LASER intervention (boot, SACH, rocker
sole and FFO) are effective at reducing the rotational force at the ankle joint as the foot
begins to dorsiflex during the ankle rocker. In the frontal plane no difference between
conditions was reported for inversion moment and a small decrease in eversion moment
however the difference was not significant suggesting little or no change in frontal plane
ankle kinetics. The individual component effect of the SACH modification was effective
at reducing plantarflexion moment. Comparison to other studies using SACH
modifications are limited, however in prosthetic foot construction report peak
plantarflexion of 1.09 Nm.kg of a SACH [322]. This study, whilst not conduct in in-vitro
showed low-level evidence to support the effect of the SACH and supports its inclusion
in the LASER intervention. Long et al. (2007) reports a rocker soled shoe with a similar
rocker design to the LASER intervention displayed decreased plantarflexion moment at
midstance and whilst peak moments were not reported, there were significant reductions
during toe-off between 0.05 and 0.11 Nm.kg [187]. The inclusion of an FFO was a
significant contributor to changes in ankle kinetics and justifies their inclusion in the
LASER intervention and highlights the potential of FFO to contribute to the overall
mechanical effect. The LASER intervention, which included the FFO when compared to
the LASER boot alone significantly reduced plantarflexion moment (0.03 Nm.kg) and
whilst small in effect the FFO does contribute a positive effect. Findings are similar to
Nester et al. (2003) who investigated the effect of FFO in a healthy cohort using 3mm
EVA insoles with an arch filler and medial/lateral wedging material [90]. The study
identified that under normal walking conditions FFO with 10 degrees of rearfoot posting
(medial and lateral) produced little effect on sagittal plane kinetics when compared to a
shod condition. The data reported in a shod condition only opposes this chapters results,
little detail was captured about the participant’s foot posture which may have influenced
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the FFO effect. Similarly, shoe-mounted markers were used which are known to
underestimate foot and ankle biomechanical data [126, 131, 323].
The proposed effect of the SACH is a pseudo-plantarflexion moment in which the SACH
compresses during the heel and ankle rocker when the plantarflexion moment occurs as
the foot begins to dorsiflex in preparation for heel lift during the propulsive phase of gait
[72]. Whilst the ankle is in a closed pack position and at its most stable, pathological
changes to the anterior joint line in combination with synovial hypertrophy, a common
presentation in ankle haemarthropathy, increase the risk of haemarthrosis and further
soft tissue trauma [306]. Therefore the decrease in peak plantarflexion moment produced
by the LASER intervention, in theory, reduces the potential for mechanical trauma to soft
tissue and bony blocking as a potential source of ankle joint haemarthrosis and pain
[293]. Changes in gait pattern have been observed by Lobet et al. (2011) in a cohort of
severe haemophilia males (n=21) with ankle haemarthropathy. Reductions in peak ankle
plantarflexion moments were 1.02 SE0.28 (IQR 0.44-1.62) Nm.kg -1 and ROM of 14.4
(SE 3.9 (IQR, 8.4 to 3.9) degrees respectively, highlighting the change in function
observed in advancing haemarthropathy of the ankle. Whilst the LASER intervention did
not decrease moments to equivalent levels, data was collected in healthy participants so
equivalent levels of change would not be expected. Reductions in kinetics were in
comparison to a standard trainer that is often worn by patients in clinical practice,
therefore providing insight into potential effects. The LASER intervention exhibits
characteristics that justify future testing in the haemophilia population and potential
therapeutic benefit that accommodates the mechanical and functional changes
associated with haemarthropathy [293].
Dorsiflexion moment was higher for the LASER intervention (-0.43 Nm.kg (SD0.08 CI -
0.46 to -0.40) than the trainer (-0.37 Nm.kg (SD 0.09 CI -0.40, -0.34) which reached
significant (P=<0.0001) The increase in dorsiflexion moment at the ankle were higher in
both conditions when compared to the literature, however, healthy participants were
used and it is unlikely the same finding would occur in a haemophilia or other pathological
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cohort. Long et al. (2007) reported very little dorsiflexion moment at IC into weight
acceptance by a rearfoot and forefoot rocker footwear but neither change was significant
when compared to a standard trainer, therefore, limiting direct comparison [187].
Observations of control footwear in research of negative rocker footwear have reported
mean (SD) small increases in peak dorsiflexion moments of (-0.26 Nm.kg(SD 0.05) to -
0.09 Nm.kg (SD 0.05)) [193]. The reason for the reduction in the negative rocker was the
use of a curved sole at the rearfoot moving the point of contact during the stance phase
of gait from the heel towards the midfoot. The Wu et al. (2004) study of rocker profiled
shoes reported an absence of dorsiflexion moment owing to the design of the footwear
which had an increased heel height, a known factor in the reduction of dorsiflexion
moment caused by a higher heel to forefoot ratio with a higher heel reducing dorsiflexion
moments [194].
The increase of ankle dorsiflexion moment of the LASER intervention, whilst significant
were relatively low (0.06 SE 0.01 Nm/kg, p<0.0001) and may not impact the clinical
management of ankle haemarthropathy. In this chapter, the increase in dorsiflexion ROM
resulted in a longer lever arm, away from the ankle fulcrum. GRF was increased at heel
strike with both changes producing the increase in ankle dorsiflexion moment. The
LASER intervention heel height is similar to the forefoot when the SACH heel is
compressed. Therefore increasing heel height may also be beneficial by reducing the
dorsiflexion moment and a potential solution in clinical practice, which commonly
includes a heel wedge to FFO increasing heel height to “fine-tune” the footwear and
orthoses effect. Encouraging results suggest further investigation is needed to establish
if the LASER intervention translates to a pathological cohort by reducing the mechanical
demand on the ankle. A decrease in dorsiflexion ROM at the ankle may explain findings,
therefore increasing the moment arm during the ankle rocker. GRF whilst not directly
reported appeared to increase at IC with the LASER intervention which may have
contributed to the increase in rotational forces posterior to the ankle. The results of this
study represent the potential to increase the eccentric burden of the anterior musculature
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during IC. It suggests the anterior muscles would require greater eccentric control during
gait. In the management of ankle haemarthropathy, the foot drifts into a plantarflexed
position with a reduction of dorsiflexion ROM [8, 79]. Muscular atrophy of the lower limbs
is common in the presence of ankle haemarthropathy and therefore rehabilitation may
be required to improve eccentric contraction of the anterior ankle musculature during IC
to negate any potential increased burden.
5.5.1.2 Kinematics
Sagittal and frontal plane ROM were reduced by the LASER intervention thereby
maintaining the ankle joint within a restricted ROM. The secondary and exploratory effect
of the LASER intervention and military boot condition, respectively, restricts ankle ROM.
A systematic reduction in both sagittal and frontal plane motion was reported with a 3.5
and 1.9-degree reduction in ROM, respectively. Reported reductions in ankle ROM are
supported by observational studies of boot stiffness. Changes in boot stiffness between
soft and stiff boot uppers restrict ankle ROM 16.71 (SD 3.3) to 18.11 (SD 3.4) between
footwear conditions were reported in ankle sagittal plane ROM and frontal plane motion
of 9.41 (SD 3.3) to 8.71 (SD 3.3) in boots with a soft and hard shaft respectively [324].
Whilst direct comparisons to this chapter are limited by different boot types and walking
conditions, the findings of this chapter provide support to the proposed boot mechanism
of action that fixation above the ankle joint reduces ROM. The explanation for the finding
may be attributed to the mixture of materials and different footwear components of the
LASER intervention that produced the overall effect on ankle kinematics. Machine
modelling of boot upper stiffness in small bespoke studies reports the stiffer the boot
upper, the less variation in ROM occurring in the sagittal plane. Whist conducted using
a robotic foot that does not represent true reciprocal gait pattern in human movement
analysis, the study provides insight into this chapters kinematic data [325]. The
properties of the boot upper were not measured in this chapter, rather the boot is used
in clinical practice at the Leeds CCC to provide some form of restriction whilst allowing
a restricted ankle ROM to occur but with a restricted range. Double rocker soled shoes
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are reported to reduce ankle ROM in footwear research with reduction in total sagittal
plane ROM of between 6.0 and 9.6 degrees [193, 194]. The individual effect of the rocker
sole on ankle ROM was not investigated but the combination of current findings and past
research on rocker sole footwear suggests the rocker sole as part of the LASER
intervention may have contributed to the reduction in sagittal plane ROM.
The military boot accounted for the largest reduction of ankle ROM in both the sagittal
(22.8°, SD3.3) and frontal 9.1°, SD1.9) planes (p=<0.0001). The results support the
hypothesis that fixation above the ankle reduces variability in ROM and therefore has
the potential to have a mechanical effect. During the IC the foot remained in a more
plantarflexed position but observed differences were small in effect with similar between
condition time curves (Figure 22). Time curves for the LASER intervention followed the
same ROM as did the trainer until terminal stance where dorsiflexion occurred, but to a
lesser extent in the LASER intervention therefore the ankle joint was less plantarflexed.
The above ankle fastening of the ankle boot is clinically important in the management of
ankle haemarthrosis for not only its restriction in ROM but the feeling of stability. Ankle
haemarthropathy is associated with loss of proprioception around the ankle and therefore
the higher fastening may provide greater somatosensory feedback as well as maintaining
a limited ankle ROM [326, 327]. The reduction may be interpreted as a negative effect
where rehabilitation would aim to maintain full ROM and lower limb strength, but in
haemophilia, ROM can be reduced by up to 80% by the third decade of life [79]. In
addition, fixation above the ankle may prevent excessive-end ROM in a pathological
cohort of patients with ankle haemarthropathy where joint margins and subtalar joint are




The LASER intervention produced minimal proximal effect at the knee with similar
moments and ROM in the sagittal and frontal planes compared to a trainer. An increase
of 0.028 Nm.kg (SE0.006) knee adduction moment was observed in the LASER
intervention. Knee biomechanics in adults with haemophilia report maximum knee flexion
and extension moment of -0.25 ( SD0.09) and 0.53 Nm/kg (SD, 0.12) respectively in
developing and established multi-joint haemarthropathy which decline as the disease
progresses [135]. Whilst significant, the increase is relatively small in isolation and the
clinical relevance of the significance is questionable as to whether such a small change
in adduction moment would have a detrimental effect in the haemophilia cohort. The
LASER intervention in the frontal plane increased knee ROM by one degree, which was
significant (P=<.0001). The clinical significance of this finding makes very little difference
to the overall functional effect at the knee. Similarly, changes in knee flexion ROM has
been reported at loading response of 12.0 (IQR,7.0;15.9) degrees which are similar to
the data reported for the LASER intervention [135]. Therefore the potential to have a
positive mechanical effect at the knee in haemophilia as the LASER intervention
maintains the knee within acceptable ROM. The level of haemarthropathy at the knee
has declined since the introduction of prophylaxis CFC and regular use of treatments but
there is still a cohort of individuals where the knee has either been a target joint of
haemarthropathy, or the lack of previous treatment means the knee has significant joint
changes with loss of ROM and flexion deformity [9]. The use of the LASER intervention
in the presence of knee haemarthropathy requires further evaluation to establish whether
the use is suitable for the presence of both knee and ankle haemarthropathy. The
decreased ROM suggests the reduction in required ROM may prevent end ROM and the
mechanical joint stresses that are detrimental to treatment and patient reported
outcomes. Therefore in the presence of knee joint pathology, the LASER intervention
should be closely monitored.
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5.5.2.2 Hip
Changes reported in hip kinetics and kinematics were very small in magnitude despite
significance in hip extension and adduction moments. Advancing haemarthropathy of the
ankle is associated with an increase in the recruitment of the hip flexors as patients
adapted their walking pattern to accommodate for the loss of ankle ROM [136]. Lobet et
al. (2010) observation of hip peak extension moment during the stance phase of gait of
0.47 (SD 0.12) Nm.kg-1 during the early stance phase of gait [135]. Therefore when
prescribing modified footwear and FFO in the management of ankle haemarthropathy,
acknowledgement of the potential proximal effect on the hip should be taken into
account. Whist comparability to this chapters data is experimental and undertaken in
healthy controls, the proposed mechanism by which the LASER intervention exerts its
effect on the hip presents a positive finding. The potential to produce large proximal
changes in hip kinetics and kinematics were a concern in this chapter owing to the multi-
joint nature of severe haemophilia and the inherent risk of causing soft tissue and joint
bleeding by producing biomechanical changes at the hip [113, 135]. However, the
proximal effect of the LASER intervention was minimal.
5.5.2.3 Ground reaction forces
Observation of GRF was similar between conditions with similar vertical GRF time curves
(Figure 25a) between conditions with the LASER boot slightly higher (0.03 force/body
weight) which was significant. However, both conditions fell within normative data sets
of 1.2 force/ body weight [91, 92]. Medial and lateral forces were reduced by the LASER
intervention with differences occurring in the early part of stance (0-20%). Again there
were significant changes in anterior and posterior (Figure 25c) forces but these were
very small in magnitude with force-time curves similar between conditions. Results
indicated that there is a minimal clinical difference between conditions and whilst findings
were significant for several of the variables the increase was less than 0.03 force/body
weight for all GRF outcomes (Table 30). The LASER intervention, therefore, produced
minimal changes to GRF with the modifications maintaining normal GRF acting on the
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foot and ankle during the stance phase of gait. This finding supports the direction of
change that the mechanical changes produced by the LASER intervention mainly occur
at the ankle joints whilst maintain normal biomechanical features of gait.
Observations of progression of GRF CoP would hypothesize that the rocker sole of the
LASER intervention would increase the length of the CoP trajectory as the compensatory
effect of the rocker means the shoe surface is in contact with the ground for longer.
Clinical significance of the change in all GRF parameters was relatively small in
magnitude with differences not exceeding 0.01cms across all despite significance
(P=<0.01) in all but the minimum GRF CoP in the frontal plane. Therefore the rocker
soled shoe did not have a large effect on GRF CoP compared to the trainer. Observation
of in-shoe pedography in haemophilia has shown a large variance in the progression of
CoP in patients with established ankle haemarthropathy [176]. The use of FFO in the
study stabilised the CoP trajectory providing stability and decreasing medial and lateral
CoP variability. Whilst no formal data were reported, CoP trajectories displayed less
variation in medial and lateral displacement and significant reduced spontaneous joint
bleeding (P=<0.001) over six months [176]. Exploratory results for the mechanical effect
of the rocker sole may therefore be isolated to the ankle kinetics and kinematics.
Observation of GRF CoP data in a pathological cohort is needed to understand the
mechanism of effect in patients with haemophilia as the FFO used may reduce
medial/lateral CoP variation.
5.5.2.4 Temporal and spatial outcomes
Walking speed, cadence and double support were all reduced by the LASER intervention
except for step length which was similar when compared to the trainer. The clinical
relevance of these findings whilst significant, represent very small differences between
the LASER intervention and the trainer that clinically would not be considered
meaningful. In a cohort of patients with ankle haemarthropathy, the very small changes
may be accounted for by the in-between session or condition variance. Findings are a
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limitation to observation in healthy controls where changes in function are less apparent.
Wu et al. (2004) reported reductions in healthy participants wearing a modified double
rocker shoe with a SACH 104.8 step/min (SD 7.2) and 107.5 (SD 4.1) in a standard shoe.
Small, non-significant reductions were also reported in walking speed for standard
footwear 0.98 (SD 0.11) step/min compared to a rocker soled shoe 0.97 (SD 0.91) m/s
which supports the suggestion that the use of healthy controls may not capture the
functional effect on temporal and spatial parameters [193]. In haemophilia cohorts,
temporal and spatial parameters are reduced in adults with ankle haemarthropathy.
Comparison to a control group with haemophilia without ankle haemarthropathy reported
small variations in cadence (109.9/109.5 step/min, p=0.847), step length (0.72/ 0.75m,
P=0.092), and stance time (64.8% vs 64.1% P=0.01) [113]. Therefore the significant
differences reported for the LASER intervention are not clinically large enough to raise
concerns about the potential for the reduction in function during gait.
5.5.3 Limitations
5.5.3.1 Carryover (period) effect
The Williams Latin square design within-subject test of fixed effects allowed the
identification of carry-over effect (period) from the previously used footwear condition
and whether the order in which footwear condition order (sequence) affected data
collection [313]. In general, there was minimal effect except for the footwear condition
itself (treatment). The exceptions were peak dorsiflexion moment, peak ankle
dorsiflexion/ plantarflexion ROM, hip abduction moment and anterior/posterior GRF, all
of which were significant for carryover (period). This period or carryover effect means the
previous condition tested may have influenced the intervention. The between conditions
effect may have therefore affected these parameters and results should be interpreted
with caution. The explanation for the carryover effect may be attributed to an inadequate
washout period whereby the participant did not have sufficient time between testing
footwear conditions to adapt to the different footwear types. A pragmatic approach was
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taken to the amount of time spent between conditions, owing in part to the large amount
of data collected in the study session. Allocation of a five-minute washout period was
based on previous research in barefoot and shod footwear conditions undertaken
previously within the host research institution [127]. Future footwear studies may not use
as many (six) footwear conditions allowing for a longer wash out period between
footwear conditions. The structure of the LASER intervention may require a longer period
of adapt especially in a pathological cohort where mobility is affected. Therefore increase
in washout time between conditions may be more achievable in future LASER
intervention studies.
5.5.3.2 Outcomes
The gait parameters were analysed during the stance phase of gait. Whilst the
measurements of kinetic parameters were appropriately reported over the stance phase
of gait, the inclusion of swing phase (approximately 40% of the gait cycle) may have
provided information as to the LASER intervention effect during unloading such as the
effect of the weight of the boot on the knee and hip kinematics [91]. Whist the primary
outcome of the LASER intervention were ankle kinetics, technical difficulties with the
capture ability to track 3D markers during terminal swing in all of the footwear conditions
resulted in the exclusion of swing data. The set-up of the Chapel Allerton Hospital, Leeds
gait laboratory camera system was static to allow the collection of multiple datasets
including stairs and slope walking for several concurrent PhD projects. Future studies
would benefit from the ability to model the full gait cycle by repositioning cameras to
optimise marker tracking or the use of upgraded camera systems that have more robust
tracking technologies. The weight of the LASER intervention may increase the burden of
the contralateral musculature of the knee and hip during the swing phase of gait as the
knee acts as a pendulum during swing [328]. Whilst we did not measure the difference
in weight between the LASER intervention and trainer, the materials used in adaptation
make the boot heavier. Evaluation of swing in patients with haemophilia may provide
further information on the potential to increase the burden on hip and knee musculature
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and potentially increase the risk of trauma, though in clinical practice no increased risk
of bleeding has been observed even anecdotally. The primary outcome of this study was
ankle moment of force in the sagittal plane during the stance phase of gait and therefore
exclusion of swing phase did not affect the study design. In pathological gait, the
inclusion of swing may provide insight into the contribution of footwear weight and
structure on the proximal joints, especially in the presence of multi-joint pathology and
associated muscle atrophy common features of joint haemarthropathy in haemophilia
[135]. Data were analysed statistically using peak values, a common method of reporting
biomechanical data where conventional analyses require a single data point for each
participant. However, the full biomechanical dataset consists of a time series and the use
of a single time point within the gait cycle may exclude the magnitude of change over the
period of interest, which in this chapter was the stance phase of gait. A small number of
recent biomechanical studies have adopted the evaluation of gait data over the full gait
cycle [329, 330]. One such method, Statistical Parametric Mapping (SPM) has been used
to identify at what point in the gait cycle changes occur and magnitude [329, 330]. The
use of SPM is a novel introduction and was beyond the scope of this thesis, however, a
future study in a haemophilia population using SPM may provide a more meaningful
interpretation of biomechanical change in a condition characterised by multi-joint
haemarthropathy and changes to ankle joint structure and function [84].
5.5.3.3 Foot model
An inverse dynamic model was used with a single segment foot model to capture in-shoe
data. Multi-segment foot modelling is preferred when investigating and understanding
how different segments of the foot move when walking. However, a pragmatic approach
was taken to capture data in-shoe with a focus on maintaining the integrity of the LASER
intervention and isolation of a single segment model allows the quantification of ankle
kinematics. The balance between assessing interventions vs the loss of shoe integrity is
associated with cutting multiple windows for the collection of a multi-segment foot model.
The use of a multi-segment would have required cutting multiple holes into the boot and
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therefore jeopardise the structural integrity of the boot and incorporate bias into data
collection [20]. Future observational studies may benefit from assessing structural
changes to footwear properties before evaluation in clinical studies. In addition, were
developing multi-segment foot models for use in-shoe validation should be undertaken
to establish the optimum marker set for modelling ankle kinematics whilst maintain
footwear integrity. More than four windows cut into footwear has also been shown to
jeopardise the integrity of footwear during footwear evaluation and whilst military
footwear is significantly more structured increasing the number of windows to allow
another marker would not have increased the reliability of data collected [130].
5.5.4 Implications of findings
The current findings indicate the LASER intervention produce beneficial changes to the
kinetic and kinematic profile of the ankle joint whilst minimising the proximal effects at
the knee and hip during the stance phase of gait. The individual and combined effect of
the LASER intervention conditions have been established and the primary outcome of
ankle moments of force was mostly reduced by the intervention and therefore represent
a decrease in the mechanical burden of the ankle joint. The implications for our findings
provide an understanding as to the potential clinical effect in a cohort of normal healthy
males. The methods used in this chapter to model the foot in-shoe have been shown
that an in-shoe foot model can be used to report ankle kinetic and kinematic data.
Therefore a future study in pathological males with ankle haemarthropathy may be
undertaken before a full RCT.
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5.5.5 Conclusion
The LASER intervention significantly improved the kinetic and kinematic profile of the
ankle joint during the stance phase of gait. The mechanism by which this combination of
primary footwear components have been confirmed and establish that the effect
hypothesised in clinical practice has the desired effect. Whilst this study has been
conducted in healthy adult males, our findings provide a basis for investigation in
pathological cohorts before a future RCT. The in-shoe modelling technique used in this
study is effective at reporting ankle kinetics and kinematics and therefore should be
considered or adapted to a multi-segment intervention model. Future studies should be
conducted in haemophilia cohorts and other diseases affecting the ankle to establish
whether the LASER intervention improves HRQoL, foot and ankle pain and the
prevalence of haemarthrosis.
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Chapter 6 - Discussion, future directions and conclusions
Several gaps identified in current literature have been addressed by the work presented
in this thesis. The prevalence of haemarthrosis and concurrent joint health are commonly
reported as total annual bleed rates (ABR) and annual joint bleed rates (AJBR) without
reference to individual joint health. This thesis has now reported the prevalence and
incidence of joint bleeding and concurrent musculoskeletal health. Ankle
haemarthropathy is a common feature of haemophilia and is cited as the most affected
joint in terms of haemarthrosis and joint disease. The impact of ankle haemarthropathy
on health-related quality of life (HRQoL), and foot and ankle patient-reported outcome
measures (PROM) has been identified. The use of footwear and functional FFO have
the potential to reduce the burden of ankle joint haemarthropathy, however, there is little
evidence to support their use in clinical practice, nor has the mechanism by which foot
and ankle interventions exert their mechanical effect. The LASER interventions
mechanical effect has been established as a potential therapy for the management of
ankle haemarthropathy.
6.1 Thesis Synopsis
This thesis aimed to explore the prevalence and impact of ankle haemarthrosis and the
resultant haemarthropathy, whilst providing a better mechanistic understanding for the
use of existing targeted footwear and FFO intervention. The observed outcomes of this
thesis are summarised in Chapters Three, Four and Five: the prevalence and incidence
of haemarthrosis and concurrent joint health; the impact of haemarthropathy on health-
related quality of life and foot and ankle specific outcome measures; and the kinetic and
kinematic mechanism of action of the Leeds Ankle Stabilising Enhancer Rocker (LASER)
intervention.
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Chapter Three - The prevalence of ankle haemarthrosis in moderate and
severe haemophilia A and B
This chapter aimed to identify the prevalence of ankle haemarthrosis and concurrent joint
health in severe haemophilia A and B. Data obtained from the National Haemophilia
Database (NHD) identified 176 individuals compliant with prophylaxis and had a
concurrent haemophilia joint health score (HJHS).
· This NHD database study identified that despite compliance to treatment, 60% of
adults had a minimum of one bleed during the 12 month study period.
· Despite 30% of participants using extended half-life (EHL) clotting factor
concentrate (CFC), AJBR have changed little since the last NHD evaluation in
2015.
· The ankles were disproportionally affected by haemarthropathy, with higher
HJHS than the knees and elbows.
Chapter Four - The impact of blood induced ankle arthritis in patients with
moderate and severe haemophilia A and B: The HAPII study
This chapter aimed to provide insight into the impact of haemarthropathy on health-
related quality of life (HRQoL) and foot and ankle specific patient-reported outcome
measures (PROMs). The analysis included 243 participants with moderate and severe
haemophilia A and B and a consultant diagnosis of ankle haemarthropathy. Patients
were recruited from haemophilia comprehensive care and haemophilia treatment centres
across England, Wales and Scotland. A concurrent consultant survey obtained details of
service provision at 43 haemophilia centres across the UK and then compared them with
the patient impact questionnaire responses.
· HRQoL and foot and ankle PROMs are poor in the presence of ankle
haemarthropathy regardless of haemophilia type, severity or treatment regime.
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· Pain was a significant feature of ankle haemarthropathy and the main
contributor to poor HRQoL and foot and ankle PROMs.
· Findings indicate that Numerical Pain Rating Scales (NPRS) of ankle pain over
the past six months may be an independent predictor of worsening HRQoL and
foot and ankle PROMs.
· The use of pharmacological pain medication was low despite multi-joint
haemarthropathy and chronic levels of ankle joint pain.
· The consultant survey reported access to a range of complementary
musculoskeletal (MSK) services in UK haemophilia centres including those for
foot and ankle problems. In comparison, patient responses to the impact
questionnaire indicate that patients did not access footwear and orthotic
services.
Chapter Five - A mechanism of action study to explore the individual and
combined components of the Leeds Ankle Stabilising Enhanced Rocker
(LASER) boot and FFO (LASER intervention)
This chapter aimed to investigate the mechanism of action of the LASER intervention.
Three dimensional (3D) gait analysis was undertaken in 36 healthy male participants to
establish the effect of the individual and combined components of the LASER
intervention on the ankle joint and proximal lower limb joints.
· The LASER intervention significantly reduced plantarflexion moment of force at
the ankle joint compared to a standard trainer.
· The proximal kinetic and kinematic effects of the LASER intervention on knees
and hips were minimal.
· Individual effects of the LASER component features; the solid ankle cushioned
heel (SACH), rocker sole and military boot were found, producing the proposed
effect for all conditions when compared to a standard trainer.
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· FFO significantly reduced ankle joint moments when used with the LASER boot.
· The preliminary evidence of efficacy and therefore safety of the LASER
intervention findings in healthy males justify future research to determine the
efficacy and effectiveness when used in a cohort of haemophilia patients with
ankle haemarthropathy.
6.2 Thesis discussion
6.2.1 Prevalence of ankle haemarthrosis and concurrent joint health
Patients with severe non-inhibitor haemophilia who were compliant with prophylaxis
reported a minimum of one bleed in 60% of haemophilia A and 40% of haemophilia B
patients over the 12 month study period [4]. The small numbers of haemarthrosis
episodes in the prevalence data are low across the most affected joints of the ankles,
knees and elbows. In Chapter Three, our findings indicate that despite improvements in
treatment, only minor improvements in haemarthrosis are reported with similar AJBR
(1.0, IQR 0.0;4.4) and 40% haemarthrosis free to Scot et al. (2019) who three years
earlier reported a median AJBR of 1.0 (IQR 0.0;4.0) with only 34% joint bleed free three
years earlier [4]. The findings of this chapter highlight the difficulties in preventing all
incidents of haemarthrosis, even where treatment compliance is deemed good. The rates
of AJBR were low, but it appears that achieving zero incidents of haemarthrosis under
current CFC treatment regimens are not achievable. The balance between obtaining
adequate trough levels, risk of complications such as inhibitor development and the
burden of regular infusion to patients represent challenges in obtaining adequate
prophylaxis [1, 4]. The prevalence chapter adds to the data on compliant patients,
however, it raises questions as to the true UK prevalence of patients who fall below the
UKHCDO NHD compliance threshold for reporting disease statistics. If the most
compliant still experience haemarthrosis it is likely that the true clinical landscape of the
cohort below the threshold for the report is worse. It, therefore, remains unclear as to the
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true UK prevalence and incidence of haemarthrosis and this thesis has highlighted the
need for a better understanding of the UK haemophilia AJBR and the effect on joint
health.
The relatively low prevalence of joint haemarthrosis may be clinically acceptable under
current treatment regimens, however, a single incident of haemarthrosis with even low
quantities of blood within the joint is known to produce pathological changes in cartilage,
with blood products at levels as low as 10% initiating an inflammatory process and
synovitis at two days after exposure [62]. Therefore even a single detectable joint bleed
may be enough to initiate a cascade of pathological joint changes. In joints already
affected by joint disease, this single incident may be more significant as the joint is
burdened longer-term by haemosiderin deposition, synovial hypertrophy and cartilage
damage [237-239]. The progression of joint disease often leads to changes in joint
structure and function as haemarthropathy progress. The ability to distinguish between
an incident of haemarthrosis or joint pain becomes more difficult as joint health declines,
especially at the ankle where clinical detection of joint health decline is often delayed
[272]. The concept of subclinical bleeding has gained more traction as the AJBR decline,
however, joint damage continues, but there is yet to be any definitive evidence to support
this hypothesis [253]. Therefore the disproportionate level of ankle haemarthropathy
reported in the prevalence Chapter Four raises further questions as to the mechanism
by which joint health declines. These findings highlight the complexities of monitoring
bleed history and establishing joint haemarthrosis status where data is often self-
reported. Confirmation of bleeding is often confirmed with use of extra CFC to arrest
symptoms, which is more complex in the presence of haemarthropathy whereby it
becomes ever increasingly difficult to distinguish between chronic joint pain and bleeding
events [271]. Therefore in the absence of a significant debilitating ankle haemarthrosis,
repeated low level non-detectable joint haemarthrosis may occur and explain the long
term deterioration of ankle joint health.
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In Chapter Three, 30% of patients used EHL treatment which is reported to decrease
annual bleed rates by 20 to 50% whilst maintaining factor VIII and IX level half-life by 1.5
to 1.6 times longer than standard half-life (SHL) treatment [241, 242]. The first published
guidance for use of EHL was published by the UKHCDO in 2016 [331]. Use of EHL in
2017 UKHCDO bleed statistics report indicating EHL accounted for 2.9% of FVIII
treatment and by 2018-19 this had increased to 15.6% [232].  From the 2018-2019
Chapter Three prevalence data it is not clear from the outcomes in this thesis whether
EHL products reduced joint haemarthrosis, as only minor reductions were identified
when compared to previously cited research [4, 13]. The sample of EHL product users
in Chapter Three was higher than UKHCDO bleeding statistics, however, this did not
influence our results. With such low and unchanging levels of ankle haemarthrosis
reported in both Chapters Three and Four, the use of EHL CFC in patients with moderate
to severe levels of ankle haemarthropathy appears to reduce the frequency of CFC
infusion only [226, 241] rather than improving joint health.
The findings in Chapter Three are reported 12 years after Stephensen et al. (2009) who
identified that the ankle had become the most commonly affected joint for incidents of
haemarthrosis in a small cohort of boys with severe haemophilia A [9]. Prevalence data
collected in addition to this thesis identifies that children with a median age of 11 (IQR
7;14) (n=97), with severe haemophilia and compliant with prophylaxis, report bleed
prevalence of 33% and 60% in haemophilia A and B, respectively [244]. The AJBR at all
joints were very low with a median (range) AJBR of 0.00 (IQR 0.00; 0.00). Levels of
clinically detectable haemarthropathy were similarly low, with a median HJHS of 0.0 (IQR
0.0; 0.0). These results suggest that current treatment regimens in children are either
effective at reducing bleed rates to a point where joints are not affected by
haemarthropathy or they are not detectable until later years. Patient-reported
haemarthrosis levels in Chapter Five were similar to the levels reported in the prevalence
chapter (Chapter Three) with mean ankle AJBR between 0 (SD 3.0) and 2.0 (SD 4.0) in
haemophilia A and B respectively, on prophylaxis and on-demand treatment. Ankle
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AJBR were higher in moderate disease with a mean of 1.0 (SD 3.0) in moderate
haemophilia A on prophylaxis and a mean of 4.0 (SD 0.0) on-demand treatment. The
similarities in AJBR in the severe haemophilia A prophylaxis groups across the
prevalence and impact studies provides insight to incidence of ankle joint haemarthrosis
in the general population of severe haemophilia with different treatment regimens and
associated joint disease in patients who may vary in their treatment compliance and
regimes.
A recent publication by Collins et al. (2021) on UKHCDO guidelines for the management
of severe and moderate haemophilia recommends that prophylaxis is initiated in any
moderate patients who experience a single haemarthrosis, or a clinically significant bleed
[253]. Where trough levels are between 1-3 IU/dL patients should be treated the same
as those with severe haemophilia, with prophylaxis offered and a treatment target of
above 3 IU/dL or to a level that halts spontaneous or breakthrough bleeding [253]. The
significance of this recommendation is a step towards reducing the burden of joint
disease not only in severe haemophilia but by way of recognition that even moderate
haemophilia can make a significant contribution to the complications of bleeding [5, 29,
253, 332]. Chapter Three finds that patients with moderate haemophilia have similar
bleed rates and ankle joint disease to severe haemophilia adds to the emergence of data
indicating better target management of moderate haemophilia is required to reduce the
patient burden of disease both physically and mentally. The number of moderate
haemophilia cases in our cohort was small (n=29) therefore drawing meaningful
inference from the results is not possible, but similarities in disease characteristics of
severe haemophilia provide insight into the incidence of haemarthrosis and the
progression of joint haemarthropathy at the ankle. Whilst HJHS was lower in patients
with moderate haemophilia when compared to those with severe haemophilia, ankle
AJBR were higher indicating that those with moderate haemophilia have delayed levels
of ankle joint haemarthropathy. It remains unclear as to whether those with moderate
haemophilia have the same intensity of bleeding as severe disease or rate of joint health
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decline, but new findings provide insight into the increased incidence of haemarthrosis
where ankle joint haemarthropathy is less detectable [253]. The data presented in the
prevalence and impact chapters (Chapters Three and Four) indicate that regardless of
prophylaxis or on-demand treatment regimens, the levels of ankle haemarthropathy
correlate to radiological levels of moderate to severe joint damage.
Examination of arthropathy at all joints indicate that in the presence of ankle
haemarthropathy, distribution of multi-joint osteoarthritis (OA) at the hips, shoulders,
wrist and hands were similar to OA cohorts, but develop up to a decade earlier [251]. It
is unclear whether the earlier reporting of joint arthropathy is related to haemarthrosis,
or rather changes in joint health are caused by muscle atrophy and altered joint
biomechanics [333]. Increases in life expectancy mean that those with severe
haemophilia are now living to a similar length of life as the general population. However,
concerns are emerging to the levels of disability experienced in older adults with
haemophilia. Patients aged over 65 who did not have access to CFC through childhood
are reported to have between four and six joints affected by haemarthropathy (ankles,
knees, elbows) [334]. Established joint disease in combination with low bone mineral
density is associated with worsening progression of multi-joint haemarthropathy
therefore the findings in this thesis present trends towards a similar decline in the
younger adult haemophilia population [335, 336]. Chapter Three highlights the
importance of monitoring and preservation of joint health not only at the most common
sites of haemarthrosis but the examination and reporting of all joint health in haemophilia
to ascertain the global effect of haemarthrosis and subsequent disability.
6.2.2 Impact of ankle haemarthrosis and haemarthropathy
This thesis has identified that in the UK haemophilia population ankle haemarthropathy
leads to poor HRQoL and foot and ankle PROMs, driven by chronic pain, the decline in
physical function and difficulties with social interaction. Haemophilia type, severity and
treatment regime were not independent predictors of worse HRQoL or decline in foot
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and ankle PROMs. The exception was haemophilia severity and the HAEMO-QoL-A
domain of physical function, which indicates that severe patients are impacted during
activities of daily living [200]. Observations of HRQoL suggest that impact is correlated
with haemophilia severity, with severe haemophilia patients the most affected by the
decline in HRQoL when compared to those with moderate and mild disease [221, 246].
Similarly, in haemophilia B, frequency, intensity and levels of haemarthropathy are lower
than in patients with haemophilia A [256]. This aligns with previous suggestions that
patients with moderate haemophilia A/B and patients with haemophilia B would have
better health HRQoL [234, 256]. This thesis reports that despite physical factors that may
reduce the impact on HRQoL, haemophilia type, severity and treatment regimen made
little difference to HRQoL.
Foot and ankle PROMs scores were similar between haemophilia types, severities and
treatment regimes.  MOXFQ total score and individual domains of walking/standing, pain
and social interaction were all poor, with similar MOXFQ scores to patients undergoing
ankle fusion and total ankle replacement surgery, indicating significant chronic pain and
disability [267]. Few studies have directly reported foot and ankle PROMs in haemophilia.
In the only two footwear and FFO studies that have taken place, the Foot Function Index
(FFI) and Foot Function Index Revised (FFI-R) scores reporting moderate levels of
haemarthropathy correlated with moderate impact [14, 175]. Higher ankle HJHS and the
correlation with higher levels of the joint disease reported by patients in Chapter Four
may explain why foot and ankle PROMs scores were more impacted than studies of
other haemophilia cohorts with ankle haemarthropathy. Pain was the most prominent
feature of ankle haemarthropathy in both HRQoL and foot and ankle PROMs. The use
of an NPRS measuring average ankle pain over six months was found to be an
independent predictor of all HAEMO-QoL-A and MOXFQ subscales. Therefore average
ankle pain over six months, measured using an NPRS has the potential in clinical
practice to monitor the impact of ankle joint haemarthropathy and predict worsening
HRQoL and foot and ankle outcomes. At what point on the NPRS scale constitutes
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decline is yet to be established, however, data captured in Chapter Four identified NPRS
of 4.8 (SD 2.7) correlated with the decline in individual and total domain scores of the
HAEMO-QoL-A and MOXFQ. The use of the NPRS has the potential to be used at other
joints affected by haemarthropathy and whilst the NPRS would not replace outcome
measures, it has the potential to be used in clinical practice as an indicator for use of
more detailed HRQoL and foot and ankle PROM tools.
Over 50% of patients did not use regular analgesia in the management of acute and
chronic ankle pain. The use of analgesia is below levels reported in similar research of
haemophilia and chronic joint pain in the United States of America (USA), where up to
76% of patients reported using analgesia and 56% of adults with haemophilia reported
opioid use [250]. It is not clear why such a low proportion of haemophilia patients did not
use analgesia in our study. In haemophilia, it has been suggested that patients adopt
coping strategies to deal with pain such as exercise, massage and distraction techniques
[268, 272]. The management of pain in the haemophilia community is reported to be
poor, with 40% of patients reporting difficulty in obtaining appropriate pain management
from their healthcare provider [271]. Surveys of pain management in adults aged
between 40 and 65 years with multi-joint haemarthropathy indicate a lack of access to
pain relief for the majority of their childhood where joints were more prone to acute painful
episodes of haemarthrosis [334]. Therefore coping with high levels of pain and managing
without pain relief is synonymous with chronic haemarthropathy [334]. The findings in
this thesis raise valid questions as to the management of pain in haemophilia and the
need for targeted pharmacological and non-pharmacological interventions, especially in
multi-joint haemarthropathy, where the ankle has been reported to account for 45% of
all joint pain [250]. A recently published systematic review of the management of pain
using physiotherapy interventions, suggests studies are lacking methodologically, and
specifically in their trial designs, to make any conclusive recommendations for pain
management [337]. Similarly in the management of ankle haemarthropathy, there is low-
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quality evidence that suggests FFO and footwear reduce pain, but no conclusive
evidence to change guidance or management [14, 175, 176].
Results from the Chapter Four consultant survey of clinical services available to patients
with ankle haemarthropathy indicated direct or indirect access to a range of MSK
services such as orthopaedics and rheumatology. Point of care MSK ultrasound
(POCUS) provides a cheap and reliable method of monitoring joint health in haemophilia
[35]. However, 43% of centres reported no access to the service. The use of POCUS in
the management of ankle haemarthropathy is particularly sensitive to detecting soft
tissue changes such as synovial hypertrophy, although is limited in the detection of
subchondral bone changes due to limited access to the ankle joint and therefore only
useful in monitoring joint margins [282, 283]. Therefore haemophilia centres without
POCUS access limit the potential for rapid assessment of acute haemarthrosis and
monitoring of joint health [280].
When the consultant survey responses were compared with the patient impact
questionnaire, the use of footwear and FFO services were somewhat different. The
consultant survey indicated access to orthotist service for footwear and ankle brace
provision at all centres. In the impact study, 88% (n=211) of patients did not use adapted
shoes and only 51% (n=117) used FFO. Access to a podiatrist for MSK assessment and
provision of FFO was also available, but the patient's responses for the impact
questionnaire indicated only 58% (n=139) patients had access to a podiatrist and only
34% (n=81) were supplied with FFO by a podiatrist.
It was unclear why the uptake of both modified footwear and FFO was low. Studies of
footwear and FFO efficacy in a Belgian cohort report good patient satisfaction, with 63%
of patients reporting significant reductions in FFI-R pain domain (P=0.007), and
improvement in patient comfort, however, there was little effect on ankle kinetic or
kinematic measures [14]. This study was underpowered, however, the authors
concluded that FFO may be beneficial to patients with moderate levels of ankle
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haemarthropathy and suitable for severe ankle haemarthropathy. This may explain to
some extent the low uptake of FFO in the Chapter Four patient questionnaire. In the UK,
two haemophilia centres have combined physiotherapy and podiatry clinics that provide
footwear and FFO services; they reported high levels of patient satisfaction [15, 16].
Research on the effects of FFO have previously reported large reductions in bleed rates,
improvement in patient-reported QoL and improved foot and ankle outcomes, but are
limited to quasi-experimental and observational studies and date there has been no full
RCT [14, 175, 176, 338]. Whilst use of FFO was low in our patients at the Leeds
Comprehensive Care Centre (CCC), combined podiatry and physiotherapy clinics use
FFO and have reported reductions in pain, increased mobility and less burden of ankle
joint disease [15]. This thesis has highlighted the need to understand how FFO and
footwear may benefit patients with ankle haemarthropathy and the need to monitor the
use in haemophilia care. Establishing the efficacy of FFO in ankle haemarthropathy is
required before any definitive conclusions can be drawn.
6.2.3 Mechanism of action of the Leeds Ankle Stabilising Enhanced
Rocker (LASER) intervention
Chapter Five aimed to understand the mechanisms of action of the LASER intervention.
The novel approach used to capture in-shoe kinetic and kinematic measures has given
an insight into the overall mechanical effect of the LASER intervention and the relative
contributions of its component feature using William’s Latin square approach.
Comparisons between the LASER intervention and a standard trainer identified
significant reductions in the internal plantarflexion moment with little change in frontal
plane kinetics. Similarly, ankle ROM in the sagittal and frontal planes was reduced by
the LASER intervention. Reduction of plantarflexion moment represents a decrease in
the rotational force at the ankle during the second ankle rocker as the foot reaches
maximum dorsiflexion [293]. Dorsiflexion ROM at the end of the ankle rocker and prior
206
to initiation of the forefoot rocker prevents end ROM dorsiflexion  The clinical significance
of finding in ankle haemarthropathy represents the potential to reduce mechanical
demand on the anterior ankle joint line as GRF is closer to the ankle joint and the
requirement for dorsiflexion is reduced and, in turn, the potential to reduce the effect of
bony blocking caused by joint margin osteophytes and limit the risk of soft tissue trauma.
Footwear modifications used in the LASER intervention contributed to the overall effect
with the SACH reducing the moment as the heel makes contact with the ground. The
use of a SACH has been limited to simulator testing in prosthetic feet but support the
proposed mechanical effect that a SACH would reduce plantarflexion moment [322].
Long et al. (2003) reported an overall reduction of plantarflexion moment of between 0.5
and 0.11 Nm.kg compared to standard footwear using a double rocker sole similar in
design to the LASER intervention [187, 194]. Therefore the double rocker soles used in
the LASER intervention may have contributed to the overall reduction of plantarflexion
moment.
Reductions of the LASER intervention sagittal plane (21.7 SD 3.7) and frontal plane (SD
1.8) ROM in comparison to a trainer support the hypothesis set out in Chapter Five that
the LASER intervention would restrict ankle ROM and therefore reduce the mechanical
demand on the ankle joint. Restriction in ankle ROM is beneficial in progressive ankle
haemarthropathy as the joint structure and function changes ROM becomes altered by
plantarflexion deformity and the control of movement is altered by muscle atrophy. The
remaining ankle ROM movement may be inhibited, or lack control, therefore exposing
the ankle joint to further risk of pain and bleeding. Increases in frontal plane motion have
been reported as a compensatory mechanism in ankle haemarthropathy. The reduction
in frontal plane ROM produced by the LASER intervention which includes an FFO is a
similarly important finding [8, 339]. Disease of the subtalar joint has been reported in
50% of patients in haemophilia. Although this may be a conservative estimate, the
biomechanical effect on the ankle joint has the potential to increase the biomechanical
burden on the joints adjacent to the ankle joint. Therefore the restriction of ankle ROM
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by the LASER intervention which included an FFO may prevent frontal plane corrections
and facilitate movement by use of the rocker sole during the three ankle rockers.
The use of an FFO in the LASER intervention produced a reduction in ankle
plantarflexion moment.  In clinical practice, FFO are adapted with additional materials
that change how forces act upon the shoe foot interface [17, 20]. However, Nester et al.
(2003) evaluation of FFO using a similar design to the FFO used in the LASER
intervention demonstrated little effect on ankle kinetics [90]. This suggests that the shoe-
mounted single segment kinetic model used by Nester et al. (2003) under-reported ankle
kinetics, or the device did not exert an effect on ankle complex moments. Direct
comparison of the findings presented in this thesis and those of Nester et al. (2003) are
limited by advancements in biomechanical modelling in the interim, specifically the use
of an in-shoe foot model in Chapter Five. In haemophilia, combined footwear and FFO
interventions in chronic ankle haemarthropathy have reported that FFO does not affect
ankle kinetics or kinematics, but this study as with Nester et al. (2003) used a shoe-
mounted marker set, a known source of error in the measurement of foot function [14].
In common with other cited research that shoe-mounted marker sets under-report ankle
kinetics and kinematics, with over-reporting in the Chapter Four pilot study. While
differences were minor a foot-mounted marker set provides the most accurate method
of reporting in-shoe ankle kinetics and kinematics [126, 131, 323]. More research is
needed to determine the effect of the FFO effect using in-shoe foot modelling and
therefore when designing intervention studies the ability to model the foot in-shoe should
be considered to obtain an optimal measurement of mechanical effects.
The proximal effect at the knee and hip kinetics were isolated to the knee adduction
moment and at the hip extension and adduction moments. Variations in ROM at the knee
were small in effect and whilst reaching statistical significance would not be clinically
meaningful. The implications of the finding suggest little proximal effect, however the
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multi-joint nature of the haemophilia warrants observation in subsequent studies to
ensure the current mechanical results are transferrable to a pathological cohort.
The findings in Chapter Five provide evidence of the mechanical effect of the LASER
intervention as a potential therapeutic mechanical device in the management of ankle
haemarthropathy. The LASER intervention has now been used in the Leeds CCC for the
past decade with reductions in patient-reported pain, disability and AJBR [15, 297].
Better understanding the mechanical effect of the LASER intervention justifies formally
testing further in a pathological group of patients with ankle haemarthrosis. The methods
used in this chapter have highlighted parameters that may have implications relating to
the proximal biomechanical effect of the LASER intervention and identify modifications
that may have clinical relevance to pathological gait in future biomechanical intervention
studies. Repeating the biomechanical methods used in Chapter 5 comparing
haemophilic patients current footwear against the LASER intervention would provide
mechanical justification for a larger intervention study in the haemophilia population. A
repeated biomechanical study in the haemophilia population would allow observations
of changes in the kinetic and kinematics at the ankle and proximal joints reported in
Chapter Five to be confirmed before a future RCT. The design of a full RCT with
embedded feasibility study would benefit from the inclusion of patients with moderate
and severe haemophilia types, treatment regimens and details of pharmacological
treatment (type, dose and trough levels) with varying levels of ankle haemarthropathy
and should include details of multi-joint haemarthropathy to capture effect. The inclusion
of HRQoL and foot and ankle PROMs similar to the outcomes used in Chapter Four
would provide a measure of the non-biomechancal impact of the intervention, as well as
allow comparison to other diseases that affect the ankle joint.
The improvement in ankle kinetics and kinematics produced by the LASER intervention
represents a potential for therapeutic benefit in the management of ankle
haemarthropathy. In haemophilia haemarthrosis are associated with a decline in joint
health structure and function that becomes a source of pain and disability as joint health
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declines [8, 135]. Therefore the LASER intervention has the potential to provide a means
of facilitating the ankle rocker mechanism where ankle ROM is limited, improving lower
limb function and reducing the mechanical burden on the ankle joint. The findings of this
chapter support anecdotal clinical evidence at the Leeds CCC that patients using the
modified footwear might experience reduced symptoms and improved HRQoL.
6.3 Limitation of current work
The specific limitations of this thesis have been presented in each chapter. In this
section, therefore, the overarching limitations of this thesis design, methods and resulting
outcomes are discussed.
The sample size in the prevalence study (Chapter Three) was small (n=157) owing to
the requirement of the patient to have been compliant with the prophylaxis CFC
treatment, reporting of treatment via Haemtrack, with concurrent full and electronic HJHS
uploaded from each centre. At the time of data collection, the use of electronic recording
was not universally adopted by UK haemophilia centres, nor were they uploaded as
individual joint HJHS, therefore limiting the number of patients that were included in
Chapter Three. It is expected that the number of patients would increase as centres
adopt electronic methods of recording the HJHS rather than paper copies. The recent
pandemic has also seen changes to how clinical data is collected and recorded, with
more centres willing to adopt electronic methods of data reporting. Therefore if the study
was undertaken today the sample size may be larger, and make the finding more
generalisable to the haemophilia population.
The samples of haemophilia B patients in both Chapter Three (n=19), Chapter Four
(n=34) and those with moderate haemophilia (n=29) in Chapter Four were small but an
appropriate proportion of the cohort. Adequate recruitment of haemophilia B participants
is an often reported limitation in the study of MSK complications of haemophilia, due to
the low prevalence [5, 234]. The small sample size highlights the difficulty in obtaining
adequate samples in rare diseases where small numbers are registered at each
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haemophilia centre. Attempts were made in Chapter Four to increase patient numbers
with 18 sites used for recruitment. Future studies may benefit from obtaining study data
from people with haemophilia B and moderate haemophilia from a much wider sample
with European and International collaboration to ascertain the true impact of disease type
and severity. Reporting of MSK disease in haemophilia has been grouped in physical
therapy and biomechanical studies [340, 341], however when examining the
consequence of bleeding, joint health and HRQoL is different between haemophilia types
[5, 235, 264]. AJBR are lower in people with haemophilia B with fewer complications
but no definitive study has been undertaken to establish whether the proposed lower
level of bleed prevalence, intensity and lower levels of joint haemarthropathy identified
in part in this thesis is true.
Haemophilia is a lifelong condition characterised by bleeding within soft tissue and joints.
Whilst the data reported in Chapter Three was obtained from a national haemophilia
database the reported bleeding data and concurrent joint health using the HJHS was a
relatively new addition to the database at the time of data reporting. Future prevalence
studies would benefit from reporting of longitudinal bleed data and concurrent joint health
to ascertain the bleeding profile and decline in joint health over time, but this was beyond
the scope of this thesis.
Additional data related to treatment and trough levels were collected, but not included in
the final report owing to incompleteness, inconsistencies in reporting and different
methods of obtaining trough levels such as length of time without treatment and reporting
methods. Obtaining trough data would have significantly strengthened treatment
findings, but the primary outcome of this study (HRQoL and foot and ankle PROMs) were
to target (n=255/245) with 243 suitable for analysis and the primary outcome unaffected.
In the mechanistic study reported in Chapter Five, some carryover effects between
footwear conditions may have affected some of the specific biomechanical parameters
reported. The carryover effect may have occurred due to an inadequate washout period
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between conditions. When testing a footwear intervention there should be an adequate
period of time between wearing different conditions [313]. A five minute washout period
was used between conditions, which may not have been adequate. The effect was only
observed in a small number of outcomes but attempts should be made in future studies
to mitigate carryover where a Williams design is not possible [127].
The kinetic and kinematic parameters of gait were only captured during the stance phase
in Chapter Five. Whilst this did not affect the study design, assessment during the swing
phase would provide further detail on the effect of the LASER intervention and individual
footwear components on the unloaded limb [91]. In the presence of multi-joint
haemarthropathy the resultant muscle atrophy, restrictions in ROM and the additional
weight of the LASER intervention may be detrimental to lower limb biomechanical
parameters [135]. The use of a single segment foot model to capture in boot kinetic and
kinematic data may be perceived as limited, owing to the complexities of the foot [111].
Multi-segment foot modelling is preferred when evaluating the complex kinematics of the
foot, however, a single segment was used to model the ankle kinetics as well as the
kinematics. This pragmatic approach was taken as ankle kinetics are mostly modelled
as a single segment (foot, shank), and biomechanical outcomes were specific to the
ankle, therefore a multi-segment model would be less necessary. In addition Chapter
Five sought to understand the mechanical effect of the LASER intervention and cutting
multiple holes in footwear to accommodate a multi-segment model may have decreased
boot integrity, a potential source of bias in data collection [20].
Limitations of the statistical approach used to analyse biomechanical data are
acknowledged. Repeated gait measures adopted to test differences between footwear
conditions typically incorporate error or “variation” in biomechanical outcomes [342].
Understanding the magnitude of error, minimally important differences of results and
minimal levels of detectable change may support the interpretation of data in a target
population such as those patients with ankle haemarthropathy. Gait analysis used in this
thesis examined data from discrete-time point(s) to test the hypothesis however
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comparisons are limited to peak values for the gait cycle [111]. Analysis over the entirety
of the gait cycle using methods such as Statistical Parametric Mapping (SPM) has been
introduced recently to provide an insight into function over the course of a time series
and detect to timing and magnitude of differences providing a more pragmatic approach
to biomechanical analysis [329, 330]. Whist the use of SPM was not within the scope of
this thesis, owing to the proposed footwear mechanisms of change and large dataset,
future research in haemophilia and pathological gait may provide further insight.
6.4 Directions of future research
The research undertaken in this thesis and the direction of future research has been
identified in the preceding chapters. Therefore an overview and further clarification are
presented here.
Evaluation of the true ankle haemarthrosis and concurrent haemarthropathy require
large longitudinal studies of bleed history and treatment regimes in those deemed
compliant with treatment. Detailed evaluations of patients who fall below the UKHCDO
threshold of 75% reporting compliance are also required to obtain the true UK prevalence
and incidence of ankle joint haemarthrosis and joint disease. This may require a different
approach to data collection with less focus on those most compliant with treatment and
collation of longitudinal HJHS data from childhood through to adulthood, and into older
adult population across UK haemophilia care. Future research designs could therefore
obtain longitudinal data on the prevalence of patients who are compliant and non-
compliant with haemophilia joint health scoring.
Further research is needed to establish the relationship between the incidence of ankle
haemarthrosis and the point at which ankle haemarthropathy starts to affect HRQoL and
foot and ankle PROMs. One major theme in the Chapter Four impact study was the
significant amount of ankle haemarthropathy in those with moderate haemophilia, with
comparable impact to severe haemophilia. Recommendations for future research would
include closer monitoring of ankle joint haemarthrosis, incidence and development of
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haemarthropathy in those with and without a history of bleeding, to understand the true
incidence in the UK haemophilia population. Similarly, with the emergence of novel factor
and non-factor treatment products such as EHL and bispecific monoclonal antibodies,
there is a need to understand the non-pharmacological contribution of treatment to
HRQoL and foot and ankle PROMs.
A mechanism of action study is next required in a cohort of haemophilia patients with
ankle and multi-joint haemarthropathy to establish the safety and confirm mechanical
effects of the LASER intervention in haemophilia cases before implementation in practice
or inclusion as part of a complex intervention trial. The LASER intervention has the
potential to reduce the burden of established ankle haemarthropathy, but also in early
joint disease before biomechanical limitations and pain are yet to be established. The
methods used in Chapter Five have produced a biomechanical protocol that may be
allied to other intervention studies that aim to obtain the true effect within footwear.
Therefore the novel biomechanical model may be applied to patients with ankle
haemarthropathy and other diseases that affect the ankle joint.
6.5 Overview of findings
The aims of this thesis were as follows; firstly to identify the prevalence of ankle
haemarthrosis and concurrent joint health in severe haemophilia A and B. The findings
of Chapter Four identified the prevalence of ankle haemarthropathy is similar to other
commonly affected joints, however, the ankle is disproportionately affected by
haemarthropathy. The second aim was to provide insight into the impact of ankle
haemarthropathy on HRQoL and foot and ankle specific PROMs. The finds of Chapter
Five have identified that patients with ankle haemarthropathy have poor HRQoL and foot
and ankle specific outcomes which are driven by chronic pain. The final aim was to
investigate the mechanism of action of the LASER intervention. Chapter Five has
established that the LASER intervention reduces the kinetic and kinematics effect at the




Ankle haemarthrosis and the resultant haemarthropathy is a significant burden to
patients with moderate and severe haemophilia. In patients with severe non-inhibitor
haemophilia who adhered to prophylaxis, haemarthrosis still occurs, with
disproportionate levels of haemarthropathy reported at the ankle. HRQoL and foot and
ankle outcomes are severely affected with, poor outcomes reported in those with
moderate to severe levels of ankle haemarthropathy. The driver for the decline in pain
and whilst patients identify high levels of chronic ankle pain, treatment is sub-optimal in
the use of pharmacological pain medication and non-pharmacological interventions.
Therapeutically useful footwear and FFO are used by only a small proportion of patients
identified in this thesis but do appear to be able to reduce the mechanical burden at the
ankle joint. It remains to be shown definitively whether the use of footwear and FFO have
a positive effect on patient-reported outcomes. The use of the LASER intervention has
been investigated and reduces the biomechanical demands on the ankle joint with
minimal proximal effect at the knee and hip, minimising the risk of subsequent
haemarthrosis at these proximal structures. In future trials of targeted treatments for
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